Antibiotics for acute rhinosinusitis in adults. by Lemiengre, Marieke et al.
Cochrane Database of Systematic Reviews
Antibiotics for acute rhinosinusitis in adults (Review)
Lemiengre MB, van Driel ML, Merenstein D, Liira H, Mäkelä M, De Sutter AIM
Lemiengre MB, van Driel ML, Merenstein D, Liira H, Mäkelä M, De Sutter AIM.
Antibiotics for acute rhinosinusitis in adults.
Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No.: CD006089.
DOI: 10.1002/14651858.CD006089.pub5.
www.cochranelibrary.com
Antibiotics for acute rhinosinusitis in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
23DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
31CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
79DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Antibiotics versus placebo for acute rhinosinusitis: cure, Outcome 1 Cure. . . . . . 81
Analysis 2.1. Comparison 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes, Outcome 1 Severity or
duration of different clinical symptoms: resolution of purulent secretion. . . . . . . . . . . . . . 83
Analysis 2.2. Comparison 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes, Outcome 2 Side effects:
total. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Analysis 2.3. Comparison 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes, Outcome 3 Side effects:
diarrhoea. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Analysis 2.4. Comparison 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes, Outcome 4 Clinical
failure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Analysis 3.1. Comparison 3 Sensitivity analyses, Outcome 1 Clinically diagnosed rhinosinusitis. . . . . . . . 87
Analysis 3.2. Comparison 3 Sensitivity analyses, Outcome 2 Rhinosinusitis confirmed by imaging. . . . . . . . 92
93APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
96WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
96HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
97CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
97DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
97SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
98DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
98INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iAntibiotics for acute rhinosinusitis in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Antibiotics for acute rhinosinusitis in adults
Marieke B Lemiengre1, Mieke L van Driel1,2,3, Dan Merenstein4 , Helena Liira5, Marjukka Mäkelä6,7, An IM De Sutter1
1Department of Family Medicine and Primary Health Care, Ghent University, Ghent, Belgium. 2Centre for Research in Evidence-
Based Practice (CREBP), Bond University, Gold Coast, Australia. 3Primary Care Clinical Unit, Faculty of Medicine, The University of
Queensland, Brisbane, Australia. 4Department of Family Medicine, Georgetown University Medical Center, Washington, DC, USA.
5University of Helsinki, Helsinki, Finland. 6THL (National Institute for Health and Welfare), Helsinki, Finland. 7Department of
Public Health / Unit of General Practice, University of Copenhagen, DK-1014 Copenhagen, Denmark
Contact address: Marieke B Lemiengre, Department of Family Medicine and Primary Health Care, Ghent University, Campus UZ
6K3, Corneel Heymanslaan 10, Ghent, 9000, Belgium. marieke.lemiengre@ugent.be.
Editorial group: Cochrane Acute Respiratory Infections Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 9, 2018.
Citation: Lemiengre MB, van Driel ML, Merenstein D, Liira H, Mäkelä M, De Sutter AIM. Antibiotics for acute rhinosinusitis in
adults. Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No.: CD006089. DOI: 10.1002/14651858.CD006089.pub5.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Acute rhinosinusitis is an acute infection of the nasal passages and paranasal sinuses that lasts less than four weeks. Diagnosis of acute
rhinosinusitis is generally based on clinical signs and symptoms in ambulatory care settings. Technical investigations are not routinely
performed, nor are they recommended in most countries. Some trials show a trend in favour of antibiotics, but the balance of benefit
versus harm is unclear.
We merged two Cochrane Reviews for this update, which comprised different approaches with overlapping populations, resulting
in different conclusions. For this review update, we maintained the distinction between populations diagnosed by clinical signs and
symptoms, or imaging.
Objectives
To assess the effects of antibiotics versus placebo or no treatment in adults with acute rhinosinusitis in ambulatory care settings.
Search methods
We searched CENTRAL (2017, Issue 12), which contains the Cochrane Acute Respiratory Infections Group’s Specialised Register,
MEDLINE (January 1950 to January 2018), Embase (January 1974 to January 2018), and two trials registers (January 2018). We also
checked references from identified trials, systematic reviews, and relevant guidelines.
Selection criteria
Randomised controlled trials of antibiotics versus placebo or no treatment in people with rhinosinusitis-like signs or symptoms or
sinusitis confirmed by imaging.
Data collection and analysis
Two review authors independently extracted data about cure and side effects and assessed the risk of bias. We contacted trial authors
for additional information as required.
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Main results
We included 15 trials involving 3057 participants. Of the 15 included trials, 10 appeared in our 2012 review, and five (631 participants)
are legacy trials from merging two reviews. No new studies were included from searches for this update. Overall, risk of bias was low.
Without antibiotics, 46% of participants with rhinosinusitis, whether or not confirmed by radiography, were cured after 1 week and
64% after 14 days. Antibiotics can shorten time to cure, but only 5 to 11 more people per 100 will be cured faster if they receive
antibiotics instead of placebo or no treatment: clinical diagnosis (odds ratio (OR) 1.25, 95% confidence interval (CI) 1.02 to 1.54;
number needed to treat for an additional beneficial outcome (NNTB) 19, 95% CI 10 to 205; I² = 0%; 8 trials; high-quality evidence)
and diagnosis confirmed by radiography (OR 1.57, 95% CI 1.03 to 2.39; NNTB 10, 95% CI 5 to 136; I² = 0%; 3 trials; moderate-
quality evidence). Cure rates with antibiotics were higher when a fluid level or total opacification in any sinus was found on computed
tomography (OR 4.89, 95% CI 1.75 to 13.72; NNTB 4, 95% CI 2 to 15; 1 trial; moderate-quality evidence). Purulent secretion
resolved faster with antibiotics (OR 1.58, 95% CI 1.13 to 2.22; NNTB 10, 95% CI 6 to 35; I² = 0%; 3 trials; high-quality evidence).
However, 13more people experienced side effects with antibiotics compared to placebo or no treatment (OR 2.21, 95%CI 1.74 to 2.82;
number needed to treat for an additional harmful outcome (NNTH) 8, 95% CI 6 to 12; I² = 16%; 10 trials; high-quality evidence).
Five fewer people per 100 will experience clinical failure if they receive antibiotics instead of placebo or no treatment (Peto OR 0.48,
95% CI 0.36 to 0.63; NNTH 19, 95% CI 15 to 27; I² = 21%; 12 trials; high-quality evidence). A disease-related complication (brain
abscess) occurred in one participant (of 3057) one week after receiving open antibiotic therapy (clinical failure, control group).
Authors’ conclusions
The potential benefit of antibiotics to treat acute rhinosinusitis diagnosed either clinically (low risk of bias, high-quality evidence) or
confirmed by imaging (low to unclear risk of bias, moderate-quality evidence) is marginal and needs to be seen in the context of the
risk of adverse effects. Considering antibiotic resistance, and the very low incidence of serious complications, we conclude there is no
place for antibiotics for people with uncomplicated acute rhinosinusitis. We could not draw conclusions about children, people with
suppressed immune systems, and those with severe sinusitis, because these populations were not included in the available trials.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for sinus infection of short duration in adults
Review question
Do antibiotics cure sinus infection faster than no antibiotics in adults?
Background
A sinus is a cavity situated in the head. Adults with short-duration sinus infection experience stuffy nose and thick, yellowdischarge from
the nose. People with sinus infection can feel slime in the back of the throat, facial pain, pain when bending forward, and pain in the
upper teeth or when chewing. A short-duration sinus infection may be suspected following physical examination and questions about
symptoms. Blood examination or images of the sinuses can support diagnosis, but are not routinely recommended in most countries.
Short-duration sinus infections are mostly caused by viruses. Nevertheless, physicians tend to prescribe antibiotics, which should only
be used to treat bacterial infections. Taking antibiotics unnecessarily results in antibiotic resistance against bacterial infections. We
investigated whether antibiotics cure adults with short-duration sinus infection faster than a dummy drug (placebo) or no treatment.
Search date
18 January 2018.
Study characteristics
We included 15 studies in which adults with short-duration sinus infection, whether or not confirmed by imaging, randomly received
antibiotics, or a dummy drug or no treatment, in ambulatory care settings. The studies included a total of 3057 adults whose average
age was 36 years; about 60% were female. Participants were followed until they were cured. Trial duration ranged from 8 to 28 days.
Study funding sources
Seven studies received financial support from government or academic institutions; six received grants from the pharmaceutical industry;
and five did not state sources of support.
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Key results
Without antibiotics, almost half of all participants were cured after one week, and two out of three were cured after 14 days. Five
(diagnosis based on symptoms described to a doctor) to 11 (diagnosis confirmed by x-ray) more people per 100 were cured faster
with antibiotics. A computed tomography (CT) scan could better predict who would benefit from antibiotics, but routine use would
cause health problems related to radiation exposure. Ten more people per 100 were relieved faster of thick, yellow discharge from the
nose with antibiotics compared to a dummy drug or no treatment. Thirteen more people per 100 experienced side effects (mostly
concerning stomach or intestines) with antibiotics compared to a dummy drug or no treatment. Compared with people who initially
started antibiotics, five more people per 100 in the dummy drug or no treatment group had to start antibiotics because their condition
worsened. Serious complications (e.g. brain abscess) were rare.
We found that antibiotics are not a first-choice treatment for adults with short-duration sinus infection. We found no evidence relating
to adults with severe sinusitis or with reduced immunity, or to children.
Quality of evidence
We found high-quality evidence when the diagnosis was based on symptoms described to a doctor. We downgraded evidence quality to
moderate when diagnosis was confirmed by x-ray or CT scan because the number of participants was small, which makes the estimates
less reliable.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antbiotics compared to placebo for acute rhinosinusitis in adults
Patient or population: acute rhinosinusit is in adults, whether clinically diagnosed or conf irmed by imaging
Settings: general pract ice (11 studies), otolaryngology outpat ient clinics of university hospitals (2 studies), medical centre (1 study), unknown (2 studies)
Intervention: ant ibiot ics
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Antibiotics
Cure in adults with clin-
ically diagnosed acute
rhinosinusitis
55 per 100 60 per 100
(56 to 65)
OR 1.25
(1.02 to 1.54)
1687
(8 studies)
⊕⊕⊕⊕
High
Combinat ion of sinusi-
t is-like symptoms. Most
f requent ly used clinical
symptoms: nasal dis-
charge, facial pain, and
common cold or upper
respiratory tract infec-
t ion
NNTB 19 (95% CI 10 to
205)
Cure in adults with
acute rhinosinusitis
confirmed by radiogra-
phy1
51 per 100 62 per 100
(52 to 72)
OR 1.57
(1.03 to 2.39)
394
(3 studies)
⊕⊕⊕©
Moderate2,3
Clinical suspicion + ra-
diography, using vari-
ous criteria:
• conf irmed
secret ion;
• > 5 mm mucosal
thickening, opacity or
f luid level; or
• the presence in at
least 1 sinus of an air-
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f luid level, a complete
opacity, or a mucosal
thickening of 10 mL.
NNTB 10 (95% CI 5 to
136)
Cure in adults with
acute rhinosinusitis
confirmed by com-
puted tomography1,4
11 per 100 39 per 100
(18 to 64)
OR 4.89
(1.75 to 13.72)
127
(1 study)
⊕⊕⊕©
Moderate5
Clinical suspicion +
computed tomography,
using as a criterion pres-
ence of f luid level or to-
tal opacif icat ion in any
sinus
NNTB 4 (95%CI 2 to 15)
Severity or duration of
different clinical symp-
toms: resolution of pu-
rulent secretion
60 per 100 70 per 100
(63 to 77)
OR 1.58
(1.13 to 2.22)
660
(3 studies)
⊕⊕⊕⊕
High
NNTB 10 (95% CI 6 to
35)
Side effects: total 15 per 100 28 per 100
(24 to 33)
OR 2.21
(1.74 to 2.82)
1816
(10 studies)
⊕⊕⊕⊕
High
NNTH 8 (95%CI 6 to 12)
Side effects: diarrhoea 10 per 100 18 per 100
(13 to 24)
Peto OR 2.00
(1.41 to 2.85)
1210
(7 studies)
⊕⊕⊕⊕
High
NNTH 13 (95% CI 8 to
29)
Clinical failure 11 per 100 6 per 100
(4 to 8)
Peto OR 0.48
(0.36 to 0.63)
2603
(12 studies)
⊕⊕⊕⊕
High
NNTH 19 (95% CI 15 to
27)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to treat for an addit ional harmful outcome; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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Only outcomes that could be pooled were presented.
1High heterogeneity (I² = 41%) for the outcome of cure in adults with acute rhinosinusit is conf irmed by imaging led us to split
the outcome into cure in adults with acute rhinosinusit is conf irmed by radiography and cure in adults with acute rhinosinusit is
conf irmed by computed tomography.
2There was a high risk of blinding bias in Axelsson 1970. Blinding was not reported and was probably not applied. Placebo
group part icipants did not receive tablets, only nose drops. It was not possible to blind sinus irrigat ion as an intervent ion. Only
group 2 part icipants underwent radiological evaluat ion every second day. Group 3 part icipants received a longer course of
tablets than group 4. For this reason, we downgraded the quality of evidence f rom high to moderate. Omitt ing this trial f rom
the meta-analysis did not substant ially change the overall result ; therefore, we did not downgrade the quality of the evidence
further.
3Three trials reported cure in adults with acute rhinosinusit is conf irmed by radiography, and conf idence intervals were wide.
We downgraded the quality of the evidence to moderate.
4Lindbaek 1996 and Lindbaek 1998 presented study results f rom two dist inct groups (those with f luid level or total
opacif icat ion in any sinus on computed tomography and those with only mucosal thickening on computed tomography,
respect ively). Consequent ly, the results of the two trials were very dif f erent (I² = 84%). We opted to report only the results
f rom Lindbaek 1996 because the benef icial ef fect of ant ibiot ics was clearly present only in this subgroup.
5Only one trial (N = 127) reported on cure in adults with acute rhinosinusit is conf irmed by computed tomography. We
downgraded the quality of the evidence to moderate because of the low number of part icipants despite this being a well-
conducted trial.
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B A C K G R O U N D
We merged two Cochrane Reviews for this update (De Sutter
2012; Ahovuo-Saloranta 2014).
Description of the condition
Acute rhinosinusitis is defined as an acute infection of the nasal
passages and the paranasal sinuses lasting fewer than four weeks (
Ah-See 2007; Lanza 1997). It is one of themost commondiagnoses
made in ambulatory care and continues to be a clinical challenge
(Blackwell 2014; Lethbridge-Cejku 2006; McCaig 1995; Okkes
2005; Schappert 1998; Willet 1994). Although guidelines have
long recommended restricted use of antibiotics for rhinosinusitis,
antibiotics continue to be prescribed for 67% to 100% of people
with suspected acute rhinosinusitis (Gulliford 2014 (UK); Rún
2015 (Denmark, Iceland); Fleming-Dutra 2016 (USA)).
Rhinosinusitis is a more exact term than sinusitis since it takes
into account that inflammation of the sinuses is unlikely to occur
without inflammation of the mucous membranes of the nose.
In this review, the term ’sinusitis’ was used when inflammation
of a specific sinus (confirmed by radiology or ultrasound) was
mentioned (e.g. maxillary sinusitis). Sinusitis was often used in
older studies when referring to rhinosinusitis.
Typical signs and symptoms of acute rhinosinusitis include puru-
lent nasal discharge, postnasal drip, sinus pain at palpation, uni-
lateral facial pain, and maxillary toothache (Autio 2015; Axelsson
1972; Williams 1993). However, there is no convincing evidence
that people with these clinical findings would benefit from an-
tibiotic treatment (Young 2008). Bacterial infections can also be
self limiting. Imaging investigations, such as x-ray and computed
tomography (CT), have been used to demonstrate fluid in the si-
nuses (air-fluid level or total opacity). Sinus ultrasound has also
been used for this purpose in Scandinavia (Varonen 2000). How-
ever, radiological methods cause radiation, are not readily available
in ambulatory care settings, and cannot differentiate between vi-
ral and bacterial infections. Rhinosinusitis could be confirmed by
sinus puncture (Lindbaek 2002), but this is not a feasible ambula-
tory care method. Acute rhinosinusitis remains a clinical diagnosis
with a non-specific clinical picture.
Description of the intervention
We investigated the effectiveness of antibiotics versus placeboor no
treatment in adults with acute rhinosinusitis, whether diagnosed
clinically or by imaging.
Two previous Cochrane Reviews (’Antibiotics for acute maxillary
sinusitis in adults’ and ’Antibiotics for clinically diagnosed acute
rhinosinusitis in adults’) described the effect of antibiotics for acute
rhinosinusitis (Ahovuo-Saloranta 2014; De Sutter 2012). The re-
views studied the same condition but looked at different popula-
tions: people diagnosed by imaging versus people diagnosed clin-
ically according to their signs and symptoms (Ahovuo-Saloranta
2014; De Sutter 2012). As different approaches resulted in
different conclusions, we therefore merged these reviews while
maintaining the relevant distinction between the two popula-
tions. We omitted comparison between antibiotics, as assessed by
Ahovuo-Saloranta 2014. Rather than clinical trials, local up-to-
date antibiotic resistance patterns should guide clinicians in mak-
ing the best choice of a particular antibiotic and dose in the sub-
group of people with suspected bacterial rhinosinusitis.
Two other Cochrane Reviews focused on antibiotic treatment for
people with acute infections of the nose, sinuses, or both (Kenealy
2013; Morris 2002). Kenealy and colleagues looked at the effect
of antibiotics in people with symptoms of acute upper respiratory
tract infection lasting less than seven days, or acute purulent rhini-
tis of less than 10 days duration (Kenealy 2013). The authors con-
cluded that there was insufficient evidence to warrant the use of
antibiotics for common cold or for persisting acute purulent rhini-
tis in children or adults (Kenealy 2013). Morris and colleagues
considered antibiotic treatment in children with persistent nasal
discharge (Morris 2002). The authors concluded that antibiotics
have some benefit in the short and medium term in children with
purulent rhinorrhoea for more than 10 days, or in older children
with radiologically confirmed rhinosinusitis (Morris 2002).
How the intervention might work
Acute rhinosinusitis can be caused by viral or bacterial infections.
Acute viral rhinosinusitis is a viral upper respiratory tract infec-
tion (or common cold) which, in most cases, also involves the
sinuses. Gwaltney 1994 showed that 87% of people with a com-
mon cold also have sinus abnormalities on CT scan. Antibiotics
are unnecessary in viral rhinosinusitis (Hickner 2001), and people
prescribed an antibiotic can develop bacterial resistance to that
antibiotic (Costelloe 2010).
Few people (0.5% to 2%) develop bacterial rhinosinusitis (Berg
1986; Gwaltney 1996). Antibiotics may be indicated for bacterial
rhinosinusitis to speed up recovery or to prevent suppurative com-
plications. Identifying people with bacterial rhinosinusitis on a
clinical basis is challenging (Ebell 2017; Lindbaek 2002). Bacterial
origin may be more likely if symptoms last for more than a week
(Gwaltney 2005). Consequently, the notions of ’viral’ and ’bacte-
rial’ are not very workable in daily practice, and there is a pressing
need to identify who would benefit from antibiotics (Lanza 1997).
Why it is important to do this review
Diagnosis of most people with acute rhinosinusitis who present
in ambulatory care settings is based on clinical signs and symp-
toms. In most countries, technical investigations are not routinely
performed, nor are they recommended (Brazzelli 2003; Hickner
2001; Low 1997). Except for theCochrane Reviews that are part of
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this amalgamation (Ahovuo-Saloranta 2014;De Sutter 2012), two
other previously published Cochrane Reviews did not focus exclu-
sively on adults or people with suspected rhinosinusitis (Kenealy
2013; Morris 2002). Results from those reviews could therefore
not indicate if this population should be treated with antibiotics.
Individual trials show a trend in favour of antibiotics for this pop-
ulation, but the balance of benefit versus harm is unclear.
O B J E C T I V E S
To assess the effects of antibiotics versus placebo in adults with
acute rhinosinusitis in ambulatory care settings.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) comparing an-
tibiotics with placebo or no treatment in participants with rhinos-
inusitis-like signs or symptoms, whether confirmed by imaging
or not. We considered trials including participants with an upper
respiratory tract infection or common cold if most participants
had rhinosinusitis-like symptoms, or if participants with rhinosi-
nusitis-like symptoms could be analysed separately.
We excluded the following studies.
1. Trials in which participants were included on the basis of a
laboratory investigations such as measurement of C-reactive
protein (CRP) or erythrocyte sedimentation rate (ESR),
bacteriological or cytological investigations.
2. Studies comparing one antibiotic with another and trials
comparing antibiotics versus other medications.
3. Trials in which more than 50% of participants were
considered to have a common cold.
4. Trials in which participants had signs and symptoms for
more than 30 days.
5. Trials in which participants were not randomised, or trials
that did not include a placebo arm.
Types of participants
We considered all trials in which adults with acute rhinosinusi-
tis, whether clinically diagnosed or confirmed by imaging, were
randomly assigned to treatment with an antibiotic, placebo, or
no treatment. The clinical diagnosis of acute rhinosinusitis was
based on the presence of clinical signs or symptoms that are as-
sociated with the presence of fluid in the sinuses in diagnostic
studies or that are mentioned in clinical practice guidelines as in-
dicating rhinosinusitis. These included: started with a common
cold or experienced both phases of the illness (i.e. catches a cold,
feels better after a few days, then feels worse again), purulent nasal
discharge, unilateral maxillary pain, pain in the upper teeth, pain
when chewing, postnasal drip, pain on bending forward, and du-
ration of symptoms for more than seven days.
We limited participants to adults (aged 18 years or over); the
Cochrane Review by Morris 2002 reviewed studies on children.
We limited the duration of symptoms to 30 days or less to ex-
clude participants with subacute or chronic rhinosinusitis, where
the infection was probably not the primary cause of inflammation
(Bachert 2003).
Types of interventions
We included only RCTs that compared antibiotic therapy versus
placebo or no treatment. We included trials that permitted con-
current use of other medications if participants were allowed equal
access in both the antibiotic and placebo groups.
Types of outcome measures
Primary outcomes
1. Cure in people with:
i) clinically diagnosed rhinosinusitis;
ii) rhinosinusitis confirmed by imaging.
Secondary outcomes
1. Ratings of measures of overall well-being.
2. Severity or duration of different clinical symptoms:
i) resolution of purulent secretion;
ii) resolution of pain;
iii) illness duration;
iv) restriction of daily activities.
3. Use of concomitant medications:
i) analgesics;
ii) nasal decongestants.
4. Side effects.
5. Clinical failure.
6. Serious adverse events.
Search methods for identification of studies
Electronic searches
We searched the following databases up to 18 January 2018 for
this update:
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1. the Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 12), which contains the Cochrane
Acute Respiratory Infections Group’s Specialised Register, in the
Cochrane Library using the strategy in Appendix 1;
2. MEDLINE via Ovid (from January 1950 to January 2018)
using the strategy in Appendix 1; and
3. Embase via Elsevier (from January 1974 to January 2018)
using the strategy in Appendix 2.
We searched the following trials registries on 18 January 2018:
1. the World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) ( apps.who.int/trialsearch)
(Appendix 3); and
2. ClinicalTrials.gov ( clinicaltrials.gov) (Appendix 4).
We did not restrict the results by language or publication status.
Searching other resources
We scrutinised the reference lists of identified trials, systematic
reviews, and relevant guidelines for other eligible trials.
Data collection and analysis
Selection of studies
Two review authors (ML, ADS) independently screened titles and
abstracts of all studies identified as a result of the search for stud-
ies that were potentially eligible for inclusion in the review. We
retrieved the full-text study reports, and two review authors (ML,
ADS) independently screened the full texts to identify studies for
inclusion, and identify and record reasons for exclusion of ineligi-
ble studies. Any disagreements were resolved through discussion
or by consulting a third review author (MVD) where necessary.
We identified and excluded duplicates and collated multiple re-
ports of the same study so that each study, rather than each report,
was the unit of interest in the review. We recorded the selection
process in sufficient detail to complete a PRISMA flow diagram
and Characteristics of excluded studies table (Moher 2009). We
did not impose any language restrictions.
Data extraction and management
We used a data collection form for study characteristics and out-
come data that had been piloted on at least one study in the re-
view. Two review authors (ML, ADS) extracted the following study
characteristics from the included studies.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (ML, ADS) independently extracted outcome
data from the included studies. We noted in the Characteristics
of included studies table if outcome data were not reported in a
usable way. There were no disagreements.One review author (ML)
transferred data into the Review Manager 5 file (Review Manager
2014). We double-checked that data were entered correctly by
comparing the data presented in the systematic review with the
study reports. A second review author (ADS) spot-checked study
characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (ML, ADS) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
Any disagreements were resolved by discussion. We assessed the
risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised the
’Risk of bias’ judgements across different studies for each of the
domains listed. We considered blinding separately for different
key outcomes, where necessary. Where information on risk of bias
related to unpublished data or correspondence with a trialist, we
planned to note this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
and reported any deviations from it in the Differences between
protocol and review section. We ensured that current Cochrane
methods were applied.
Measures of treatment effect
We entered outcome data for each study into the data tables in Re-
viewManager 5 to calculate the treatment effects (Review Manager
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2014). We used odds ratio for dichotomous outcomes, and mean
differences or standardised mean differences for continuous out-
comes.
We conducted meta-analyses only where this was meaningful, that
is the treatments, participants, and the underlying clinical question
were similar enough for pooling to make sense.
Unit of analysis issues
In trials with multiple treatment groups, we compared event rates
in the antibiotic treatment arms (intervention) with placebo event
rates (control). We did not include cluster-RCTs.
Dealing with missing data
Where numerical outcome data were missing and could not be
obtained from the authors, these were calculated from other avail-
able statistics, according to the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b).
Assessment of heterogeneity
We assessed variability among studies for statistical heterogeneity
using Cochran’s test for heterogeneity and the I² statistic. The I²
statistic describes the percentage of variability in effect estimates
that is due to heterogeneity rather than to sampling error.We con-
sidered a value greater than 50% to represent substantial hetero-
geneity, in which case we used a random-effects model.
Assessment of reporting biases
We planned to construct funnel plots to assess the likelihood of
publication bias if 10 studies or more were available for analysis.
Data synthesis
We pooled data from studies judged to be clinically homogeneous
usingReviewManager 5 software (Review Manager 2014). Ifmore
than one study provided usable data in any single comparison, we
performed a meta-analysis.
GRADE and ’Summary of findings’ table
We created Summary of findings for the main comparison using
the following outcomes.
1. Cure in adults with clinically diagnosed rhinosinusitis.
2. Cure in adults with rhinosinusitis confirmed by
radiography.
3. Cure in adults with rhinosinusitis confirmed by CT scan.
4. Resolution of purulent secretion.
5. Side effects: general.
6. Side effects: diarrhoea.
7. Clinical failure.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence as it relates to the stud-
ies that contributed data to the meta-analyses for the prespecified
outcomes (Atkins 2004).We usedmethods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011b),using
GRADEpro GDT software (GRADEpro GDT 2015). We justi-
fied all decisions to down- or upgrade the quality of studies using
footnotes, and made comments to aid the reader’s understanding
of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Clinically diagnosed rhinosinusitis.
2. Rhinosinusitis confirmed by imaging.
We used the Chi² test to test for subgroup interactions using Re-
view Manager 5 software (Review Manager 2014).
Sensitivity analysis
We carried out the following sensitivity analyses.
1. Excluding studies at higher risk of bias.
2. Assessing the influence of missing data: adding dropouts as
failures, successes or as having the same cure rate as control
group.
3. Adding participants who were ’improved’ to those who
were cured.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
For the 2018 update, after deleting duplicates, we identified 524
new records from electronic searches. We rejected 354 records on
the basis of title or keyword assessment, 52 records after assessing
abstracts, and three records following full-text record assessment.
We rejected 115 trials based on information from trials registers
(WHO ICTRP or ClinicalTrials.gov). No new studies were added
for this update as a result of 2018 searches (Figure 1).
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Figure 1. Study flow diagram.
Included studies
Because we merged two Cochrane Reviews (Ahovuo-Saloranta
2014; De Sutter 2012), we revised search results from De Sutter
2012, and included five studies (631 participants) from Ahovuo-
Saloranta 2014 (Axelsson 1970; Lindbaek 1996; Lindbaek 1998;
Rantanen 1973; Van Buchem 1997a; Van Buchem 1997b). (Van
Buchem 1997b was a Dutch translation of Van Buchem 1997a;
we used data from Van Buchem 1997a). We retained 10 trials
(2450 participants) that were included in De Sutter 2012 (Bucher
2003; De Sutter 2002; Garbutt 2012; Kaiser 2001; Meltzer 2005;
Merenstein 2005;Norrelund 1978; Stalman 1997; Varonen 2003;
Williamson 2007).
We included 15 trials involving a total of 3057 participants for
this update.
Design
With one exception, all included trials were randomised controlled
trials (RCTs) that compared an antibiotic with a placebo. Axelsson
1970 (most probably) compared antibiotic treatment to no treat-
ment.
Sample sizes
Ten trials involving 2450 participants concerned clinically diag-
nosed rhinosinusitis (Bucher 2003;De Sutter 2002;Garbutt 2012;
Kaiser 2001; Meltzer 2005; Merenstein 2005; Norrelund 1978;
Stalman 1997; Varonen 2003; Williamson 2007).
Five trials involving 631 participants concerned rhinosinusitis
confirmed by imaging (radiology investigation: 431 participants
(Axelsson 1970; Rantanen 1973; Van Buchem 1997a); CT scan:
200 participants (Lindbaek 1996; Lindbaek 1998)). In addition,
Kaiser 2001 identified a subgroup of 82 participants in which rhi-
nosinusitis was confirmed by radiography.
Setting
Eleven trials recruited participants from ambulatory care settings
(Bucher 2003; De Sutter 2002; Garbutt 2012; Lindbaek 1996;
Lindbaek 1998; Merenstein 2005; Norrelund 1978; Stalman
1997; Van Buchem 1997a; Varonen 2003; Williamson 2007).
One trial also enrolled walk-in and non-referred participants
from otolaryngology outpatient clinics of the university hospital
(Bucher 2003). Kaiser 2001 recruited participants from an outpa-
tient clinic of a university hospital. Meltzer 2005 enrolled partic-
ipants from 14 medical centres worldwide, but settings were not
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described. Axelsson 1970 and Rantanen 1973 did not describe
study settings.
Participants
Inclusion criteria
All included studies used clinical signs and symptoms to enrol par-
ticipants. The three most common inclusion criteria were nasal
discharge (Bucher 2003; De Sutter 2002; Garbutt 2012; Kaiser
2001; Meltzer 2005; Merenstein 2005; Norrelund 1978; Stalman
1997;Varonen 2003;Williamson 2007), facial pain (Bucher 2003;
Garbutt 2012; Meltzer 2005; Merenstein 2005; Norrelund 1978;
Stalman 1997; Varonen 2003; Williamson 2007), and common
cold or upper respiratory tract infection (De Sutter 2002; Kaiser
2001; Stalman 1997; Varonen 2003). Two studies included par-
ticipants with pus in the nasal cavity on rhinoscopy (Bucher 2003;
Kaiser 2001), but this symptom was a clinical criterion for inclu-
sion in three trials (Merenstein 2005; Varonen 2003; Williamson
2007).
Five studies used imaging criteria to include participants: con-
firmed secretion on radiography (Axelsson 1970), homogenous
shadows in the sinuses or a fluid level on radiography (Rantanen
1973), more than 5 mmmucosal thickening, opacity or fluid level
on radiography (Van Buchem 1997a), presence of fluid level or
total opacification in any sinus on CT (Lindbaek 1996), and pres-
ence of mucosal thickening without fluid levels or total opacifi-
cation on CT (Lindbaek 1998). In these trials, participants were
preselected on clinical suspicion of having sinusitis. No further
details about the clinical criteria used to select participants were
provided. Kaiser 2001 used the presence, in at least one sinus, of
an air-fluid level, a complete opacity, or a mucosal thickening of
10 mm as a criterion to identify participants for their subgroup of
participants with radiologically confirmed maxillary sinusitis.
Exclusion criteria
Common exclusion criteria were recent antibiotic use (Axelsson
1970; Bucher 2003; De Sutter 2002; Garbutt 2012; Kaiser 2001;
Lindbaek 1996; Lindbaek 1998; Merenstein 2005; Rantanen
1973; Stalman 1997; Van Buchem 1997a; Varonen 2003;
Williamson 2007), severe illness (Kaiser 2001; Lindbaek 1996;
Lindbaek 1998;Meltzer 2005; Stalman 1997), symptoms of com-
plicated rhinosinusitis (De Sutter 2002; Garbutt 2012; Varonen
2003), long-lasting symptoms before inclusion (Bucher 2003;
De Sutter 2002; Lindbaek 1996; Lindbaek 1998; Stalman 1997;
Van Buchem 1997a; Varonen 2003), chronic ear, nose, and
throat disease (Bucher 2003; Kaiser 2001; Meltzer 2005; Van
Buchem 1997a; Varonen 2003; Williamson 2007), comorbidity
(De Sutter 2002; Kaiser 2001; Lindbaek 1996; Lindbaek 1998;
Merenstein 2005; Stalman 1997; Van Buchem 1997a;Williamson
2007), previous sinus surgery (Lindbaek 1996; Lindbaek 1998;
Merenstein 2005; Varonen 2003), immune deficiency (Bucher
2003; De Sutter 2002; Garbutt 2012; Kaiser 2001; Merenstein
2005), allergy for studymedication (Bucher 2003;De Sutter 2002;
Garbutt 2012; Kaiser 2001; Meltzer 2005; Merenstein 2005;
Norrelund 1978; Stalman 1997; Van Buchem 1997a; Varonen
2003; Williamson 2007), pregnancy or lactation (Bucher 2003;
De Sutter 2002; Norrelund 1978; Stalman 1997; Varonen 2003;
Williamson 2007), and inability to follow the protocol (language
or mental problems) (Bucher 2003; De Sutter 2002; Garbutt
2012; Stalman 1997; Van Buchem 1997a). Due to the occur-
rence of a brain abscess in a placebo group participant, after 2000,
Bucher 2003 excluded people with CRP levels greater than 100
mg/L or between 50 and 99 mg/L as a safety measure is there
was clinical deterioration or CRP increase greater than 100 mg/
L within three days of inclusion. No participants had to be ex-
cluded due to this new exclusion criterion. Axelsson 1970 excluded
participants who were recently treated with nasal decongestants.
Kaiser 2001 excluded participants with a positive pharyngeal cul-
ture for Streptococcus pyogenes. Lindbaek and colleagues excluded
participants who misused alcohol or narcotics and those who had
rheumatic disease (Lindbaek 1996; Lindbaek 1998).Garbutt 2012
excluded participants who rated their symptoms as very mild or
mild. Stalman 1997 excluded participants who used xylometazo-
line nose drops for more than seven days, received antacid or iron
treatment, or were referred to an ear, nose, and throat specialist.
Characteristics of the participants
The average age of participants was approximately 36 years.
Norrelund 1978 did not report participants’ mean age, but we cal-
culated a median age of between 30 and 39 years. Axelsson 1970,
Lindbaek 1996, and Lindbaek 1998 permitted younger partici-
pants, but the mean age of the study population was comparable
to the average (33 years in Axelsson 1970, 38.6 years in Lindbaek
1996, and 39.7 years in Lindbaek 1998).
The male-to-female ratio was about 5:8.
The mean duration of symptoms before inclusion was around or
at least seven days in seven trials (De Sutter 2002; Lindbaek 1996;
Lindbaek 1998; Meltzer 2005; Merenstein 2005; Stalman 1997;
Williamson 2007). Participants had symptoms for about four to
five days before inclusion in two trials (Bucher 2003; Kaiser 2001).
The mean duration of symptoms at baseline was longer in two
studies (11 days in Garbutt 2012 and 15.4 days in Van Buchem
1997a). Axelsson 1970, Norrelund 1978, Rantanen 1973, and
Varonen 2003 did not report the mean duration of symptoms
before inclusion.
Interventions
Treatment group
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Nine studies compared amoxicillin to placebo (De Sutter 2002;
Garbutt 2012; Lindbaek 1996; Lindbaek 1998; Meltzer 2005;
Merenstein 2005;VanBuchem1997a;Varonen2003;Williamson
2007). Of these nine studies, five had more than one treatment
arm, and three compared several antibiotic courses to placebo
(penicillin V and amoxicillin (Lindbaek 1996; Lindbaek 1998);
amoxicillin, penicillin V, and doxycycline (Varonen 2003)).
Two studies compared an antibiotic course and/or corticos-
teroid spray to placebo (Meltzer 2005; Williamson 2007) Meltzer
2005 compared mometasone furoate nasal spray once daily only,
mometasone furoate nasal spray twice daily only, and amoxicillin
only. Williamson 2007 compared budesonide nasal spray only,
amoxicillin only, budesonide nasal spray and amoxicillin.
Norrelund 1978 compared pivampicillin to placebo; Kaiser 2001
compared azithromycin to placebo; Rantanen 1973 and Stalman
1997 compared doxycycline to placebo; and Bucher 2003 com-
pared amoxicillin/clavulanic acid to placebo. Axelsson 1970 com-
pared irrigation, phenoxymethylpenicillin and lincomycin to no
treatment.
Treatment arms without antibiotic treatment were excluded from
analyses (irrigation arm (44 participants) in Axelsson 1970;
mometasone furoate nasal spray once daily only (243participants),
mometasone furoate nasal spray twice daily (235 participants) in
Meltzer 2005).
All antibiotics were administered orally.
Co-interventions
Ten studies permitted nasal decongestants and analgesics (Bucher
2003; De Sutter 2002; Garbutt 2012; Kaiser 2001; Lindbaek
1996; Lindbaek 1998; Norrelund 1978; Stalman 1997; Van
Buchem 1997a; Varonen 2003). Meltzer 2005 did not permit use
of nasal decongestants. Six studies prescribed nasal decongestants
for all participants (Axelsson 1970; Bucher 2003; Garbutt 2012;
Norrelund 1978; Rantanen 1973; Van Buchem 1997a). Two stud-
ies did not describe use of nasal decongestants (Merenstein 2005;
Williamson 2007). Four studies did not describe use of analgesics
(Axelsson 1970; Merenstein 2005; Rantanen 1973; Williamson
2007). One study prescribed cough syrup (dextromethorphan hy-
drobromide or guaifenesin) for all participants (Garbutt 2012).
Outcomes
Primary outcome: cure
Definitions of cure and time of evaluation varied among trials
that used cure as primary outcome (Axelsson 1970; Bucher 2003;
De Sutter 2002; Kaiser 2001; Lindbaek 1996; Lindbaek 1998;
Merenstein 2005; Norrelund 1978; Rantanen 1973; Stalman
1997; Van Buchem 1997a; Varonen 2003; Williamson 2007).
This was reflected in variations in cure rates in placebo groups
(clinical diagnosis: 30% to 74%; diagnosis confirmed by imaging:
11% to 59%).
Clinically diagnosed rhinosinusitis
Eight trials defined cure or improvement as primary outcome
(Bucher 2003; De Sutter 2002; Kaiser 2001; Merenstein 2005;
Norrelund 1978; Stalman 1997; Varonen 2003; Williamson
2007). The common denominator of all definitions was the res-
olution or improvement of major symptoms, evaluated only by
the participant (Bucher 2003; De Sutter 2002; Merenstein 2005;
Varonen 2003; Williamson 2007), or by the participant and the
investigator (Kaiser 2001; Norrelund 1978; Stalman 1997).
The two remaining trials used change on a symptom score as the
main outcome measure: Garbutt 2012 used the mean change in
Sino-Nasal Outcome Test-16 score, a validated and responsive
measure, to assess the effect of treatment on disease-specific quality
of life at day 3, and Meltzer 2005 used the mean AM/PM major
symptom score (sumof scores for rhinorrhoea, postnasal drip, nasal
decongestion/stuffiness, sinus headache, and facial pain/pressure/
tenderness on palpation over the paranasal sinuses) over days 2 to
15 of the treatment phase as a primary outcome measure.
Rhinosinusitis confirmed by imaging
Six studies defined cure as primary outcome (Axelsson 1970;
Kaiser 2001 (subgroup of participants with radiologically con-
firmed maxillary sinusitis); Lindbaek 1996; Lindbaek 1998;
Rantanen 1973; Van Buchem 1997a). The common denominator
in all definitions was resolution or improvement of major symp-
toms, evaluated by the participant alone (Axelsson 1970; Lindbaek
1996; Lindbaek 1998; Van Buchem 1997a), or by the partici-
pant and the investigator (Kaiser 2001; Rantanen 1973). How-
ever, Rantanen 1973 evaluated sinus recovery rather than partici-
pants.
Secondary outcomes
Some trials provided information on effects on purulent secretion
(Bucher 2003; De Sutter 2002; Meltzer 2005; Norrelund 1978;
Stalman 1997), pain (De Sutter 2002; Meltzer 2005; Stalman
1997; Van Buchem 1997a; Williamson 2007), malaise (De Sutter
2002; Merenstein 2005; Van Buchem 1997a; Williamson 2007),
illness duration (Lindbaek 1996; Lindbaek 1998; Merenstein
2005; Norrelund 1978; Varonen 2003;Williamson 2007), restric-
tion of daily activities (Bucher 2003; De Sutter 2002; Garbutt
2012; Stalman 1997; Williamson 2007), intake of analgesics (De
Sutter 2002; Norrelund 1978; Stalman 1997; Varonen 2003), in-
take of nasal decongestants (Stalman 1997;Varonen 2003), side ef-
fects (Axelsson1970; Bucher 2003;DeSutter 2002;Garbutt 2012;
Kaiser 2001; Lindbaek 1996; Meltzer 2005; Merenstein 2005;
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Norrelund 1978; Stalman 1997; Van Buchem 1997a; Varonen
2003), clinical failure (Bucher 2003; De Sutter 2002; Garbutt
2012;Kaiser 2001; Lindbaek 1996; Lindbaek 1998;Meltzer 2005;
Stalman 1997; Van Buchem 1997a; Varonen 2003; Williamson
2007), and serious adverse events (Bucher 2003; Garbutt 2012;
Williamson 2007).
Seven studies collected laboratory samples (Bucher 2003; Kaiser
2001; Lindbaek 1996; Lindbaek 1998; Rantanen 1973; Van
Buchem 1997a; Varonen 2003). Four studies obtained nasopha-
ryngeal secretions for culture (Kaiser 2001; Lindbaek 1996;
Lindbaek 1998; Varonen 2003). Rantanen 1973 performed a si-
nus puncture. Two studies measured CRP, leukocytes and neu-
trophils (Bucher 2003; Van Buchem 1997a). Only Kaiser 2001
reported interaction between culture result, cure and treatment
group. Kaiser 2001 found that participants in the antibiotic group
with positive culture had lower symptom scores (P = 0.002) and
a higher rate of symptom resolution on day 7 (73% versus 47%;
P = 0.007) and a higher cure rate on day 8 (65% versus 41%; P =
0.032) compared to placebo group participants. There was no sig-
nificant difference in symptom resolution on day 7 in the culture-
negative group between antibiotic and placebo group participants
(63% versus 69%; P = 0.75).
See Characteristics of included studies.
Excluded studies
We had previously excluded five studies. Three RCTs included
participants with clinical symptoms of acute rhinosinusitis and
specific bacteriological criteria (Gananca 1973; Gananca 1977;
Hadley 2010). One excluded study had included participants
with clinical symptoms (maxillary pain) and raised values of ei-
ther C-reactive protein (CRP) or erythrocyte sedimentation rate
(ESR) (Hansen 2000a; Hanssen 2000b was a Danish translation
of Hansen 2000a). Haye 1998 was excluded because participants
with empyema (defined as complete opacity or an air-fluid level, or
amucosal thickness of 6mmormoremeasured at the upper lateral
border of the maxillary sinus) were withheld. See Characteristics
of excluded studies.
Risk of bias in included studies
’Risk of bias’ assessments are reported in Characteristics of
included studies and graphically presented in Figure 2 and Figure
3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The risk of selection bias was low in nine studies (Bucher 2003;
De Sutter 2002; Garbutt 2012; Lindbaek 1996; Lindbaek 1998;
Meltzer 2005;Merenstein 2005; Van Buchem 1997a; Williamson
2007), and unclear in four studies (Axelsson 1970; Kaiser 2001;
Norrelund 1978; Rantanen 1973; Stalman 1997; Varonen 2003).
Ten studies reported adequate allocation sequencing (Bucher
2003; De Sutter 2002; Garbutt 2012; Lindbaek 1996; Lindbaek
1998; Meltzer 2005; Merenstein 2005; Stalman 1997; Van
Buchem 1997a; Williamson 2007). Four studies used block ran-
domisation (Garbutt 2012; Merenstein 2005; Stalman 1997;
Williamson 2007); two used unrestricted randomisation (De
Sutter 2002; Van Buchem 1997a); and four studies combined
blocked and stratified randomisation (Bucher 2003; Lindbaek
1996; Lindbaek 1998; Meltzer 2005). Six studies used a comput-
erised random number generator (Bucher 2003; De Sutter 2002;
Garbutt 2012; Meltzer 2005; Merenstein 2005; Van Buchem
1997a; Stalman 1997). Lindbaek 1996 and Lindbaek 1998 used
dice. Williamson 2007 used random number tables to select the
blocks. Four studies presented insufficient information about the
sequence generation process to inform assessment (Axelsson 1970;
Kaiser 2001; Norrelund 1978; Varonen 2003). Axelsson 1970 and
Kaiser 2001 reported only random assignment. Two studies re-
ported using a block randomisation procedure but did not specify
the process to select blocks (Norrelund 1978; Varonen 2003).
Ten trials concealed allocation adequately (Bucher 2003;De Sutter
2002; Garbutt 2012; Lindbaek 1996; Lindbaek 1998; Meltzer
2005; Merenstein 2005; Van Buchem 1997a; Varonen 2003;
Williamson 2007). Four trials did not provide information on
methods used to blind participants and investigators enrolling
participants (Axelsson 1970; Norrelund 1978; Rantanen 1973;
Stalman1997).One study reported only that themedicationboxes
or envelopes were identical for drugs and placebo, but did not state
use of sequential numbering (Kaiser 2001).
Blinding
The risk of performance and detection bias was low in 12 stud-
ies (Bucher 2003; De Sutter 2002; Garbutt 2012; Kaiser 2001;
Lindbaek 1996; Lindbaek 1998; Meltzer 2005; Merenstein 2005;
Stalman 1997; Van Buchem 1997a; Varonen 2003; Williamson
2007), unclear in 2 studies (Norrelund 1978; Rantanen 1973),
and high in 1 study (Axelsson 1970).
Eleven trials blinded allocated intervention adequately (Bucher
2003; De Sutter 2002; Garbutt 2012; Kaiser 2001; Lindbaek
1996; Lindbaek 1998; Merenstein 2005; Stalman 1997; Van
Buchem 1997a; Varonen 2003; Williamson 2007). The inter-
vention and placebo tablets were identical in colour, shape, and
taste, and blinding of participants and investigators was assured
in these studies. Two studies indicated double-blinding, but did
not provide information about the blinding procedure (Norrelund
1978; Rantanen 1973). Meltzer 2005 did not provide precise in-
formation on how the randomisation result was concealed, but the
method of random sequence generation (computer-randomised
code) and information on double-dummy design gave the impres-
sion that concealment had been fulfilled (additional information
requested but not received from the trial authors). Axelsson 1970
did not mention blinding in the methods section, and close ex-
amination of the study design led us to strongly believe that there
was no blinding: placebo group participants did not take tablets,
only nose drops; it is not possible to blind sinus irrigation as an
intervention; only group 1 participants received radiological eval-
uation every second day; and group 2 participants took a longer
course of tablets than group 3. We therefore graded the risk of bias
for this domain as high for Axelsson 1970.
Incomplete outcome data
The risk of attrition bias was low in 13 studies (Axelsson 1970;
Bucher 2003; De Sutter 2002; Garbutt 2012; Kaiser 2001;
Lindbaek 1996; Lindbaek 1998; Merenstein 2005; Norrelund
1978; Stalman 1997; Van Buchem 1997a; Varonen 2003;
Williamson 2007), and unclear in 2 studies (Meltzer 2005;
Rantanen 1973).
The overall post-randomisation dropout rate was 5.1%. Rantanen
1973 did not report post-randomisation dropout rates.
The ratio of participants with missing data to participants with
events is a good marker of bias due to incomplete data (Higgins
2011a). In the 13 included studies with cure as the primary out-
come, the ratio ranged from 0.01 to 0.33 (Axelsson 1970; Bucher
2003; De Sutter 2002; Kaiser 2001; Lindbaek 1996; Lindbaek
1998; Merenstein 2005; Norrelund 1978; Stalman 1997; Van
Buchem 1997a; Varonen 2003; Williamson 2007). However, the
ratio was low (0.09) for Garbutt 2012, who reported “significant
improvement at day 10.” The risk of bias due to dropout was low
in these 13 studies. We could not calculate the ratio of participants
with missing data to participants with events for Meltzer 2005,
because the primary outcome was not cure, but a difference in
symptom scores. However, the post-randomisation dropout rate
was low (2.6% at day 15) in Meltzer 2005 and probably did not
cause bias.
Two studies performed sensitivity analyses. In De Sutter 2002 and
Williamson 2007, different scenarios did not reveal a significant
difference in cure rate between the intervention and control group.
Garbutt 2012 conducted a sensitivity analysis for participants who
completed the study drug and those with symptoms for seven days
or more and 28 days or less. Varonen 2003 imputed dropouts as
treatment failures.
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Ten studies followed the intention-to-treat (ITT) principle for
analysis of the main outcome (Bucher 2003; De Sutter 2002;
Garbutt 2012; Lindbaek 1996; Lindbaek 1998; Meltzer 2005;
Merenstein 2005; Stalman 1997; Van Buchem 1997a; Varonen
2003). Four trials included only participants with complete
outcome data (Axelsson 1970; Kaiser 2001; Norrelund 1978;
Williamson 2007).
Selective reporting
The risk of reporting bias was low in 12 studies (Bucher 2003;
De Sutter 2002; Garbutt 2012; Kaiser 2001; Lindbaek 1996;
Lindbaek 1998;Merenstein 2005; Rantanen 1973; Stalman 1997;
Van Buchem 1997a; Varonen 2003; Williamson 2007), and un-
clear in 3 studies (Axelsson 1970;Meltzer 2005; Norrelund 1978).
Twelve studies predefined primary and secondary endpoints
(Bucher 2003; De Sutter 2002; Garbutt 2012; Kaiser 2001;
Lindbaek 1996; Lindbaek 1998; Meltzer 2005; Merenstein 2005;
Rantanen 1973; Stalman 1997; Varonen 2003;Williamson 2007).
Definitions of primary outcomes were unclear in two studies
(Axelsson 1970; Norrelund 1978). Norrelund 1978 predefined
symptoms, side effects, and medication intake that were to be
recorded, but provided the definition of cure for the first time
in the results section of the report. Meltzer 2005 reported most
outcomes of interest incompletely; data could not be pooled with
other trials. Young 2008 performed an individual participant data
meta-analysis and had the results of an unpublished Schering-
Plough trial. This trial had the same design as Meltzer 2005, but
had a lower odds ratio. This could suggest selective reporting in
Meltzer 2005.
Other potential sources of bias
The risk of other potential sources of bias was low in 12 stud-
ies (Bucher 2003; De Sutter 2002; Garbutt 2012; Kaiser 2001;
Lindbaek 1996; Lindbaek 1998; Meltzer 2005; Merenstein 2005;
Norrelund 1978; Stalman 1997; Varonen 2003; Williamson
2007), and unclear in 3 studies (Axelsson 1970; Rantanen 1973;
Van Buchem 1997a).
No included studies contained design-specific risks of bias or were
stopped early. Two studies had small, unimportant imbalances
of baseline participant characteristics (Stalman 1997; Williamson
2007). Rantanen 1973 did not describe participants’ characteris-
tics at baseline, and Axelsson 1970 provided only limited informa-
tion about these characteristics. One blinded trial broke blinding
12 times due to side effects (3 participants) or clinical failure (9
participants) (Lindbaek 1996). Following the ITT principle, these
participants were included in the analyses in the groups to which
they were originally randomised (Lindbaek 1996). Van Buchem
1997a possibly selected participants with worse symptoms, since
only 20% of participants with possible maxillary sinusitis entered
the trial.
Study protocols for participants in intervention and placebo
groups were similar. There was a low risk of bias due to increased
or different diagnostic activity.
Seven studies were financially supported by government or aca-
demic institutions (Garbutt 2012; Lindbaek 1996; Lindbaek
1998; Merenstein 2005; Stalman 1997; Varonen 2003;
Williamson 2007). Researchers in six studies received grants from
pharmaceutical industry sources (Bucher 2003; De Sutter 2002;
Meltzer 2005; Stalman 1997; Varonen 2003; Williamson 2007).
Five studies did not state sources of support (Axelsson 1970; Kaiser
2001; Norrelund 1978; Rantanen 1973; Van Buchem 1997a).
More than 276 practices recruited participants. Two trials re-
cruited participants fromone site (Kaiser 2001;Merenstein 2005).
Eight trials recruited participants from multiple sites, with an av-
erage of 9.9 participants per practice (range 3.6 to 15.8, 25th per-
centile = 6.5, 75th percentile = 15.5) (Bucher 2003; De Sutter
2002; Garbutt 2012; Meltzer 2005; Norrelund 1978; Stalman
1997; Varonen 2003; Williamson 2007). The number of partic-
ipating practices was not reported in five trials (Axelsson 1970;
Lindbaek 1996; Lindbaek 1998; Rantanen 1973; Van Buchem
1997a).
Effects of interventions
See: Summary of findings for the main comparison Antibiotics
compared to placebo for acute rhinosinusitis in adults
Primary outcome
1. Cure
Without antibiotics, 46% of participants with rhinosinusitis,
whether or not confirmed by radiography, were cured after one
week (Bucher 2003; Kaiser 2001; Norrelund 1978; Williamson
2007), and 64% after 14 days (Bucher 2003; Merenstein 2005;
Van Buchem 1997a; Varonen 2003; Williamson 2007).
1.1 Clinically diagnosed rhinosinusitis
The ITT population included 2450 participants (10 trials). We
analysed data from1687 participants (69%).We excludedMeltzer
2005 (499 participants) and Garbutt 2012 (166 participants) be-
cause the proportion of participants cured at a specific time point
was not reported as cure was not their main outcome measure.
Stalman 1997 reported only the total cure rate for both groups
and stated there was no difference between groups. We used the
same percentages in both groups for pooling.
Despite choices made by some trial authors, we considered par-
ticipants who started other antibiotics as treatment failures, not
dropouts. The total dropout rate was 5.3%.
Almost half (47%) of participants were cured after one week (
Bucher 2003; Kaiser 2001; Norrelund 1978; Williamson 2007),
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51% after 10 days (De Sutter 2002; Stalman 1997; Williamson
2007), and 71% after 14 days (Bucher 2003; Merenstein 2005;
Varonen 2003;Williamson 2007), irrespective of treatment group.
The estimated odds ratio (OR) for the overall treatment effect of
antibiotics relative to placebo was 1.25 (95% confidence interval
(CI) 1.02 to 1.54; number needed to treat for an additional ben-
eficial outcome (NNTB) 19, 95% CI 10 to 205; I² = 0%; high-
quality evidence; Analysis 1.1.1; Figure 4).
Figure 4. Forest plot of comparison: 1 Antibiotics versus placebo in acute rhinosinusitis, outcome: 1.1 Cure.
We categorised studies into three groups: cure assessed at one week
(Bucher 2003; Kaiser 2001; Norrelund 1978; Williamson 2007);
cure assessed at around day 10 (De Sutter 2002; Stalman 1997;
Williamson 2007); and cure assessed at day 14 (Bucher 2003;
Merenstein 2005; Varonen 2003;Williamson 2007). Heterogene-
ity among studies was very low (0% at 1 week and 10 days; 6% at
14 days).
There were no significant differences between treatment groups:
after one week, the OR for cure was 1.07 (95% CI 0.81 to 1.41;
Analysis 3.1.1); after 10 days OR for cure was 1.19 (95% CI
0.92 to 1.53; Analysis 3.1.2); and after 14 days OR for cure was
1.37 (95% CI 0.98 to 1.91; Analysis 3.1.3). Meltzer 2005 did
not find any difference in symptom score between the antibiotic
and placebo groups at day 15, so we assumed that adding data
from this study would not change our overall result. Garbutt 2012
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found a significant difference in symptom score at day 7, favouring
amoxicillin (mean difference (MD) 0.19, 95% CI 0.02 to 0.35).
This study also provided data about “significantly improved” par-
ticipants. Including these data (Analysis 3.1.4 and Analysis 3.1.5)
did not substantially change the overall result.
We used three methods to impute data to assess the influence
of missing data on the overall results: assuming the outcomes of
participants for whom no outcome was recorded as cured; not
cured; or according to the cure rate observed in the control group.
Twelve analyses revealed no clear differences for the baseline anal-
yses (Analysis 3.1.6 to Analysis 3.1.17).
Excluding studies that included ITT analyses removed antibiotic
benefit (OR 1.06, 95% CI 0.76 to 1.47) (Bucher 2003; De Sutter
2002; Merenstein 2005; Stalman 1997; Varonen 2003). Pooling
studies with ITT analyses confirmed benefit of antibiotics (OR
1.39, 95% CI 1.07 to 1.79).
Pooling studies in which participants declared themselves as cured
endorsed the benefit of antibiotics (OR 1.40, 95% CI 1.08 to
1.82) (Bucher 2003; De Sutter 2002; Merenstein 2005; Varonen
2003;Williamson 2007). Pooling studies inwhich the investigator
decided if the participant was cured showed no benefit of antibi-
otics (OR 1.05, 95% CI 0.76 to 1.46) (Kaiser 2001; Norrelund
1978; Stalman 1997).
Studies that included only participants with pus on rhinoscopy
revealed no benefits with antibiotics (OR 1.07, 95% CI 0.74 to
1.56) (Bucher 2003; Kaiser 2001).
1.2 Rhinosinusitis confirmed by imaging
The ITT population included 713 participants, and we analysed
data from 652 participants (91.4%). We excluded 61 participants
from the Rantanen 1973 study because the primary outcome was
sinus recovery progress instead of cure.
Four trials included participants on the basis of clinical signs and
symptoms (Bucher 2003; De Sutter 2002; Kaiser 2001; Varonen
2003); radiographs were taken, but only one study used images to
assess cure rates (Kaiser 2001). All participants underwent sinus
ultrasound in Varonen 2003. The impact of ultrasound result cure
rates was not reported.
We considered participants who started other antibiotics as treat-
ment failures, not dropouts. The total dropout rate was 4.3%.
Rantanen 1973 did not report post-randomisation dropout rates.
Cure was evaluated at day 8 (Kaiser 2001), day 10 (Axelsson 1970;
Lindbaek 1996; Lindbaek 1998), or day 14 (Van Buchem 1997a).
The estimated OR for the overall treatment effect of antibiotics
relative to placebo was 1.71 (95%CI 1.20 to 2.45; NNTB 8, 95%
CI 5 to 23; I² = 41%; Analysis 3.2.1). Heterogeneity was high,
so we looked for outliers and split analyses for participants with
rhinosinusitis confirmed by radiography or CT.
However, treatment effects among those who underwent CT dif-
fered significantly from effects in participants selected by radiog-
raphy. Pooling these data was therefore not possible, and analyses
were performed separately.
Three studies used radiography to confirm maxillary sinusitis (
Axelsson 1970; Kaiser 2001; Van Buchem 1997a). The estimated
OR was 1.57 (95% CI 1.03 to 2.39; NNTB 10, 95% CI 5 to
136; I² = 0%; moderate-quality evidence; Analysis 1.1.2; Figure
4). Omitting Axelsson 1970, which was assessed as at high risk of
bias due to lack of blinding, did not have a significant impact on
this result (OR 1.67, 95% CI 1.04 to 2.70, NNBT 9, 95%CI 5
to 104).
Lindbaek 1996 and Lindbaek 1998 reported on two distinct par-
ticipant groups who underwent CT examination: those with fluid
level or total opacification in any sinus on CT, and those with
mucosal thickening on CT. The effect of antibiotics relative to
placebo was only significant in the group with fluid level or total
opacification in any sinus on CT (Lindbaek 1996: estimated OR
4.89, 95% CI 1.75 to 13.72; NNTB 4, 95% CI 2 to 15; moder-
ate-quality evidence; Analysis 1.1.3; Figure 4; ) (Lindbaek 1998:
estimated OR 0.74, 95% CI 0.25 to 2.16).
Four studies reported on cure or improvement (Axelsson 1970;
Lindbaek 1996; Lindbaek 1998; Van Buchem 1997a). The es-
timated OR for overall treatment effect of antibiotics relative to
placebo was 2.08 (95% CI 1.35 to 3.21; NNTB 8, 95% CI 6
to 18; I² = 33%; Analysis 3.2.2). Heterogeneity was high. Stud-
ies that used radiography to confirm maxillary sinusitis indicated
no difference in improvement rates between participants who re-
ceived antibiotics versus those who received placebo (estimated
OR 1.59, 95% CI 0.90 to 2.80; I² = 0%, NNTB 9, 95% CI 5
to 40) (Axelsson 1970; Van Buchem 1997a). The effect of antibi-
otics relative to placebo on ’improvement’ was significant only in
participants with fluid level or total opacification in any sinus on
CT (Lindbaek 1996: estimated OR 4.5, 95% CI 1.91 to 10.57;
NNTB 4, 95% CI 3 to 7) (Lindbaek 1998: estimated OR 1.60,
95% CI 0.51 to 5.06).
Secondary outcomes
1. Ratings of measures of overall well-being
Three studies investigated whether participants’ general feeling
of illness improved faster with antibiotics (De Sutter 2002;
Merenstein 2005; Van Buchem 1997a). It was not possible to pool
data for meta-analysis because De Sutter 2002 used data from a
diary, Merenstein 2005 compared Likert scores at different time
points, and Van Buchem 1997a looked at differences in symptom
scores for “sickness” after one and two weeks. Only Van Buchem
1997a found a marginal but significant difference in symptom
score for sickness after two weeks evaluated by the investigator
(mean change 1.2 for placebo versus 0.8 for antibiotics, “P < 0.05”
reported by Van Buchem 1997a). This finding did not persist
when the degree of sickness was evaluated by the participant.
Williamson 2007 found no significant interaction between base-
line severity (feeling unwell and level of daily activity restriction)
and treatment group (antibiotic versus placebo).
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2. Severity or duration of different clinical symptoms
2.1. Resolution of purulent secretion
Five studies reported outcome data for purulent secretion (De
Sutter 2002; Meltzer 2005; Norrelund 1978; Stalman 1997; Van
Buchem 1997a). We extracted data from one study on day 8
(Norrelund 1978), and two studies on day 10 (De Sutter 2002;
Stalman 1997). De Sutter 2002 provided data upon request.
Meltzer 2005 published only least-square means data. Outcomes
were reported by participants in two studies (De Sutter 2002;
Meltzer 2005), the investigator in two studies (Norrelund 1978;
Stalman 1997), and by both participants and investigators in one
study (Van Buchem 1997a).
The estimated OR for resolution of purulent secretion was 1.58,
irrespective of endpoint timing (95% CI 1.13 to 2.22; NNTB 10,
95% CI 6 to 35; I² = 0%; high-quality evidence; Analysis 2.1).
We could not pool some data on purulent secretion. Norrelund
1978 found that 75% of participants in the antibiotic group and
56% in the placebo group had at least 50% reduction in secretion
on day 8 (OR 2.29, 95% CI 1.11 to 4.74; NNTB 6, 95% CI 4
to 40; P = 0.002). Furthermore, De Sutter 2002 found a signif-
icant mean change in mean score on the symptom “thick nasal
discharge” between baseline and 10-day follow-up (P ≤ 0.001).
These results were confirmed by Meltzer 2005, who found a sig-
nificant difference in least-square means for rhinorrhoea between
days 2 and 15 (P ≤ 0.01). Van Buchem 1997a found a signifi-
cant difference in symptom score for secretion at the right side
after one week (reported by the participant) (mean change 1.0
for placebo versus 1.2 for antibiotics, “P < 0.05” reported by Van
Buchem 1997a), but this difference disappeared after two weeks.
Evaluation of secretion at clinical examination did not confirm
this finding.
2.2. Resolution of pain
Five studies provided outcome data for pain (De Sutter 2002;
Meltzer 2005; Stalman 1997; Van Buchem 1997a; Williamson
2007). Unfortunately, as the outcome measures were too different
and raw data were not available, pooling of data was not possible.
Considering pain in general, no study found a difference in pain
duration between the antibiotic and placebo groups (De Sutter
2002; Stalman 1997; Williamson 2007). Full resolution of pain
occurred between day 4 and day 7 in most participants. Also,
when considering specific types of pain such as unilateral facial
pain (De Sutter 2002), pain on bending forward (De Sutter 2002;
Stalman 1997), pain in upper teeth or when chewing (De Sutter
2002; Stalman 1997), facial pain, pressure, or tenderness (De
Sutter 2002; Meltzer 2005), and sinus headache (De Sutter 2002;
Meltzer 2005), none of the trials detected a significant difference
in pain duration when comparing antibiotic and placebo groups.
Evaluating differences in symptom scores, Van Buchem 1997a
found no differences after one and two weeks for frontal pain,
maxillary pain, headache on bending, or tapping pain.
2.3. Illness duration
Five studies calculated the mean illness duration (Kaiser 2001;
Lindbaek 1996; Lindbaek 1998;Norrelund1978; Varonen 2003).
All studies compared illness duration between antibiotic and
placebo groups. We could not pool the data because the standard
deviations were not available. Kaiser 2001 reported the mean ill-
ness duration for participants with or without Streptococcus pneu-
moniae,Haemophilus influenzae, orMoraxella catarrhalis in their na-
sopharyngeal secretions (with bacteria: five days in the azithromy-
cin group versus seven days in the placebo group; without bacteria:
six days in the azithromycin group versus six days in the placebo
group), but not for the total group. Norrelund 1978 found a sub-
jective improvement after an average of 3.5 days in the antibiotic
group compared with 3.7 days in the placebo group. They did not
mention if this was a significant difference, but we can assume that
it was not. Varonen 2003 also did not find a significant difference:
the mean illness duration in participants taking antibiotics was
6.0 days, compared with 6.4 days in the placebo group (P = 0.66).
Lindbaek 1996 found that participants with a fluid level or total
opacification in any sinus on CT were cured seven days faster with
antibiotic treatment than without (median time of the sinusitis
episode: nine days in the amoxicillin group, 11 days in the peni-
cillin group, and 17 days in the placebo group). Participants with
only mucosal thickening on CT showed no significant difference
in illness duration across the intervention groups (median time
of the sinusitis episode: 10 days in the placebo and amoxicillin
groups and 13.5 days in the placebo group) (Lindbaek 1998).
2.4. Restriction of daily activities
Four studies collected data on the restriction of daily activities
due to rhinosinusitis (Bucher 2003; De Sutter 2002; Garbutt
2012; Stalman 1997). Pooling of data was not possible because the
outcome measures were too different. None of the studies found a
significant difference in activity restriction between the antibiotic
and placebo groups.
Williamson 2007 found no significant interaction between base-
line severity (feeling unwell and level of restriction on daily activ-
ity) and treatment group (antibiotic versus placebo).
3. Use of concomitant medications
3.1. Analgesics
Ten studies allowed the use of analgesics, that is paracetamol, in
Bucher 2003, De Sutter 2002, Garbutt 2012, Lindbaek 1996,
Lindbaek 1998, Norrelund 1978, Stalman 1997, Van Buchem
1997a, and Varonen 2003, and/or ibuprofen, in De Sutter 2002,
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Kaiser 2001, Norrelund 1978, and Varonen 2003. Five of these
studies also recorded the use of analgesics (De Sutter 2002;Garbutt
2012; Norrelund 1978; Stalman 1997; Varonen 2003). It was not
possible to pool the data because the raw data were not available
or the outcome measures were too different. There was no effect
of antibiotics on the use of analgesics in four studies (De Sutter
2002; Garbutt 2012; Norrelund 1978; Stalman 1997). Varonen
2003 revealed that participants receiving placebo used analgesics
more often than those receiving antibiotics (43% in the placebo
group and 26% in the antibiotic group, P = 0.03).
3.2. Nasal decongestants
Eleven studies allowed the use of xylometazoline nose drops
(Axelsson 1970; Bucher 2003; De Sutter 2002; Kaiser 2001;
Lindbaek 1996; Lindbaek 1998; Norrelund 1978; Rantanen
1973; Stalman 1997; Van Buchem 1997a; Varonen 2003).
Six studies prescribed nasal decongestants for every participant
(Axelsson 1970; Bucher 2003; Garbutt 2012; Norrelund 1978;
Rantanen 1973; Van Buchem 1997a). Garbutt 2012 permitted
the use of pseudoephedrine-sustained action.Merenstein 2005 did
not mention if nose drops were permitted. Corticosteroid nose
drops were part of the intervention in two studies (Meltzer 2005;
Williamson 2007). Meltzer 2005 explicitly stated that use of con-
comitant medication that could interfere with the study medica-
tion was not permitted.
Only two studies registered intake of nose drops (vasoconstrictors),
Stalman 1997 and Varonen 2003, and antihistamines, Varonen
2003. Pooling of data was not possible because the outcome mea-
sures were too dissimilar. Neither study found a significant differ-
ence between groups in use of these medications. Garbutt 2012
found no difference between groups in use of pseudoephedrine-
sustained action.
4. Side effects
The side effects described in the trials were nausea, vomiting, ab-
dominal pain, stomach pain, diarrhoea, skin rash, dizziness, fa-
tigue, hot flushes, jittery feeling, dry mouth, headache, epistaxis,
and vaginal discharge or pruritus. The most common side effects
were gastrointestinal.
We pooled data from 10 trials on side effects in general (Axelsson
1970; De Sutter 2002; Garbutt 2012; Kaiser 2001; Lindbaek
1996; Merenstein 2005; Norrelund 1978; Stalman 1997; Van
Buchem 1997a; Varonen 2003). De Sutter 2002 reported only
data about diarrhoea. We did not add data from Lindbaek 1998
because the only side effects reported in this study were those that
caused participants to stop their study medication. Of the partic-
ipants who experienced side effects, 68.3% received antibiotics.
This difference was statistically significant (OR2.21, 95%CI 1.74
to 2.82; number needed to treat for an additional harmful out-
come (NNTH) 8, 95% CI 6 to 12; I² = 16%; high-quality evi-
dence; Analysis 2.2; Figure 5).
Figure 5. Forest plot of comparison: 2 Antibiotics versus placebo in acute rhinosinusitis whether or not
confirmed by imaging, outcome: 2.2 Side effects: general.
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More specifically, we could pool data on diarrhoea from seven
trials (Axelsson 1970; De Sutter 2002; Garbutt 2012; Lindbaek
1996; Merenstein 2005; Stalman 1997; Varonen 2003). Garbutt
2012 reported only the percentage of diarrhoea for both groups
and stated there was no difference between groups. We used the
same percentages in both groups for pooling.
Of participants who received antibiotics, 16.7% reported diar-
rhoea, versus 9.6% of participants who received placebo. This re-
sult was statistically significant (Peto OR 2.00, 95% CI 1.41 to
2.85); NNTH 13, 95% CI 8 to 29; I² = 20%; high-quality ev-
idence; Analysis 2.3). We could not pool the results of Bucher
2003 because the raw data were not available, but their results
were consistent with ours (OR 3.89, 95% CI 2.09 to 7.25 at day
7; OR 1.71, 95% CI 0.91 to 3.23 at 14 days).
Meltzer 2005 only mentioned that there were no differences in
treatment-emergent side effects among the treatment groups. In
that trial, five participants in the amoxicillin group and six in
the placebo group discontinued treatment because of side effects.
Williamson 2007 and Rantanen 1973 did not provide any infor-
mation for this outcome.
5. Clinical failure
We pooled data on clinical failure from 12 trials (Axelsson 1970;
Bucher 2003; De Sutter 2002; Garbutt 2012; Kaiser 2001;
Lindbaek 1996; Lindbaek 1998; Meltzer 2005; Stalman 1997;
Van Buchem 1997a; Varonen 2003; Williamson 2007). In eight
trials, clinical failure was assessed as an abnormal course of rhinos-
inusitis (exacerbation, ongoing symptoms, respiratory complica-
tions, treatment failure) leading to commence or extend antibiotic
therapy. The number of treatment failures in the control and active
treatment groups were compared (Bucher 2003; De Sutter 2002;
Garbutt 2012; Kaiser 2001; Lindbaek 1996; Lindbaek 1998; Van
Buchem 1997a; Varonen 2003). Axelsson 1970 reported numbers
of participants who deteriorated at day 5 and 10. Meltzer 2005
and Stalman 1997 reported numbers of participants who met the
criteria for treatment failure, but did not report whether these were
prescribed open antibiotic therapy.Williamson 2007 reported the
number of participants that withdrewbecause of treatment failure.
The pooled result showed that clinical failure occurred less fre-
quently in participants receiving antibiotics compared to placebo
(6.1% versus 11.2%, PetoOR0.48, 95%CI 0.36 to 0.63; NNTH
19, 95% CI 15 to 27; I² = 21%; high-quality evidence; Analysis
2.4; Figure 6).
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Figure 6. Forest plot of comparison: 2 Antibiotics versus placebo in acute rhinosinusitis: secondary
outcomes, outcome: 2.4 Clinical failure.
6. Serious adverse events
Only one serious disease-related adverse event occurred in the
placebo group (Bucher 2003): after two weeks of symptomatic
treatment, a participant who was treated for one week with amox-
icillin-clavulanate (1 g twice daily, open antibiotic therapy) expe-
rienced a brain abscess caused by an amoxicillin-clavulanate-sen-
sitive strain of Streptococcus milleri. The participant was operated
on and recovered but was reported to have a residual frontal syn-
drome.
There were two additional serious adverse events in the placebo
group: onemyocardial infarction andone severe depressive episode
(Bucher 2003). Both were thought to be neither disease nor drug
related. Other trials did not report any serious adverse events,
which means that serious complications in participants with clin-
ically diagnosed acute rhinosinusitis are rare.
D I S C U S S I O N
Summary of main results
The intention-to-treat (ITT) population included 3057 partici-
pants (15 trials). Without treatment, almost half of participants
with acute rhinosinusitis, whether or not confirmed by radiog-
raphy, recovered within one week, and two of three participants
within 14 days. Antibiotics may slightly shorten the time to cure,
but only 5 (diagnosis based on symptoms, range 1 to 10) to 11
(diagnosis confirmed by x-ray, range 1 to 21) more participants
per 100 would achieve cure faster by taking antibiotics instead
of placebo. When a fluid level or total opacification was present
on computed tomography (CT), 28 more participants per 100
(range 7 to 53) achieved cure faster with antibiotics. Antibiotics
do not reduce the time to pain relief or the general feeling of ill-
ness. People who take antibiotics do not resume daily activities
earlier and do not take less analgesics or nasal decongestants than
people treated with placebo. In people with purulent rhinorrhoea,
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10 more people per 100 (range 3 to 17) would experience a faster
resolution of nasal discharge by taking antibiotics. However, we
found that 13 more people per 100 (range 9 to 18) would expe-
rience side effects of the treatment. This potential harm needs to
be compared to the possible benefit of people with purulent rhin-
orrhoea taking antibiotics. Five fewer people per 100 (range 3 to
7) would experience clinical failure if they took antibiotics instead
of placebo (Summary of findings for the main comparison). This
review did not investigate the effect of antibiotics in people with
proven positive bacterial sinus cultures.
Overall completeness and applicability of
evidence
We investigated if antibiotic therapy could speed up the recovery
process in people with acute rhinosinusitis, whether clinically di-
agnosed or confirmed by imaging. The main symptoms used for
participant inclusion among the included studies were the pres-
ence of nasal discharge, facial pain, and a common cold or upper
respiratory tract infection. This is in line with the clinical presen-
tation of rhinosinusitis in patients in ambulatory care settings. We
included studies where participant inclusion depended on clinical
symptoms and abnormalities on radiography or CT. The reason
for this was that in some countries, imaging is used to confirm
diagnosis of rhinosinusitis. Based on included study populations,
we are reasonably confident that this review covers the general
population of people with rhinosinusitis-like symptoms.We could
draw no conclusions about the efficacy of antibiotics in children,
people with suppressed immune systems, or those with serious dis-
eases (e.g. very high fever, prolonged symptoms, septic symptoms
such as tachycardia, sweating, and low blood pressure) and people
referred to an ear, nose, and throat specialist because of the serious
course of the disease or fear of complications, since trials did not
include these groups of patients, and it is unlikely that they will
be included in future placebo-controlled trials.
Quality of the evidence
We used GRADEpro GDT 2015 to assess evidence quality for
each outcome (Summary of findings for the main comparison).
We assessed high-quality evidence for the followingoutcomes: cure
in adults with clinically diagnosed acute rhinosinusitis; severity or
duration of different clinical symptoms - resolution of purulent
secretion; general side effects; side effects relating to diarrhoea;
and clinical failure. We assessed moderate-quality evidence for
cure in adults with acute rhinosinusitis confirmed by radiography,
downgrading the quality of the evidence due to few trials reporting
this outcome (n = 3) and wide confidence intervals. It is unlikely
that participants in Axelsson 1970 were blinded: the study report
not provide any information about blinding and give the study
design, it is highly likely that “treatment” was compared to “no
treatment”. Therefore we assessed this study as at high risk of bias
for this domain. Nevertheless, omitting the results of Axelsson
1970 did not substantially changed the odds ratios (OR1.67, 95%
CI 1.04 to 2.70, NNTB 9, 95%CI 5 to 104). For this reason, we
did not further downgrade evidence quality for this outcome.
Only one study with few participants (N = 127) reported cure
in adults with acute rhinosinusitis confirmed by CT (Lindbaek
1996). Although this was a robust trial, we downgraded the quality
of the evidence to moderate because of the limited number of
participants.
All but three included studies reported on the main review
outcome of rhinosinusitis cure (Garbutt 2012; Meltzer 2005;
Rantanen 1973). The analyses show a consistent result.
Potential biases in the review process
We carried out thorough searches in several different databases on
18 January 2018. We used a predefined selection procedure for
including and excluding studies and followed this strategy consis-
tently. We documented reasons for exclusion. We predefined the
research questions and answered them in the same sequence.
We assessed the included studies and summarised information in
the Characteristics of included studies table. We assessed risk of
bias rigorously. It is possible we evaluated three studies as poor
undeservedly, but this does not mean that the studies were per-
formed incorrectly (Rantanen 1973; Meltzer 2005; Norrelund
1978); rather, we evaluated them as unclear risk of bias due to
insufficient information reported in the articles.
Some studies did not report raw data. In such cases, we estimated
numbers of events by multiplying the percentage with the total
number of participants in the group to make pooling of results
possible. Stalman 1997 reported only the total cure rate for both
groups and stated there was no difference between groups. We
used the same percentages in both groups for pooling. This as-
sumption could be imprecise; however, omitting these data did
not substantially change odds ratios. Young 2008 performed a
meta-analysis on clinically diagnosed acute rhinosinusitis using
individual patient data meta-analysis (IPDMA). Young 2008 had
raw data from Stalman 1997 at his disposal, and reported that the
exact cure rate was 63% in the placebo group and 66% in the
antibiotic group when the primary outcome was assessed. Using
these cure rates in our analysis did not substantially change odds
ratios (OR 1.27, 95% CI 1.04 to 1.56; number needed to treat
for an additional beneficial outcome (NNTB) 18, 95% CI 10 to
104; Analysis 3.1.18). Garbutt 2012 reported only the percentage
of diarrhoea for both groups and stated there was no difference
between groups. We used the same percentages in both groups
for pooling. Omitting these data from the analyses did not sub-
stantially change the odds ratios (OR 2.19, 95% CI 1.51 to 3.18;
NNTB 11, 95% CI 7 to 24).
Definitions of cure varied among trials, and this raised questions
about the comparability of studies; however, the underlying in-
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terpretation of cure was similar. As well as calculating the overall
treatment effect, we divided the studies into three groups (cure at
one week, 10 days, and 14 days) to assess the effect at various time
points.
For the primary outcome of cure, we checked if inputting missing
data in three different ways changed the overall result (Analysis
3.1.6 to Analysis 3.1.17).
For the secondary outcome, resolution of purulent secretion, data
were collected once by the participant, and once by the clinician
(inspection). Due to the low number of studies, we did not take
this into account.
There was important variation in choices of antibiotics and dosage
schedules. This may be due to differences in antibiotic resistance
at different time points and in different countries. We assumed
that the trial authors’ choice of antibiotics was suitable for their
countries and local resistance patterns at that point in time, and
that this did not influence the effect of the antibiotic treatment
on cure rates. However, since the trials did not perform bacterial
cultures, we cannot prove this.
As we considered only studies that included adults without bacte-
riological cultures, the proportion of adults with bacterial rhinos-
inusitis is unknown. However, as described, we wanted to focus
on adults who visited general practitioners with acute rhinosinusi-
tis symptoms and who are treated empirically, with or without
imaging. This review answers the important clinical question of
whether these people should be treated with antibiotics or not.
Agreements and disagreements with other
studies or reviews
We compared our meta-analysis results with those from Rosenfeld
2007, Young 2008, Falagas 2008, Fokkens 2012, and Burgstaller
2016.
Rosenfeld 2007 included trials based on a clinical diagnosis, as well
as trials that used technical investigations to establish the diagnosis
(Gananca 1973 (bacteriology); Hansen 2000a (elevated CRP or
ESR); Haye 1998 (radiography); Lindbaek 1996 (CT); Lindbaek
1998 (CT);VanBuchem1997a (radiography). Rosenfeld 2007 ex-
cluded Norrelund 1978 because of a language barrier. Williamson
2007 and Garbutt 2012 were not yet published. This study group
found a modest antibiotic benefit for people with uncomplicated
acute rhinosinusitis 7 to 12 days after entering a clinical trial (ab-
solute risk difference 0.15, 95% CI 0.04 to 0.25; risk ratio 1.28, P
= 0.007; NNTB 7), based on data from Bucher 2003, De Sutter
2002, Gananca 1973, Hansen 2000a, Haye 1998, Kaiser 2001,
Lindbaek 1996, Lindbaek 1998, and Stalman 1997. However,
there was a high level of heterogeneity (I² = 80%). The forest
plot shows that the benefit of antibiotics is higher in studies with
an inclusion based on specific technical investigations (bacteriol-
ogy, diagnostic algorithm, including CRP, CT; (NNTB 3)). The
risk difference of studies that enrolled participants with a nega-
tive imaging or based strictly on clinical criteria was 0.03 (95%
CI -0.02 to 0.08; NNTB 12.5 to 50). This is in accordance with
our results. At 14 to 15 days, there was no longer any statistical
benefit (results based on data from Bucher 2003; Meltzer 2005;
Merenstein 2005; Van Buchem 1997a). Benefits were offset by a
relative increase of 83% in adverse events (number needed to treat
for an additional harmful outcome (NNTH) 9), which is similar
to our calculations.
Young 2008 performed a IPDMA on clinically diagnosed acute
rhinosinusitis. An IPDMA is the best way of performing subgroup
analyses given that individual patient data from a number of RCTs
can be obtained. As well as investigating the effect of antibiotics
in the total group, the authors were able to investigate the ef-
fect of antibiotics in subgroups, such as people with at least seven
days of rhinosinusitis-like symptoms, as guidelines advocate pre-
scribing antibiotics for this patient group (Hickner 2001). Young
2008 completed this IPDMA by further analysis of the effect of
antibiotics in people with specific signs and symptoms, with the
aim of identifying people who benefit most from antibiotic ther-
apy. Young 2008 included the same trials, except for Norrelund
1978, because they could not get the raw data for the IPDMA,
and Garbutt 2012 because this trial was not yet published.Young
2008 included the raw data of Meltzer 2005 and of an identical
unpublished trial run by Schering-Plough. The estimated OR for
the overall treatment effect of antibiotics relative to placebo was
1.37 (95% CI 1.13 to 1.66; NNTB 15, 95% CI 7 to 190, data
IPDMA). The ORs of analyses of aggregated data of Young 2008
were similar (OR 1.35, 95%CI 1.15 to 1.59). This OR for overall
treatment effect in clinically diagnosed rhinosinusitis is slightly
higher than in this review, probably due to the favourable results
of Meltzer 2005. Young 2008 found that older people and peo-
ple reporting severe symptoms or longer duration of symptoms
(six days or more) took longer to cure but were no more likely
to benefit from treatment than other people. For other patient-
reported symptoms (previous common cold or two stages of ill-
ness, pain on bending, unilateral facial pain, pain in the teeth, and
purulent nasal discharge), estimates were not sufficiently precise
to draw any conclusion about their prognostic value. Participants
with purulent discharge in the pharynx, ascertained by a physi-
cian, seemed to cure more slowly and to have some non-significant
benefits from antibiotics (OR 1.60, 95% CI 0.95 to 2.76; NNTB
8, 95% CI 4 to 47). The same was found for people with a higher
temperature (OR 1.28, 95% CI 0.87 to 1.88). As we did not have
the raw data, we could not perform this subgroup analyses. Young
2008 did not investigate adverse events.
Falagas 2008 included trials in adults or children based on clini-
cal diagnosis and/or specific technical investigations (extra trials:
Gananca 1973 (bacteriology); Garbutt 2001 (children); Hansen
2000a (elevated CRP or ESR); Haye 1998 (radiography); Kristo
2005 (children); Lindbaek 1996 (CT); Lindbaek 1998 (CT);Wald
1986 (children)).Falagas 2008 excluded Norrelund 1978 due to
a language barrier. For Kaiser 2001, Falagas 2008 only took into
account the subgroup of people with rhinosinusitis confirmed by
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radiography. Falagas 2008 did not include Garbutt 2012 because
this study was not yet published. Falagas 2008 made a distinction
between “cured or improved” and “cured”. Considering the differ-
ent definitions, “cure” or “improvement” seem to be a subjective
interpretation of how a patient feels at one time point, expressed
in resolution of symptoms, restriction in daily activities, or feeling
cured; therefore, we did not choose to make this distinction in this
review. Taking cure as an outcome measure, Falagas 2008 found a
higher cure rate in people taking antibiotics compared to placebo
(OR 1.82, 95% CI 1.34 to 2.46; NNTB 7, 95% CI 5 to 14). In
this analysis, the diagnosis was made on clinical criteria only in
only 4 of the 12 trials. Falagas 2008 omitted the trials by Kaiser
2001, Meltzer 2005, Stalman 1997, and Varonen 2003 because
these trials did not report rates for cure (as defined by Falagas 2008)
separately. As in Rosenfeld 2007, the forest plot revealed hetero-
geneity (I² = 50%): the trials with inclusion based on specific tech-
nical investigations (CT or laboratory tests) showed more benefit
for antibiotics than the trials with inclusion on a clinical basis.
Furthermore, taking cure or improvement as an outcomemeasure,
Falagas 2008 found that people with rhinosinusitis benefit from
antibiotics (OR 1.64, 95% CI 1.35 to 2.00; NNTB 11, 95% CI
8 to 17). However, for the Meltzer 2005 study, Falagas 2008 used
the number of treatment failures as the number of people who
were not cured, which makes the cure rate artificially high. Het-
erogeneity was low, but the same trend (more technical investiga-
tions, more benefit of antibiotics) can be seen. Falagas 2008 put
their positive result into perspective by comparing theNNTB of 7
(95% CI 5 to 14) to a NNTH (adverse events) of 9 (95% CI 5 to
30), a number that is, irrespective of the different kinds of studies
included in the analysis, comparable to our results. Falagas 2008
found no significant difference in cure or improvement for adults
versus children, imaging versus clinical criteria for inclusion, as-
sessment at 7 to 11 versus 14 to 15 days, or year of publication.
Burgstaller 2016 included original studies that compared treat-
ment of any antibiotic with placebo in people with symptoms and
signs of acute rhinosinusitis lasting for seven or more days. The
reason given by Burgstaller 2016 for this inclusion criterion was
the recommendation of the ’European position paper on rhinos-
inusitis and nasal polyps’ (Fokkens 2012). Fokkens 2012 recom-
mend antibiotic treatment only in people with duration of symp-
toms of more than 10 days; however, as no original study in-
cluded this kind of participant, Burgstaller 2016 used seven days
or more as their criterion. Only Garbutt 2012 (clinical criteria),
Merenstein 2005 (clinical criteria), Hadley 2010 (radiography and
bacteriology), Lindbaek 1996 (CT), and Lindbaek 1998 (CT)
were selected. Burgstaller 2016 looked separately at improvement
and cure, finding a significantly higher proportion of people with
improvement of symptoms after 3 and 7 days in people treated
with antibiotics compared to placebo (OR 2.78, 95% CI 1.39 to
5.58 at day 3, based on data from Garbutt 2012, Hadley 2010,
Lindbaek 1996, and Lindbaek 1998; and OR 2.29, 95% CI 1.19
to 4.41 at day 7, based on data from Garbutt 2012). There was
no relevant difference in the rate of cure at day 10 (OR 1.92, 95%
CI 0.63 to 5.8, based on data from Lindbaek 1996 and Lindbaek
1998) or at day 14 (OR 1.57, 95% CI 0.79 to 3.13, based on
data from Merenstein 2005). It was difficult to compare results
because there was minimal overlap in pooled studies. Furtermore,
we questioned if symptoms lasting for seven days or more is a
good criterion for selecting participants who could benefit from
antibiotics. Lindbaek 2002 reviewed the clinical diagnosis of acute
purulent sinusitis in general practice. The strongest predictor for
the diagnosis of purulent sinusitis is the presence of purulent se-
cretion in the nasal cavity. Pain in the teeth and an elevated ESR
were associated in two of the four studies. Two phases in the illness
history, ineffectiveness of decongestants and transillumination of
the sinuses, might be of some value. We found no evidence that
people with symptoms lasting seven days or more before consult-
ing their physician are more likely to have bacterial sinusitis. Of
the 440 people in Lindbaek 1996 and Lindbaek 1998 combined,
202/254 (80%) of people withCT-confirmed sinusitis were symp-
tomatic for more than seven days, while 131/186 (70%) of people
without CT-confirmed sinusitis were symptomatic for more than
seven days. The difference is statistically significant (P = 0.03), but
has not been analysed in a multivariate logistic regression. This
means that about 60% of people presenting to general practices
with sinusitis symptoms for more than seven days would have
CT-confirmed sinusitis, and 40% would have a prolonged viral
infection. But of people presenting with symptoms of seven days
or less duration, about 50% will have a CT-confirmed sinusitis,
and about 50% viral upper respiratory tract infections (Lindbaek
2015 [pers comm]). Consequently, despite only 20% of people
with CT-confirmed sinusitis having symptoms for seven or fewer
days (Hickner 2001), duration of symptoms is a poor predictor of
acute bacterial sinusitis.
In conclusion, people with clinically diagnosed rhinosinusitis and
rhinosinusitis confirmed by imaging (radiography, CT) or labora-
tory findings (CRP, bacteriology) constitute different groups, and
we are convinced that they cannot be pooled in one analysis, as per-
formed by Burgstaller 2016, Falagas 2008, and Rosenfeld 2007.
The separate results are very relevant: when a clinician makes a
clinical diagnosis, the one analysis is applicable; when a decision
is made to confirm the diagnosis by imaging, the other analysis is
applicable. This would be clear for any clinician and avoids con-
fusion.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review showed that there could be a beneficial therapeutic
effect of antibiotics in adults with clinically diagnosed acute rhi-
nosinusitis. But this effect is small, and only around 5 more peo-
ple per 100 will be cured faster if they receive antibiotics instead
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of placebo. The lack of effect of antibiotics could be related to
the non-specificity of the clinical presentation of acute bacterial
sinusitis. Performing radiography increases this number from 5
to 11 per 100. In adults with a fluid level or total opacification
present on computed tomography, 28 more people per 100 cured
faster with antibiotics. In clinically diagnosed rhinosinusitis, the
subgroup of people with purulent discharge could benefit slightly
more than those without. However, the benefits need to be seen
in the context of the risk of experiencing adverse effects, especially
of a gastrointestinal nature, and health risks of radiation exposure.
Five fewer people per 100 will experience clinical failure if they re-
ceive antibiotics instead of placebo. This review addresses mainly
people assessed in a ambulatory care setting and excluded people
who were investigated further with laboratory tests. Considering
the worldwide high antibiotic prescription rate for rhinosinusitis,
growing antibiotic resistance, and the very low incidence of com-
plications, we can conclude that there is no place for the use of
antibiotics in adults with uncomplicated acute rhinosinusitis. For
subgroups that are potentially more vulnerable, such as children,
adults with a suppressed immune system, and adults with severe
sinusitis (e.g. very high fever, prolonged symptoms, findings sug-
gestive of severe sepsis such as hypotension) and people referred
to an ear, nose, and throat specialist because of confirmed or per-
ceived complications, no evidence is available from randomised,
placebo-controlled trials. Complications are so rare (1/3057 par-
ticipants in our review) that only case reports can give information
about their course, hence evidence that serious complications can
be prevented by giving antibiotics early is lacking.
Implications for research
Despite the availability of several studies and meta-analyses, there
is still insufficient clinical data to enable subgroup analysis of peo-
ple who probably could benefitmore from antibiotics, for example
people with high fever, severe facial pain, or rhinorrhoea. It may be
unlikely that such data will become available, as they pose ethical
(exposing vulnerable people to placebo treatment) and feasibility
(a relatively small group that would take a long time to collect data)
issues. Better recording of routinely collected data and morbidity,
as well as adverse drug reaction registers, might be helpful in an-
swering this question. The possibility of C-reactive protein (CRP)
measurement or bacteriological investigations to select people that
benefit from antibiotics should be further explored.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Axelsson 1970
Methods Study design: RCT
Study duration: not reported
Participants Setting: not reported
Country: Sweden
Health status: clinically suspected sinusitis with secretion confirmed on radiography
(different projections were used to prove fluid in the sinus, and thereby called an “affected
sinus”). Completely opaque maxillary sinuses were only accepted if the secretion was
confirmed by a single diagnostic irrigation
Number: treatment (78 (38 penicillin V and 40 lincomycin)); control (34)
Age: mean 33 (range 13 to 80 years)
Sex: 60% women
Exclusion criteria: history of nasal allergy and people recently treated with nasal decon-
gestants or antibiotics
Interventions Treatment group:
• Group 1
◦ intervention: irrigation
◦ dose, duration, frequency, administration: every second day until the lavage
was clear, after radiological examination
◦ This intervention was excluded from the analyses, since it comprises neither
placebo nor an antibiotic treatment
• Group 2
◦ intervention: penicillin V
◦ dose, duration, frequency, administration: 400 mg, 10 days, 3 times daily,
orally
• Group 3
◦ intervention: lincomycin 500 mg
◦ dose, duration, frequency, administration: 500 mg, 8 days, 3 times daily,
orally
Control group:
• intervention: no treatment
• dose, duration, frequency, administration: /
Co-interventions: concomitant use of oxymetazoline (three drops in each nostril three
times daily) was prescribed for all treatment arms
Outcomes Primary outcomes:
1. Radiological evaluation (mean number of severity points per sinus) at days 5 and
10
2. Subjective evaluation of the treatment (recovered, improved, unimproved,
deteriorated) at days 5 and 10
Secondary outcome:
1. Adverse effects
Correlation between subjective and radiological improvement
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Axelsson 1970 (Continued)
Notes Funding source: not stated
Contact with study authors for additional information: none
Other notes:
• Results:
◦ Recovered (patients’ evaluation):
⋄ treatment group: 6/75 (day 5), 27/74 (day 10)
⋄ control group (no treatment): 2/34 (day 5), 10/32 (day 10)
◦ Improved (patient’s evaluation)
⋄ treatment group: 60/75 (day 5), 62/74 (day 10)
⋄ control group (no treatment): 24/34 (day 5), 23/32 (day 10)
◦ Side effects:
⋄ No serious side effects
⋄ Nausea: treatment group (2/75); control group (2/34)
⋄ Diarrhoea: treatment group (1/75); control group (0/34)
◦ Clinical failure (defined as “deterioration”)
⋄ treatment group: 3/75 (day 5), 4/74 (day 10)
⋄ control group (no treatment): 2/34 (day 5), 1/32 (day 10)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: it is unclear if participants were
a convenience sample or a consecutive se-
ries of eligible patients. Participants were
randomly divided into 4 treatment groups.
No details about randomisation (simple,
unrestricted, restricted) were provided
Allocation concealment (selection bias) Unclear risk Comment: no information provided about
randomisation list or numbering or appear-
ance of drug containers
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: blinding not reported, but
probably not done since
1. The placebo group did not take tablets,
only nose drops.
2. It was not possible to blind “sinus irriga-
tion” as an intervention (group 1)
3. Only group 1 underwent radiological
evaluation every second day
4. Group 2 received a longer course of
tablets than group 3
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate: 6/98 (6.
1%)
• treatment group: 4 (3 penicillin V
group, 1 lyncomycin group)
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Axelsson 1970 (Continued)
• control group: 2
The reasons for missing data: not reported.
The ratio of participants with missing data
to participants with events: 0.16
Compliance with treatment: not reported
Selective reporting (reporting bias) Unclear risk Comment: the study protocol was de-
scribed in the methods. The primary
endpoints (cure, improvement) were not
adequately defined. Nevertheless, study
authors reported which outcomes were
recorded
Other bias Unclear risk Comment: it appears that groups were
balanced, although information on demo-
graphic characteristics was limited (similar
according to mean age, radiological state)
Bucher 2003
Methods Study design: RCT
Study duration: from November 1 to April 30 of 1997 to 2001 (4 winter seasons)
Participants Setting: general practice and the internal medicine and otolaryngology outpatient clinics
of the University Hospital Basel (only walk-in patients and not referred patients) (24
general practices and 2 outpatient clinics)
Country: Switzerland
Health status: people presenting with a history of repeated purulent nasal discharge and
maxillary or frontal unilateral or bilateral pain for at least 48 hours, but less than 1
month, and presence of pus under rhinoscopy (this last criterion was withdrawn after
the first winter season)
Number:
• total: treatment (125); control (127)
• analysed at day 7: treatment (122); control (125)
• analysed at day 14: treatment (124); control (126)
Age: mean 37
Sex: 54% women
Exclusion criteria: age younger than 18, an upper respiratory tract infection or use
of antibiotics for any reason within the previous 4 weeks, an upper respiratory tract
infection or intermittent fever that persisted for more than 4 weeks, pathologic features
or malformation of nasal cavities or the pharynx, immunosuppressive treatment, HIV
infection, allergy to amoxicillin-clavulanate, pregnancy or breastfeeding, and no fluency
in one of the national languages. After 2000, an extra exclusion criterion was introduced
because of a brain abscess in the placebo group: (1) people with a CRP level greater than
100 mg/L (2) people with a CRP level between 50 and 99 mg/L if 3 days after inclusion
clinical worsening or an increase in CRP level higher than 100 mg/L occurred
34Antibiotics for acute rhinosinusitis in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bucher 2003 (Continued)
Interventions Treatment group:
• intervention: amoxicillin with clavulanic acid
• dose, duration, frequency, administration: 875 mg/125 mg, 6 days, 2 times daily,
orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 6 days, 2 times daily, orally
Co-interventions: decongestant therapy (xylometazoline hydrochloride spray) and parac-
etamol tablets (500 mg with a maximum dose of 6 tablets a day) were provided. Steam
inhalation was allowed
Outcomes Primary outcomes:
1. Time to cure (7 days, 14 days, 28 days)
i) Cure, defined as 0 days (since the previous interview) during which
rhinosinusitis restricted activities at home or work
ii) Cure, defined as a rating of 1 on a 10-point, equal-distance scale for the
severity of restricted activity at home or work
Secondary outcomes:
1. Number of days during which rhinosinusitis restricted activities at home or work
2. Frequency of adverse effects
3. Recurrence rate of rhinosinusitis at 28 days
Notes Funding source: not stated
Contact with study authors for additional information: none
Other notes:
• Registration: medical history for rhinosinusitis-like symptoms, number of days
during which rhinosinusitis restricted activities at home or work, previous upper
respiratory tract infections, clinical examination, questionnaire (rating of severity),
radiograph maxillary and frontal sinus (occipitomental view), blood sampling (white
blood cell count and CRP level) at inclusion
• Follow up:
◦ day 7: clinical examination, number of tablets taken, and 2nd questionnaire
◦ day 14 and 28: telephone interview by study nurse (questions about
rhinosinusitis-related symptoms, adverse effects, use of other drugs or other visits to
physicians)
• Results:
◦ Cure at day 7:
⋄ treatment group: 36/122
⋄ control group: 38/125
◦ Cure at day 14:
⋄ treatment group: 95/124
⋄ control group: 93/126
◦ Side effects:
⋄ diarrhoea: OR 3.89 (95% CI 2.09 to 7.25) at 7 days and OR 1.71
(95% CI 0.91 to 3.23) at 14 days (exact numbers not available)
⋄ vaginal discharge or pruritus and abdominal pain: no significant
differences
⋄ 4 possibly drug-related adverse events of moderate or severe intensity:
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Bucher 2003 (Continued)
treatment (2, diarrhoea); control (2, diarrhoea and vomiting)
◦ Clinical failure (requiring open antibiotic therapy)
⋄ treatment group: 11/124
⋄ control group: 19/126 (1 serious adverse event)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: a computer random number
generator was used. Stratified randomisa-
tion: general practice or outpatient clinic as
stratification unit, participants randomised
in blocks of 6
Allocation concealment (selection bias) Low risk Comment: tablets were provided in iden-
tical, numbered containers. The allocation
sequence was performed by a statistician
who was not involved in the final analysis
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: tablets of equal size, colour, and
taste. All study physicians and the study
nurse were blinded to the treatment given
to each participant. Data were entered by
the study nurse. Randomisation code was
kept at the 24-hour emergency call centre
in Basel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Postrandomisation dropout rate: 2/252 (0.
8%)
• treatment group: 1
• control group: 1
Reasons for missing data: loss of follow-
up (1 participant) or adherence problems
(1 participant). 1 participant with a serious
adverse event was considered as a dropout
by the authors but included in this review
as a failure
Ratio of participants with missing data to
participants with events: 0.01
Comment:
• intention-to-treat principle was
followed (all participants except 1
participant who never started treatment
were included in the analysis). The
authors did not mention how they
imputed information from the
participants who were lost to follow-up at
certain time points
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Bucher 2003 (Continued)
• people taking fewer tablets than
instructed: 24 participants in the
treatment group and 15 in the control
group
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined
Other bias Low risk Comment:
• inclusion criteria: in this study, the
inclusion criteria changed (omission of
the criterion “presence of pus at
rhinoscopy”) after the first winter season,
and the exclusion criteria changed after 1
serious adverse effect in 2000 (people with
CRP level greater than 100 mg/L or
people with CRP level between 50 and 99
mg/L if clinical worsening or an increase
in CRP higher than 100 mg/L occurred 3
days after inclusion). With the available
information, we could not detect other
reasons for bias (no design-specific risks of
bias, the study was not stopped early, no
imbalance of participant characteristics at
baseline, blinding was not broken due to
side effects, no bias due to increased or
different diagnostic activity)
• grants: Dr Bucher has received
honorarium for presentations and
financial support for participation in
scientific meetings from GlaxoSmithKline
• number of patients included per
practice: 9.6
De Sutter 2002
Methods Study design: RCT
Study duration: from October 1998 to December 1999
Participants Setting: general practice (69 practices)
Country: Belgium
Health status: adults presenting with a respiratory tract infection and purulent rhinor-
rhoea
Number:
• total: treatment (207); control (209)
• analysed: treatment (189); control (195) (incorporating all available information
from the questionnaire, diary, physical examination and dropouts)
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De Sutter 2002 (Continued)
Age: mean 37 in amoxicillin group and 39 in placebo group
Sex: 54% women
Exclusion criteria: allergy to penicillin or ampicillin, having received antibiotic therapy
within the previous week, symptoms lasting more than 30 days, abnormality on clinical
chest examination, complications of sinusitis (facial oedema or cellulitis; orbital, visual,
meningeal, or cerebral signs), pregnancy or lactation, comorbidity that might impair
immune competence, and inability to follow the protocol because of language or mental
health problems
Interventions Treatment group:
• intervention: amoxicillin
• dose, duration, frequency, administration: 500 mg, 10 days, 3 times daily, orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 10 days, 3 times daily, orally
Co-interventions: decongestant therapy (xylometazoline 1% nose drops) and paraceta-
mol or ibuprofen
Outcomes Primary outcomes:
1. cure after 10 days of treatment (all the symptoms that the participant had
included in the list of “most important item affecting my health” scored 0 (absent) or 1
(very mild present))
2. duration of general illness (as noted in the diary)
3. duration of pain (as noted in the diary)
4. duration of purulent rhinorrhoea (as noted in the diary)
Secondary outcomes:
1. mean change in severity score (between day 1 and day 10 of the various symptoms)
2. incidence of unfavourable evolution
3. incidence of side effects
4. intake of analgesics stopped
5. duration of sick leave
Notes Funding source: a grant from Eurogenerics NV, Brussels
Contact with study authors for additional information: none
Other notes:
• Registration: history, generally ill to very ill, unilateral facial pain, pain on bending
forward, pain in upper teeth or when chewing, physical examination, sinus tenderness,
pain on bending forward, postnasal discharge on throat inspection, purulent
rhinorrhoea on rhinoscopy, and body temperature > 37 °C at inclusion. Completion of
a symptom questionnaire (SNOT-20, 0-to-5 Likert scale) and 3 questions about pain,
indication of the most troublesome symptoms (max 5) at inclusion. Invitation for an
optional radiologic examination of the maxillary sinuses (single Waters view) for the
estimation of the proportion of sinusitis cases among included participants
• Follow-up:
◦ diary for 10 days (daily drug intake (trial medication and symptomatic
medication), general feeling of illness, presence of nasal discharge, pain and cough,
body temperature, occurrence of presumed adverse drug effects, and absence from
school or work)
◦ Clinical evaluation at day 10 (physical examination, symptom questionnaire
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De Sutter 2002 (Continued)
(SNOT-20, 0-to-5 Likert scale) and 3 questions about pain, indication of the most
troublesome symptoms (max 5)). If participants were insufficiently recovered, general
practitioner could prescribe an antibiotic without revealing the previous treatment
phase. These participants completed their diary until day 15 and got a new evaluation
at day 15.
• Results:
◦ Cure after 10 days of treatment:
⋄ treatment group: 73/189
⋄ control group: 59/195
◦ Side effects:
⋄ treatment group: 55/189 (diarrhoea)
⋄ control group: 37/195 (diarrhoea)
⋄ no differences concerning skin rash, abdominal pain, vomiting (no
numbers reported)
◦ Clinical failure (requiring open antibiotic treatment)
⋄ treatment group: 16/189 (1 before day 10, 7 after day 10)
⋄ control group: 26/195 (7 before day 10, 19 after day 10)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: assignment via a computer-
generated random number list to receive
antibiotics or placebo
Allocation concealment (selection bias) Low risk Comment: the randomisation list was kept
at the pharmacy of theUniversity Hospital.
The randomisation list was accessible to the
participating family physician only in case
of a serious adverse event. The trial medi-
cation was supplied in numbered, uniform
cardboard boxes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: capsules had the same size,
colour, and shape for active and placebo
treatment. To assess effectiveness of mask-
ing, participants and family physician
guessed their treatment group at day 10.
Data were encoded and entered without
knowledge of allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Postrandomisation dropout rate: 32/416
(7,6%)
• treatment group: 18 participants (5
violation inclusion criteria (symptoms >
30 days), 2 concurrent pathology, 1
allergic reaction, 1 gastrointestinal side
effect, 9 lost to follow-up)
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• control group: 14 participants (3
violation inclusion criteria (2 symptoms >
30 days, 1 allergy to penicillin), 4
suspected allergic reaction, 7 lost to
follow-up)
Reasons for missing data: loss to follow-
up or withdrawal without knowing if they
were cured or not
Ratio of participants with missing data to
participants with events: 0.18
Withdrawal with “known” illness course:
• treatment group: 2 participants (1
clinical exacerbation, 1 complete recovery)
• control group: 8 participants (7
clinical exacerbation, 1 complete recovery)
Open antibiotic therapy (after 10 days fol-
low-up)
• treatment group: 15 participants
• control group: 19 participants
Sensitivity analysis performed.
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined
Other bias Low risk Comment:
• with the available information, we
could not detect reasons for bias (no
design-specific risks of bias, the study was
not stopped early, no imbalance of
participant characteristics at baseline,
blinding was not broken due to side
effects, no bias due to increased or
different diagnostic activity)
• number of patients included per
practice: 5.6
Garbutt 2012
Methods Study design: RCT
Study duration: between November 1, 2006 and May 1, 2009
Participants Setting: ambulatory care (10 offices)
Country: USA
Health status: people presenting with a history of maxillary pain or tenderness in the
face or teeth, purulent nasal secretions, and rhinosinusitis symptoms for 7 days or more
and 28 days or less that were not improving or worsening, or rhinosinusitis symptoms
lasting for less than 7 days that had significantly worsened after initial improvement.
Symptoms had to be moderate, severe, or very severe
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Numbers:
• total: treatment (85), control (81)
• analysed: treatment (81), control (74)
Age: median 32 in the amoxicillin group, 31 in the placebo group
Sex: 64% women
Exclusion criteria: allergy to penicillin or amoxicillin, prior antibiotic treatment within
4 weeks, complications of sinusitis, a comorbidity that could impair their immune re-
sponse, cystic fibrosis, requiring an antibiotic for a concurrent condition, pregnancy, and
people who rated their symptoms as very mild or mild
Interventions Treatment group:
• intervention: amoxicillin
• dose, duration, frequency, administration: 500 mg, 10 days, 3 times daily, orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 10 days, 3 times daily, orally
Co-interventions: to be used as needed during 5 to 7 days (except if contra-indications)
• paracetamol for pain or fever at a dose of 500 mg every 6 hours
• guaifenesin to thin secretions at a dose of 600 mg every 12 hours,
• 10 mg/5 mL of dextromethorphan hydrobromide and 100 mg/5 mL of
guaifenesin for cough at a dose of 10 mL every 4 to 6 hours,
• pseudoephedrine-sustained action for nasal congestion at a dose of 120 mg every
12 hours
• 0.65% saline spray using 2 puffs per nostril as needed,
Outcomes Primary outcome:
1. effect of treatment on disease-specific quality of life at day 3 (measured using the
SNOT-16)
Secondary outcomes:
1. significant improvement (“symptom change” based on symptom scores (6-point
scale), reporting their symptoms a lot better or absent)
2. change in functional status
3. recurrent sinus infection
4. satisfaction with treatment
5. adverse effects of treatment
6. treatment compliance
7. adequacy of blinding
Notes Funding source: grant U01-AI064655-01A1 from the National Institute of Allergy and
Infectious Diseases. This institute did not have a role in the design and conduct of the
study; in the collection, management, analysis, or interpretation of the data; or in the
preparation, review, or approval of the manuscript
Contact with study authors for additional information: none
Other notes:
• registration at inclusion: brief interview with research assistant, SNOT-16
questionnaire, registration of demographic and disease-related information, signs and
symptoms. Telephone interview later that day to standardise the mode of data
collection.
• follow-up with telephone interview 3, 7, 10, and 28 days after treatment
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initiation (structured questionnaire, trained research assistants)
• results:
◦ Significant improvement at day 3
⋄ treatment group: 30/81
⋄ control group: 25/74
◦ Significant improvement at day 7
⋄ treatment group: 60/81
⋄ control group: 41/74
◦ Significant improvement at day 10
⋄ treatment group: 63/81
⋄ control group: 59/74
◦ Side effects:
⋄ Discontinuating intervention because of adverse effects from the study
medication: treatment group (16/81); control group (14/77)
⋄ Headache: treatment group (18/81), control group (17/74)
⋄ Extensive tiredness: treatment group (8/81), control group (16/74)
⋄ Other side effects (no numbers reported): no differences between the
treatment groups (nausea (7%), diarrhoea (9%), abdominal pain (5%), vaginitis (6%
of women)
⋄ No serious side effects
◦ Clinical failure (needing treatment with other antibiotics)
⋄ treatment group: 5/85
⋄ control group: 11/81
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: blocked randomisa-
tion scheme. Computer-generated random
numbers were used to determine how the 2
study drugs were allocated to the consecu-
tively numbered study treatment packages.
Randomisation occurredwhen the research
assistant assigned the treatment package
Allocation concealment (selection bias) Low risk Comment: randomisation was performed
in advance by the investigational pharma-
cist who did not participate in participants’
enrolment or outcome assessment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: the tablets were similar in
appearance and taste and dispensed in
the same fashion. Research assistants were
blinded to group assignment. The percent-
age of participants who guessed their treat-
ment assignment correctly did not differ by
study group (36% in amoxicillin group and
37% in placebo group, P = 0.2)
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate: 11/166
(6.6%) due to missing data
• treatment group: 4 participants
• control group: 7 participants
Discontinuation of treatment rate: 23/166
(13.9%)
• treatment group: 11 out of 85
participants (2 failure to improve, 3
worsening symptoms, 4 improved
symptoms, 1 adverse events, 1 unknown
reasons)
• control group: 12 out of 81
participants (6 failure to improve, 4
worsening symptoms, 2 unknown
reasons)
Treatment with other antibiotics: 16/166
(9.6%)
• treatment group: 5 participants
• control group: 11 participants
Ratio of participants with missing data to
participants with events (outcome: signifi-
cant improvement after 10 days): 0.09
Intention-to-treat analysis
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined. Sen-
sitivity analysis for participants who com-
pleted 10 days of treatment with the study
drug and those with symptoms for 7 days
or more and 28 days or less. Findings were
consistent with the primary analysis
Other bias Low risk Comments:
• approval by the institutional review
board at Washington University.
• written consent obtained from each
participant.
• average number of participants per
practice: 15.5
Kaiser 2001
Methods Study design: RCT
Study duration: unknown
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Participants Setting: outpatient clinic of the University of Geneva Hospital
Country: Switzerland
Health status: people presenting with common cold or acute sinusitis and had a history
of rhinorrhoea of less than 4 weeks and a confirmed upper respiratory tract infection at
physical examination, including rhinoscopy
Number:
• total: 269
• analysed: treatment (133); control (132)
Age: median 35
Sex: 52% women (gender of 4 dropouts not reported)
Exclusion criteria: high fever (> 38.5 °C) and an overall clinical impression that antibiotic
treatment was absolutely required (~ 4% of the screened population), chronic ear, nose,
and throat disease, a positive pharyngeal culture for Streptococcus pyogenes, known allergy
to macrolides, antibiotic treatment in the previous 10 days, immunosuppression, and
underlying pulmonary disease
Interventions Treatment group:
• intervention: azithromycin
• dose, duration, frequency, administration: 500 mg, 3 days, once daily, orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 3 days, once daily, orally
Co-interventions: ibuprofen and nasal drops containing oxymetazoline was offered to
all participants
Outcomes Primary outcome:
1. Cure at day 8
Secondary outcomes:
1. Occurrence of a respiratory complication that required the introduction of open
antibiotic treatment
2. Occurrence of severe sinusitis (defined as worsening of initial symptoms
accompanied by facial pain, discharge at middle meatus, or fever)
Definitions of cure:
1. Reduction of more than 80% of the mean baseline symptom score (evaluated at
day 7) (definition 1)
2. Clinical evaluation (definition 2)
Subgroup analysis: predefined subset of participants with and without Streptococcus pneu-
moniae, Haemophilus influenzae, or Moraxella catarrhalis
Notes Funding source: not stated
Contact with study authors for additional information: none
Other notes:
• registration: medical history, examination, including anterior rhinoscopy by ear,
nose, and throat specialist. Participants were submitted to a rhinoscopy (with
aspiration of nasopharyngeal secretions) and sinus radiography (occipitomental view).
• follow-up:
◦ diary for 7 days (nasal obstruction, rhinorrhoea, fatigue, headache, facial
pain, feverishness, cough, sputum, sore throat, postnasal drip, and loss of voice)
◦ clinical evaluation at day 8 (cured, improved, same, or worsened; rhinoscopy)
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◦ Questionnaire after 1 month
• results:
◦ cure at day 8
⋄ treatment group: 93/133 (definition 1), 76/133 (definition 2)
⋄ control group: 77/132 (definition 1), 75/132 (definition 2)
◦ cure at day 8 in the subgroup with radiologically confirmed sinusitis
⋄ treatment group: 27/38
⋄ control group: 26/44
◦ side effects:
⋄ treatment group: 32/133 (gastrointestinal disturbances)
⋄ control group: 14/132 (gastrointestinal disturbances)
⋄ no side effect required withdrawal of treatment
◦ clinical failure (requiring open antibiotic treatment)
⋄ treatment group: 1/133
⋄ control group: 14/132
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: random assignment. No fur-
ther information available
Allocation concealment (selection bias) Unclear risk Comment: drugs and placebowere in iden-
tical containers. No further information
available. No information about the cen-
tralisation of randomisation or the num-
bering of the containers
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: drugs and placebo had the same
shape and taste. Participants and investiga-
tors were blinded to the treatment admin-
istered. This investigator remained blinded
to bacteriological and radiological results,
even if an open antibacterial treatment was
deemed necessary. The sinus radiograph
(occipitomental view) was interpreted in-
dependently by 2 radiologists blinded to
the clinical results
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate: 4/269
(1.5%)
• Dropout balance: not known
(reasons for losses to follow-up were not
reported).
Ratio of participants with missing data to
participants with events: 0.03
Open antibiotic treatment (treatment fail-
ure): 15/265 (5.7%)
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• treatment group: 1 (severe sinusitis)
• control group: 14 out of the placebo
group (severe sinusitis, purulent
bronchitis, exudative pharyngitis, otitis
media).
Comment: it appeared that all these par-
ticipants receiving open antibiotic therapy
were included in the analysis
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined
Other bias Low risk Comment:
• with the available information, we
could not detect reasons for bias (no
design-specific risks of bias, the study was
not stopped early, no imbalance of
participant characteristics at baseline,
blinding was not broken due to side
effects, no bias due to increased or
different diagnostic activity).
• participants were recruited from 1
outpatient clinic at the University of
Geneva Hospital.
Lindbaek 1996
Methods Study design: randomised, double-blind trial
Study duration: January to May 1994 and November 1994 to May 1995
Participants Setting: general practice
Country: Norway
Health status: clinical diagnosis of acute sinusitis, confirmed by computed tomography
(presence of fluid level or total opacification in any sinus, independently scored by 2
experienced radiologists). Ear, nose, and throat comorbidity was not assessed
Number:
• total: treatment (86 (penicillin V (41); amoxicillin 45); control 44
• analysed: treatment (83 (penicillin V (39); amoxicillin (44)); control (44)
Age: mean 38.6 (range 16 to 74)
Sex: 65% women
Exclusion criteria: age 15 or under, pregnancy, ongoing antibiotic treatment, immuno-
suppressive treatment, previous operations in the nose or sinus region, misuse of alcohol
or narcotics, rheumatic disease, and allergy to penicillin. Participants with symptoms for
more than 30 days were excluded because of possible chronic sinusitis. Participants with
high fever and strong pain were not included because of ethical considerations
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Interventions Treatment group:
• group 1
◦ intervention: penicillin V
◦ dose, duration, frequency, administration: 1320 mg, 10 days 3 times daily,
orally
• group 2
◦ intervention: amoxicillin
◦ dose, duration, frequency, administration: 500 mg, 10 days, 3 times daily,
orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 10 days, 3 times daily
Co-interventions: concomitant use of nasal decongestants and paracetamol was allowed
Comment: For this review, group 1 and 2 were combined in the analyses
Outcomes Primary outcomes:
1. subjective status: evaluation of the clinical condition by the participant
(recovered, much better, somewhat better, unimproved, worse) at days 3 and 10
2. difference in clinical severity score (day 10 vs day 0) evaluated by the general
practitioner
3. difference in score from computed tomography scans (day 10 vs day 0)
4. duration of the illness episode (cure) (answering ”no“ at the question ”Do you
think you still have sinusitis today?“)
Secondary outcomes:
1. bacteriology
2. side effects
3. clinical failure
Notes Funding source: government
Contact with study authors for additional information: none
Other notes:
• Clinical evaluation (clinical severity score) and bacteriological sample from the
nasopharynx at inclusion
• Follow-up:
◦ diary (scoring degree of nasal obstruction, rhinorrhoea, sinus-related pain,
and malaise on VAS scale and answering the question ”Do you think you still have
sinusitis today?“ (yes, uncertain, or no)). If they did not answer ”no“ at day 10, they
went on with the daily registering until they could answer ”no“, with a maximum of 30
days.
◦ Clinical evaluation at day 10 combined with computed tomography
• Results:
◦ Recovered:
⋄ treatment group: 0/83 at day 3, 32/83 at day 10
⋄ control group: 0/44 at day 3, 5/44 at day 10
◦ Recovered or much better:
⋄ treatment group: 17/83 at day 3, 71/83 at day 10
⋄ control group: 1/44 at day 3, 25/44 at day 10
◦ Improved:
⋄ treatment group: 67/83 at day 3, 81/83 at day 10
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⋄ control group: 17/44 at day 3, 39/44 at day 10
◦ Answering ”no“ at the question ”Do you think you still have sinusitis today?
(day 10) (data from Kaplan-Meier plot)
⋄ treatment group: 33/83
⋄ control group: 11/44
◦ Side effects:
⋄ Total: treatment group (49/86); control group (16/44)
⋄ Diarrhoea: treatment group (36/86); control group (5/44)
⋄ Nausea/vomiting: treatment group (24/86); control group (5/44)
⋄ Rash: treatment group (5/86); control group (2/44)
⋄ Vaginal discharge: treatment group (5/86), control group (1/44)
⋄ Other (headache, asthenia): treatment group (4/86), control group (6/
44)
◦ Clinical failure (requiring therapy changes)
⋄ 9 stopped original treatment and received open antibiotic treatment:
treatment group (2/83, both amoxicillin); control group (7/44)
⋄ 25 extended treatment because not better at day 10: treatment group
(12/83), control group 13/44 )
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: restricted
randomisation (blocks of 3 within each of
6 subgroups). A dice was used to generate
the random allocation
Stratified randomisation: according to clin-
ical severity score (breakpoint 9.0) and lo-
calisation of the sinusitis (unilateral max-
illary, bilateral maxillary or in at least 1 of
the remaining sinus regions). If maxillary
sinusitis in combination with sinusitis in 1
of the other sinus regions: stratification to
1 of the maxillary sinusitis groups
Allocation concealment (selection bias) Low risk Comment: the statistician sent the ran-
domisation list to the company that pro-
duced the medication boxes with num-
bers according to the list. The author re-
ceived the numbered boxes for each of the
subgroups from the company (information
from the main investigator). Tablets ap-
peared similar
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: the trial was double-blind (at
participant, general practitioner, and ra-
diologist level). The randomisation codes
were broken after the whole study was fin-
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ished. If another antibiotic was prescribed
because of clinical failure (evaluation day
10), the randomisation code was not bro-
ken
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate at day 10:
3/130 (2.3%)
• treatment group: 3 (2 out of the
penicillin (severe gastrointestinal side
effects) and 1 out of the amoxicillin group
(severe gastrointestinal side effects)
• control group: 0
The ratio of participants with missing data
to participants with events: 0.07
Discontinuation of trial medication rate:
12/130 (9.2%).
• treatment group: 5 (2 out of the
penicillin group (severe gastrointestinal
side effects), 3 out of the amoxicillin
group (1 severe gastrointestinal side
effects, 1 sinus puncture executed and
changed to doxycycline, 1 changed to
doxycycline without reported reason from
day 5),
• control group: 7 (6 changed to
amoxicillin, 1 referred to ENT specialist,
sinus puncture and penicillin V).
Treatment compliance was not reported.
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined
Other bias Low risk Comment:
• detailed description of demographic
characteristics and sinusitis severity rating
at baseline, but actual numbers are not
given.
• 93/130 had maxillary sinusitis on
CT
Lindbaek 1998
Methods Study design: RCT
Study duration: January to May 1994 and November 1994 to May 1995
Participants Setting: general practice
Country: Norway
Health status: clinical diagnosis of acute sinusitis (> 7 and < 30 days), confirmed by
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computed tomography (presence of mucosal thickening of 5 mm without fluid levels or
total opacification, independently scored by 2 experienced radiologists). Ear, nose, and
throat comorbidity was not assessed
Number:
• total: 68
• analysed: treatment (42, penicillin V (20); amoxicillin (22)); control (21)
Age: mean 39.7 (range 16 to 83)
Sex: 61% women
Exclusion criteria: age 15 or under, pregnancy, ongoing antibiotic treatment, immuno-
suppressive treatment, previous operations in the nose or sinus region, misuse of alcohol
or narcotics, rheumatic disease, and allergy to penicillin. Participants with symptoms for
more than 30 days were excluded because of possible chronic sinusitis. Participants with
high fever and strong pain were not included because of ethical considerations
Interventions Treatment group:
• Group 1
◦ intervention: penicillin V
◦ dose, duration, frequency, administration: 1320 mg, 10 days 3 times daily,
orally
• Group 2
◦ intervention: amoxicillin
◦ dose, duration, frequency, administration: 500 mg, 10 days, 3 times daily,
orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 10 days, 3 times daily
Co-interventions: concomitant use of nasal decongestants and paracetamol was allowed
Comment: For this review, group 1 and 2 were combined in the analyses
Outcomes Primary outcomes:
1. subjective status: evaluation of the clinical condition by the participant
(recovered, much better, somewhat better, unimproved, worse) at days 3 and 10
2. difference in clinical severity score (day 10 vs day 0) evaluated by the general
practitioner
3. difference in score from computed tomography scans (day 10 vs day 0)
4. duration of the illness episode (cure) (answering “no” to the question “Do you
think you still have sinusitis today?”)
Secondary outcomes:
1. Bacteriology
2. Side effects
3. Clinical failure
Notes Funding source: government
Contact with study authors for additional information: none
Other notes:
• Clinical evaluation (clinical severity score) and bacteriological sample from the
nasopharynx at inclusion
• Follow-up:
◦ diary (scoring degree of nasal obstruction, rhinorrhoea, sinus-related pain,
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and malaise on VAS scale and answering the question “Do you think you still have
sinusitis today?” (yes, uncertain, or no)). If they did not answer “no” at day 10, they
went on with the daily registering until they could answer “no”, with a maximum of 30
days.
◦ Clinical evaluation at day 10 combined with computed tomography
• Results:
◦ Recovered:
⋄ treatment group: 15/42 at day 10
⋄ control group: 9/21 at day 10
◦ Recovered or much better:
⋄ treatment group: 32/42 at day 10
⋄ control group: 14/21 at day 10
◦ Side effects (serious, reason to stop treatment; GI origin):
⋄ treatment group: 3/42
⋄ control group: 0/21
◦ Clinical failure, requiring extended treatment with amoxicillin:
⋄ treatment group: 1/42
⋄ control group: 1/21
◦ Clinical failure, no recovery after 30 days:
⋄ treatment group: 4/42
⋄ control group: 2/21
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: restricted
randomisation (blocks of 3 within each of
6 subgroups). A dice was used to generate
the random allocation
Stratified randomisation: according to clin-
ical severity score (breakpoint 9.0) and lo-
calisation of the sinusitis (unilateral max-
illary, bilateral maxillary or in at least 1 of
the remaining sinus regions). If maxillary
sinusitis in combination with sinusitis in 1
of the other sinus regions: stratification to
1 of the maxillary sinusitis groups
Allocation concealment (selection bias) Low risk Comment: the statistician sent the ran-
domisation list to the company that pro-
duced the medication boxes with num-
bers according to the list. The author re-
ceived the numbered boxes for each of the
subgroups from the company (information
from the main investigator). Tablets ap-
peared similar
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Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: the trial was double-blind (at
participant, general practitioner, and ra-
diologist level). The randomisation codes
were broken after the whole study was fin-
ished. If another antibiotic was prescribed
because of clinical failure (evaluation day
10), the randomisation code was not bro-
ken
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/70 participants were taken out of the
study because of bad-quality CT scans
Post-randomisation dropout rate at day 10:
5/68 (7.4%)
• Dropout balance: unknown
Ratio of participants with missing data to
participants with events: 0.11
Discontinuation of trial medication rate: 5/
63
• Treatment group: 4 (1 out of the
penicillin group (marked gastrointestinal
side effects), 3 out of the amoxicillin
group (2 marked gastrointestinal side
effects, 1 unknown reason but recovered
without further treatment)
• Control group: 1 (unknown reason
but recovered without further treatment)
Treatment compliance: not reported
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined
Other bias Low risk Comment: detailed description of demo-
graphic characteristics and sinusitis severity
rating with which to assess the comparabil-
ity of the groups at baseline
Meltzer 2005
Methods Study design: RCT
Study duration: January to September 2003
Participants Setting: not specified (71 medical centres)
Country: 14 countries
Health status: people presenting with signs and symptoms of acute rhinosinusitis for ≥
7 days but ≤ 28 days and major symptom score ≥ 5 but ≤ 12 at screening and baseline
visits with no more than 3 of the 5 following symptoms rated severe at the baseline visit:
rhinorrhoea, postnasal drip, nasal congestion/stuffiness, sinus headache and facial pain/
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pressure/tenderness on palpation over the paranasal sinuses
Numbers:
• total: treatment group 1 (243); treatment group 2 (235); treatment group 3 (251)
; control group (248)
• analysed for the purpose of this review: treatment group 3 (242); control group
(231)
Age: age 35.9 in treatment group 3, 34.4 in control group
Sex: 66% women
Exclusion criteria: signs or symptoms suggestive for fulminant bacterial sinusitis (fever
≥ 101 °F/38.3 °C, persistent severe unilateral facial or tooth pain, facial swelling, dental
involvement, or a worsening of symptoms after initial improvement), chronic rhinosi-
nusitis (or sinus or nasal surgery for this condition within 6 months before screening)
, otitis or atrophic rhinitis, nasal polyps noted on anterior rhinoscopic examination,
symptomatic seasonal allergic rhinitis (after pollen exposure during the study), an al-
lergy to corticosteroids, any other condition that would interfere with study evaluations,
unstable asthma or with a history of exacerbations within 30 days before screening or
forced expiratory volume in 1 second (FEV1) < 65% of predicted within 3months before
screening
Interventions Treatment group:
• Group 1
◦ intervention: mometasone furoate nasal
◦ dose, duration, frequency, administration: 200 µg, 10 days 1 time daily
(AM), nose spray
◦ intervention: placebo
◦ dose, duration, frequency, administration: 10 days 1 time daily (PM), nose
spray
◦ intervention: placebo
◦ dose, duration, frequency, administration: 10 days, 3 times daily, orally
◦ This group was excluded from the analyses, since it comprises neither only
placebo nor an antibiotic treatment.
• Group 2
◦ intervention: mometasone furoate nasal spray
◦ dose, duration, frequency, administration: 200 µg, 10 days 2 times daily
(AM), nose spray
◦ intervention: mometasone furoate nasal spray
◦ dose, duration, frequency, administration: 200 µg, 10 days 2 times daily
(PM), nose spray
◦ intervention: placebo
◦ dose, duration, frequency, administration: 10 days, 3 times daily, orally
◦ This group was excluded from the analyses, since it comprises neither only
placebo nor an antibiotic treatment.
• Group 3
◦ intervention: placebo
◦ dose, duration, frequency, administration: 10 days 1 time daily (AM), nose
spray
◦ intervention: placebo
◦ dose, duration, frequency, administration: 10 days 1 time daily (PM), nose
spray
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◦ intervention: amoxicillin
◦ dose, duration, frequency, administration: 500 mg, 10 days, 3 times daily,
orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 10 days 1 time daily (AM), nose spray
• intervention: placebo
• dose, duration, frequency, administration: 10 days 1 time daily (PM), nose spray
• intervention: placebo
• dose, duration, frequency, administration: 10 days, 3 times daily
Co-interventions: forbidden (nasal saline, nasal cromolyn sodium ipratropium bromide,
corticosteroids (excluding oral inhaled corticosteroids for mild to moderate persistent
asthma), antihistamines, decongestants, leukotriene pathway modifiers, analgesics, non-
steroidal anti-inflammatory drugs)
Outcomes Primary outcome:
1. Mean AM/PM major symptom score over days 2 to 15 of the treatment phase
Secondary outcomes:
1. Mean major symptom score
2. Total symptom score
3. Individual scores for each symptom (average weekly and for days 2 to 15 and 16
to 29)
4. Global response to treatment (at visit 4 or last treatment visit, scale 0 (complete
relief ) to 4 (no relief )) evaluated by the investigator and the participant
5. Time to onset of action (the first day of active treatment on which major symptom
score was statistically significantly different from placebo and sustained thereafter)
6. Evaluation of the proportion of participants presenting with symptoms suggestive
of fulminant bacterial rhinosinusitis or worsening or no improvement of symptoms by
day 3 or 4 (Kaplan-Meier)
7. Adverse effects related to treatment (mild, moderate, severe, life-threatening)
8. The proportion of participants, as assessed by the physician, who met disease
criteria for recurrence/relapse during the follow-up phase
Notes Funding source: Schering-Plough Research Institute
Contact with study authors for additional information: none
Other notes:
• Registration: major symptom score (rhinorrhoea, postnasal drip, nasal
congestion/stuffiness, sinus headache, facial pain/pressure/tenderness on palpation over
the nasal sinuses), total symptom score, vital signs, nasal examination, clinical
laboratory test, and physical examination
• Follow-up:
◦ telephone call on days 3 and 4 and by diary (symptom recording, 2 times
daily)
◦ treatment visits on days 8, 15, and 29: evaluation of major symptom score,
total symptom score, examination and treatment compliance
• Results:
◦ No significant difference in mean AM/PM major symptom score over days 2
to 15 of the treatment phase (no numbers or P values reported)
◦ Side effects:
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⋄ No exact numbers reported
⋄ Loss to follow up due to adverse events: treatment group 3 (5); control
group (6)
⋄ Treatment-emergent adverse events: treatment group 3 (33.5%);
control group (38%)
⋄ Detailed information concerning treatment-emergent adverse events):
treatment group (9/251 nausea, 7/251 diarrhoea, 3/251 abdominal pain); control
group (7/252 nausea, 10/252 diarrhoea, 3/252 abdominal pain)
◦ Clinical failure (evaluation of participants with symptoms suggestive of
fulminant bacterial rhinosinusitis or worsening or no improvement of symptoms by
day 3 to 4 or thereafter to determine whether they had failed to respond to treatment)
⋄ treatment group: 18/251
⋄ control group: 27/248
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects ... were randomized in a
1:1:1:1 ratio to 4 treatment arms”
Quote: “Randomisation was performed ac-
cording to a computer-generated code,
stratified on the basis of duration of rhinos-
inusitis symptoms before baseline (7 to 14
days and 15 to 28 days)”
Allocation concealment (selection bias) Low risk Quote: “The study was conducted in ac-
cordance with the Declaration of Helsinki
and guidelines on Good Clinical Practice.”
Comment: the randomisation schedule for
blinding of treatments was maintained by
the sponsor and was disclosed only after
the study completion and database clo-
sure. A set of sealed envelopes correspond-
ing to the individual participant supplies,
which contained the identification of the
test drug, was provided to each site to en-
able the investigator to identify the treat-
ment assignment of an individual partic-
ipant, in the event of an emergency that
requires this knowledge, without compro-
mising the blinding of other study partic-
ipants. These envelopes were returned to
the sponsor, and open envelopes were ac-
companied by a written explanation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: a double-dummy blinding
technique was used during the treatment
phase. Participants units were numbered
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from 0001 to 3000. All study drugs dis-
pensed were labelled with the study num-
ber, packaging requisition number, treat-
ment unit number, and the investiga-
tional use statement with the instruc-
tions for proper storage conditions. Placebo
or amoxicillin were identical in appear-
ance. Mometasone furoate nasal spray and
placebo spray were identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Post-randomisation dropout rate: 13/499
(2.6%) at day 15, 26/499 (5.2%) at day 29
(4/503 participants were excluded after
randomisation since they did not meet the
protocol criteria for entry. These were not
considered as drop outs)
• Dropout balance:
◦ treatment group: 9 (6 after
treatment phase, 3 during follow-up
phase)
◦ control group: 17 (7 after
treatment phase, 10 during follow-up
phase)
Reasons for missing data: loss to follow-up
(13 lost to follow-up after treatment phase,
13 during follow-up phase)
Ratio of participants with missing data to
participants with events: not calculable, be-
cause the primary outcome was not ’cure’
but a difference in symptom scores
Discontinuation of treatment: 49/499 (9,
8%)
• treatment group: 20
• control group: 29
• (We used the numbers of the table,
because there was a discrepancy between
the text and the table.)
Reasons for discontinuation of treatment:
adverse events, treatment failure, lost to fol-
low-up, wish to discontinue, non-compli-
ance with the protocol
The authors stated that the analyses were
based on an ITT population
Selective reporting (reporting bias) Unclear risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined. The
outcomes of interest in the review are re-
ported incompletely so that they cannot be
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entered in a meta-analysis
Other bias Low risk Comment:
• with the available information, we
could not detect reasons for bias (no
design-specific risks of bias, the study was
not stopped early, no imbalance of
participant characteristics at baseline,
blinding was not broken due to side
effects, no bias due to increased or
different diagnostic activity).
• E Meltzer received grant support
from Schering-Plough for this study and
is a consultant on the speakers’ bureau
and has received grants from numerous
pharmaceutical companies. H Staudinger
and C Bachert have disclosed no conflict
of interest.
• number of participants per centre: 6.
8 participants (instead of 16 as foreseen).
Merenstein 2005
Methods Study design: RCT
Study duration: 1 October 2001 to 31 March 2003
Participants Setting: ambulatory care (1 suburban ambulatory care office)
Country: USA
Health status: people presenting with at least 1 cardinal feature described by the clinical
prediction rule and having symptoms for at least 7 days
• cardinal features: purulent nasal discharge predominating on 1 side, local facial
pain predominating on 1 side, purulent nasal discharge on both sides and pus in the
nasal cavity
Numbers:
• total: treatment (67); control (68)
• analysed: treatment (56); control (60)
Age: mean 35.1 in the amoxicillin group and 32.6 in the placebo group
Sex: 69% women
Exclusion criteria: antibiotic treatment within the past month in the history, allergy to
penicillin, sinus surgery in history, compromised immunity, pneumonia in history, and
streptococcal pharyngitis in history
Interventions Treatment group:
• intervention: amoxicillin
• dose, duration, frequency, administration: 500 mg, 10 days, twice daily, orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 10 days, twice daily, orally
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Outcomes Primary outcome
1. Entirely improved (yes or no) at day 14
Secondary outcomes
1. Day of improvement
2. Side effects (diarrhoea, nausea, emesis, abdominal pain, rash, hot flashes, jittery,
dizziness, dry mouth, vaginal infection)
Notes Funding source: supported by a grant from the American Academy of Family Physicians
and the AmericanAcademy of Family Physicians Foundation Joint AAFP/F-AAFPGrant
Awards Program. Support was also provided by the Capitol Area Primary Care Research
Network
Contact with study authors for additional information: about random sequence gener-
ation, allocation concealment, blinding
Other notes:
• Follow-up: telephone interviews on days 3, 7, and 14 following patients’ visits for
sinusitis to the physician to assess clinical improvement (12 follow-up questions
(clinical improvement)
• Results:
◦ Entirely improved at day 14
⋄ treatment group: 32/56
⋄ control group: 25/60
◦ Side effects:
⋄ treatment group:13/56 (diarrhoea 4, nausea 4, emesis 1, abdominal
pain 2, rash 2, hot flashes 0, jittery 0, dizziness 3, dry mouth 1, vaginal infection 2)
⋄ control group: 7/60 (diarrhoea 1, nausea 5, emesis 0, abdominal pain 1,
rash 0, hot flashes 1, jittery 1, dizziness 0, dry mouth 0, vaginal infection 0)
⋄ No dropouts due to side effects
◦ Clinical failure: no data reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: they used stratified randomisa-
tion with each physician representing the
strata, and participants were randomised
in block sizes of 6. A computer random
number generator was used to create the
permuted blocks. A biostatistician who was
not employed by Georgetown University
performed the allocation sequence
Allocation concealment (selection bias) Low risk Comment: prior to the start of the trial, en-
velopes containing amoxicillin or placebo
were prepared by the pharmacy, and each
envelope was labelled with a study ID.
The envelopes given to each participant
contained 40 capsules, either placebo or
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amoxicillin, with instructions to take twice
daily for 10 days. The randomisation codes
were sent to the Pharmacy Department at
Georgetown and were kept in a locked cab-
inet. Participants were consecutively en-
rolled over the 18-month enrolment period
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: the envelopes were opaque, and
the pills within were identical in appear-
ance, size, shape, colour, and taste. All
study physicians, participants, and research
co-ordinators were blinded to the treat-
ment given to each participant. Through
this process allocation concealment was
achieved over the entire course of the en-
rolment period; neither physician nor par-
ticipant could determine which treatment
the next participant would receive
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate: 19/135
(14%)
• treatment group: 11
• control group 8
Reasons for missing data: loss to follow-up
(only baseline data collected)
Ratio of participants with missing data to
participants with events: 0.33
The authors state that the primary analy-
ses were performed using the ITT princi-
ple. The dropouts were counted as “not im-
proved” in the ITT analysis
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined. The
analysis of the subgroups was not specified
in the methods section
Other bias Low risk • With the available information, we
could not detect reasons for bias (no
design-specific risks of bias, the study was
not stopped early, no imbalance of
participant characteristics at baseline,
blinding was not broken due to side
effects, no bias due to increased or
different diagnostic activity)
• None of the authors report any
conflicts of interest
• Participants were recruited from 1
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general practice
Norrelund 1978
Methods Study design: RCT
Study duration: between January 10, 1977 and June, 30, 1977
Participants Setting: general practice (19 general practitioners)
Country: Denmark
Health status: participants showing at least 3 symptoms, including at least 1 of the main
symptoms
• main symptoms: yellow or yellowish-green or possibly blood-stained nasal
discharge on blowing the nose; good nasal passage together with a nasal voice
• other symptoms: feeling of malaise; headache, particularly behind the eyes,
behind the bridge of the nose, or corresponding to the maxilla; irritative cough
Number:
• total: treatment (73); control (67)
• analysed: treatment (71); control (64)
Age: older than 14 years, mean unknown
Sex: 61% women
Exclusion criteria: penicillin allergy, pregnancy
Interventions Treatment group:
• intervention: pivampicillin
• dose, duration, frequency, administration: 700 mg, 6 days, 2 times daily, orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 6 days, 2 times daily, orally
Co-interventions: concomitant use of nasal decongestants allowed (xylometazoline 0.
1% nasal spray, 4 times daily)
Outcomes Primary outcome:
1. Cure at day 8 (sum of endpoints for the individual participant was reduced by at
least 2/3 at follow-up investigation on day 8)
Secondary outcomes:
1. Resolution of purulent secretion
2. Resolution of irritative cough
3. Subjective improvement
4. Side effects
Notes Funding source: not stated
Contact with study authors for additional information: none
Other notes:
• Registration: symptom score at days 1 and 8 (purulent secretion, nasal stenosis,
general feeling of illness, headache, cough) during visit
• Follow-up:
◦ diary for 6 days (drug intake, intake of analgesics, intake of nose drops)
◦ Questionnaire of side effects (sore throat, nausea, vomiting, stomachache,
loose stools, diarrhoea, ’other’) during second visit
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• Results:
◦ cure at day 8
⋄ treatment group: 40/71
⋄ control group: 33/64
◦ cure or improvement at day 8
⋄ treatment group: 53/71
⋄ control group: 36/64
◦ side effects:
⋄ treatment group: 31/71 (all from gastrointestinal tract)
⋄ control group: 17/64 (2/3 from gastrointestinal tract)
⋄ no severe side effects
◦ clinical failure: no data reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: blocked randomisation (each
doctor had been sent a box containing 10
glasses, of which half in random sequence
contained an active ingredient). No infor-
mation about the process of selecting the
blocks
Allocation concealment (selection bias) Unclear risk Comment: no information about the cen-
tralisation of randomisation or the num-
bering of the glasses
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Comment: the glasses contained pivampi-
cillin or identical-looking placebo tablets.
No information about the blinding of
healthcare providers and outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate: 5/140
(3.6%)
• treatment group: 2 (adherence
problems)
• control group: 3 (2 because of
adverse events, 1 because of adherence
problems)
The ratio of participants with missing data
to participants with events: 0.07
No ITT analysis: participants who needed
referral to an ENT specialist or discontin-
ued medication because of side effects were
allowed to be removed from the trial
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Selective reporting (reporting bias) Unclear risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were not predefined.
Nevertheless, they predefined which symp-
toms, side effects, and medication intakes
theywould register. The definition of ’cure’
is described for the first time in the results
section
Other bias Low risk Comment:
• no information was provided about
the balance of participant characteristics
at baseline, except for gender.
• with the available information, we
could not detect other reasons for bias (no
design-specific risks of bias, the study was
not stopped early, blinding was not
broken due to side effects, no bias due to
increased or different diagnostic activity).
• average number of participants per
practice: 7.1
Rantanen 1973
Methods Study design: RCT
Study duration: not reported
Participants Setting: “outpatients”
Country: not specified
Health status: participants were diagnosed with acute maxillary sinusitis. The diagnosis
was based on anamnestic data, clinical examination, and irrigation findings (ratedmacro-
scopically with respect to the amount and quality of the secretion: purulent secretion,
mucous secretion, no secretion). X-ray examination (4 projections) revealed homoge-
nous shadows in the sinuses or fluid level. Secretion for bacteriological examination was
withdrawn through a puncture needle under sterile conditions
Number: treatment (27); control (34)
Age: mean 34 years
Sex: 64% women
Exclusion criteria: cases of sinusitis who were treated previously
Interventions Treatment group:
• intervention: doxycycline
• dose, duration, frequency, administration: 200 mg first day, followed by 100 mg,
5 days, once daily, orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 6 days, once daily, orally
Co-interventions (for all participants):
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• weekly irrigation of the maxillary sinuses with 100 mL (0.9% saline)
• xylometazoline chloride 0.1% 3 times daily
Outcomes Primary outcome:
1. cure, with respect to clinical picture, irrigation findings, and ostium function
Secondary outcomes:
1. a negative irrigation
2. regained ostial patency
Separate analyses were performed for sinuses with bacterial inflammation and sterile
inflammation
Notes Funding source: not stated
Contact with study authors for additional information: none
Other notes:
• Results:
◦ Recovery progress of sinuses (not participants) with respect to clinical
picture, irrigation findings, and ostium function:
⋄ Treatment group: 14/32 sinuses at day 7, 24/32 sinuses at day 14, 30/
32 sinuses at day 21, 32/32 sinuses at day 28
⋄ Control group: 19/44 sinuses at day 7, 36/44 sinuses at day 14, 42/44
sinuses at day 21, 44/44 sinuses at day 28
◦ Macroscopic changes of secretion after 1 week “good”:
⋄ Treatment group: 16/32 sinuses
⋄ Control group: 21/44 sinuses
◦ No retention in secretion
⋄ Treatment group: 10/32 sinuses after 1 week, 22/32 sinuses after 2
weeks
⋄ Control group: 10/44 sinuses after 1 week, 34/44 sinuses after 2 weeks
◦ Improvement of the patency of the ostium:
⋄ Treatment group: 22/32 sinuses obstructed at the start, 10/32 sinuses
after 1 week, 5/32 after 2 weeks
⋄ Control group 30/44 sinuses obstructed at the start, 17/44 after 1
week, 5/44 after 2 weeks
◦ Side effects: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no information provided about
assignment.
Allocation concealment (selection bias) Unclear risk Comment: no information provided about
randomisation list. Information about
numbering or appearance of drug contain-
ers is lacking
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Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “The examiners did not know to
which of the therapeutic schemes each par-
ticipant belonged.”
Comment: double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “All participants recovered com-
pletely within 4 weeks.”
Comment:
• exclusion after randomisation: not
reported
• post-randomisation dropout rate and
missing data: not reported
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary
and secondary endpoints were predefined.
“Cure” was measured for each “sinus” in-
stead of each participant, which was con-
fusing andmade pooling with other studies
impossible
Other bias Unclear risk Comment: insufficient power (number of
participants far too low)
Stalman 1997
Methods Study design: RCT
Study duration: between September 1, 1993 and August 31, 1995
Participants Setting: general practice (12 family practices)
Country: the Netherlands
Health status: people with symptoms of an upper respiratory tract infection for at least
5 days, and 3 main symptoms or 2 main symptoms and 1 other symptom
• main symptoms: symptoms after a common cold or influenza, purulent nasal
discharge, pain in the maxillary sinuses on bending forward
• other symptoms: predominantly unilateral maxillary pain, toothache, or pain
when chewing
Number:
• total: treatment (98); control (94)
• analysed: treatment (94); control (92)
Age: mean 37
Sex: 65% women
Exclusion criteria: people with xylometazoline nose drop treatment lasting more than
7 days, comorbidity (diabetes mellitus, heart failure, immune deficiency), pregnancy
or breastfeeding, symptoms lasting longer than 3 months, antibiotic treatment in the
previous 4 weeks, allergy to doxycycline, severe illness resulting from a sinusitis in 1 of
the other sinuses, antiacid or iron treatment, referral to an ENT specialist, inability to
speak Dutch
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Interventions Treatment group:
• intervention: doxycycline
• dose, duration, frequency, administration: 100 mg, two tablets for the first day,
followed by 100 mg, 9 days, once daily, orally (coated tablets)
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 2 tablets first day, followed 1 tablet, 9
days, once daily, orally (coated tablets)
Co-interventions (for all participants):
• xylometazoline 0.1% nose drops and steam inhalation for 15 minutes 3 times
daily as long as they had symptoms
• paracetamol 500 mg if needed
Outcomes Primary outcomes:
1. resolution of facial pain (McGill-Melzack Pain Questionnaire, recorded daily by
the participant, score: none or mild)
2. resumption of daily activities (recorded daily by the participant, score: normal
level)
Secondary outcomes:
1. resumption of school or work
2. intake of analgesics stopped
3. intake of nose drops stopped
4. resolution of all initial symptoms except preceding common cold or influenza 10
and 42 days after inclusion
5. cure at day 10 (’completely cured’: meeting all primary and secondary outcome
events)
6. side effects (nausea, vomiting, abdominal pain, diarrhoea, rash, dizziness)
Notes Funding source: supported by grants from the Nederlandse organisatie voor Weten-
schappelijk Onderzoek and Pharbita Ltd
Contact with study authors for additional information: none. Young 2008 had contact
with the study authors and obtained the exact cure rates at day 10
Other notes:
• registration: medical history, sex, age, health insurance, season, multiple-choice
questions about the duration of symptoms, reason for encounter, demand for help,
medical history and ear, nose, and throat examination during the first visit
• follow-up:
◦ diary for 10 days (absenteeism from school or work, frequency of steaming,
intake of nose drops and analgesics, intake of study medication, adverse effects)
◦ Evaluation by the general practitioner at 10 and 42 days (evaluation of
symptoms, repeated ear, nose, and throat examination)
• Results:
◦ cure at day 10 (“completely cured”)
⋄ We estimated numbers of events by multiplying the percentage with
the total number of participants in the group to make pooling of results possible.
⋄ treatment group: 56/94
⋄ control group: 55/92
◦ cure at day 10 (meeting the primary outcome)
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⋄ Since exact numbers for each treatment group were not reported, we
used the numbers obtained by Young 2008
⋄ treatment group: 63/95
⋄ control group: 59/93
◦ improvement at day 10
⋄ treatment group: 80/94
⋄ control group: 79/92
◦ side effects:
⋄ treatment group: 17/94 (nausea 9, vomiting 5, abdominal pain 5,
diarrhoea 2, rash 2, dizziness 1)
⋄ control group: 2/92 (nausea 2)
◦ clinical failure (discontinuation of trial medication due to treatment failure,
no information about whether or not open antibiotic treatment was started)
⋄ treatment group: 3/94
⋄ control group: 7/92
◦ relapse:
⋄ treatment group: 5/94
⋄ control group: 1/92
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: participants were assigned to
doxycyline or placebo treatment in blocks
of 4 according to a computer-generated
randomisation schedule
Allocation concealment (selection bias) Unclear risk Comment: no information about central-
isation of randomisation, numbering of
drug containers, or opaque, sealed en-
velopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: doxycycline and placebo ap-
peared and tasted the same. Blinding of
participants and treatment team was main-
tained throughout the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate at day 10:
6/192 (3.1%)
• treatment group: 4 (2 of them
because of vomiting and abdominal pain)
• control group: 2
Ratio of participants with missing data to
participants with events: 0.05
Discontinuation of trial medication rate:
20/186 (10.7%)
• treatment group: 12 (3 for treatment
failure, 5 for recurrence, 4 for side effects)
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• control group: 8 (7 for treatment
failure, 1 for recurrence)
All these participants were included in the
analysis following the ITT principle
Selective reporting (reporting bias) Low risk The study protocol is described in the
methods section. The primary and sec-
ondary endpoints were predefined. Only
the definition of “improvement” was not
stated clearly
Other bias Low risk Comment:
• concerning the characteristics at
baseline, there were slight differences
between treatment groups with regard to
reason for encounter, demand for help,
season, relapse of sinusitis, nasal speech,
and cervical lymphatic glands.
• with the available information, we
could not detect other reasons for bias (no
design-specific risks of bias, the study was
not stopped early, blinding was not
broken due to side effects, there was no
bias due to increased or different
diagnostic activity).
• number of recruited participants per
practice: 15.6
Van Buchem 1997a
Methods Study design: RCT
Study duration: between 1 March 1993 and 1 March 1994
Participants Setting: general practice
Country: the Netherlands
Health status: adults with a clinical diagnosis of maxillary sinusitis (history, physical
examination), for whom antibiotic therapy was considered, confirmed by radiograph (>
5 mm mucosal thickening, opacity or air-fluid level). Ear, nose, and throat comorbidity
was assessed; approximately 12% had allergic disease
Number:
• total: treatment (108); control (106)
• analysed: treatment (105); control (101)
Age: mean 34
Sex: 63% women
Exclusion criteria: other nasal disorders (e.g. nasal polyps), concurrent bronchitis, current
episodes of longer than 3 months, antibiotic treatment during the previous month,
known hypersensitivity to amoxicillin, hepatic, renal, or immunological disorder, and
coagulation abnormalities
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Interventions Treatment group:
• intervention: amoxicillin
• dose, duration, frequency, administration: 750 mg, 7 days, 3 times daily, orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 7 days, 3 times daily, orally
Co-interventions (for all participants):
• xylometazoline 0.1%
• steam inhalation (duration not specified) (mentholated spirit)
• concomitant use of paracetamol was allowed.
Outcomes Primary outcomes:
1. cure rate after 14 days (“Cure” was defined as “no symptoms”)
2. symptom scores after 7 and 14 days.
• “Cure” was defined as “no symptoms”
• “Greatly decreased symptoms” was defined as “at most two patient accounts of
symptoms or sets of examination data had a score lower than 5” (which means that
they are still present)
Secondary outcomes:
1. resolution of radiographic abnormalities after 14 days
2. occurrence of side effects
3. relapses (during 1-year follow-up)
4. chronic evolution
Bacteriological outcomes were not assessed.
Notes Funding source: not stated
Contact with study authors for additional information: none
Other notes:
• All participants were referred to the ENT specialist after inclusion for an extended
anamnesis and profound physical examination with rhinoscopy and blood
examination.
• Follow-up:
◦ at day 7 by ENT specialist (intercurrent history and physical examination,
number of capsules, side effects)
◦ at day 14 by ENT specialist (intercurrent history, physical examination,
number of capsules, side effects, blood examination, sinus radiograph) (or earlier when
extra follow-up was needed).
◦ When extra therapy was needed after day 14, a maxillary puncture was
performed.
◦ Relapses and complications were registered by the general practitioner
during 1 year
• Results:
◦ Cure at 14 days:
⋄ treatment group: 68/105
⋄ control group: 53/101
◦ Greatly decreased symptoms at 14 days:
⋄ treatment group: 87/105
⋄ control group: 78/101
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◦ Side effects (mostly gastrointestinal symptoms or rash)
⋄ treatment group: 29/105
⋄ control group: 9/101
◦ Clinical failure (open antibiotic therapy to start due to severe symptoms)
⋄ treatment group: 3/105
⋄ control group: 1/101
◦ Relapse:
⋄ treatment group: 23/105
⋄ control group: 18/101
◦ Chronic evolution: none
◦ Complications:None during 1-year follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: unrestricted randomisation
(computer-generated list used for alloca-
tion)
Quote: “The randomisation of allocation
of the amoxicillin or placebo (distributed in
identical bottles) was computer generated”
Allocation concealment (selection bias) Low risk Quote: “Randomisation of participants
was carried out and capsules were provided
by the hospital pharmacy in the hospital
to which participants were referred to the
ENT specialist.”
Quote: “During the trial, the code of al-
location schedule was kept in the office of
the head of the hospital pharmacy, and was
broken prematurely only if severe clinical
development or severe adverse effects oc-
curred”
Comment: the capsules with amoxicillin
or placebo looked and tasted identical and
were prescribed in the same frequency and
for the same duration. The capsules were
distributed in identical bottles
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: nature of the medication
blinded for the pharmacist’s assistant, par-
ticipant, and ENT specialist
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate: 8/214
(3.7%)
• treatment group: 3
• control group: 5
Reason for missing data: not attending fol-
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low-up visit
Ratio of participants with missing data to
participants with events: 0.07
Discontinuation of trial medication rate: 1/
210 (0.5%)
• treatment group: 0
• control group: 1 (adverse effects)
Treatment compliance reported as 98% as-
sessed by pills taking by participants
Intention-to-treat analysis
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined
Other bias Unclear risk Comment:
• selection of participants with worse
symptoms: only 20% of participants with
possible maxillary sinusitis entered the
trial (declining participation, meeting
exclusion criteria, infringement of
protocol, or participants with symptoms
that did not justify antibiotics).
Varonen 2003
Methods Study design: RCT
Study duration: from November 1998 to October 1999
Participants Setting: ambulatory care (9 practices)
Country: Finland
Health status: people with an upper respiratory tract infection and having at least 3 main
symptoms and 1 clinical sign
• main symptoms: nasal obstruction, nasal discharge, headache, post-nasal drip,
cough, sinus pain, unilateral facial pain, maxillary toothache, hyposmia, anosmia,
malaise, or fever
• clinical signs: purulent secretion in the nasal cavity, discharge in the pharynx, and
tenderness in sinus tapping
Numbers:
• total: treatment (88); control (60), missing treatment data (2)
• analysed: treatment (85); control (57)
Age: mean 40.6 in treatment group and 38.1 in control group
Sex: 70% women (2 unknown sex)
Exclusion criteria were acute maxillary sinusitis symptoms lasting over 30 days, antibi-
otics during the previous month, allergy to study medications, pregnancy, breastfeeding,
exacerbation of a diagnosed chronic maxillary sinusitis, previous paranasal sinus surgery,
clinical suspicion of dental or frontal sinusitis or pansinusitis, suspicion of a severe com-
plication, and previous sinus surgery
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Interventions Treatment group:
• Group 1
◦ intervention: amoxicillin
◦ dose, duration, frequency, administration: 750 mg, 7 days, twice daily, orally
• Group 2
◦ intervention: penicillin V
◦ dose, duration, frequency, administration: 1500 IU, 7 days, twice daily, orally
• Group 3
◦ intervention: doxycycline
◦ dose, duration, frequency, administration: 100 mg, 7 days, twice daily, orally
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 7 days, twice daily
Co-interventions: allowed if the physician considered them necessary
• xylometazoline
• paracetamol
• anti-inflammatory agents
For this review, group 1, 2, and 3 were combined in the analyses
Outcomes Primary outcome:
1. recovery rate after 2 weeks (according to the telephone interview)
Secondary outcomes:
1. incidence of side effects
2. subjective symptom score (at days 3 and 10)
3. duration of sinusitis
4. use of additional medication
5. frequency of chronic or recurrent sinusitis during 1-year follow-up
6. number of physician consultations during 1-year follow-up
Notes Funding source: Stakes, the National Research and Development Centre for Welfare
and Health covered the administrative and travel costs of this study. Leiras-Schering and
SmithKline Beecham provided the study medication
Contact with study authors for additional information: none
Other notes:
• Registration:
◦ Completion of a questionnaire (12 symptoms (3-step scale), duration of
symptoms, double sickening)
◦ Recording of history and clinical findings
◦ Performance of ultrasound examination, nasal samples, and sinus
radiography (occipitomental, Waters view)
• Follow-up:
◦ diary for 2 weeks (12 symptoms (3-step scale), possible self medication, side
effects, overall estimate whether they thought they continued to have sinusitis)
◦ Telephone interview after 2 weeks (subjective symptoms, severity, possible
side effects, participants’ estimate of recovery or recurrence)
◦ Check of patient records after 1 year to register recurrent or chronic sinusitis
• Results:
◦ Cure at 2 weeks:
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⋄ treatment group: 70/85
⋄ control group: 39/57
◦ Side effects:
⋄ treatment group:32/82 (29/79 + 3 loss to follow-up due to side effects)
(diarrhoea 7% (6/82), stomach pain 22%, headache 6%, rash 2%, vaginal discharge
4%, fatigue 6%)
⋄ control group: 13/48 (12/47 + 1 loss to follow-up due to side effects)
(diarrhoea 6% (3/48), stomach pain 12%, headache 4%, rash 0%, vaginal discharge
0%, fatigue 6%)
◦ Clinical failure (requiring open antibiotic treatment)
⋄ treatment group: 6/85
⋄ control group: 10/57
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The treatments were previously
randomised in blocks of 20 consecutive
participants at the Military Pharmacy in
Helsinki.”
Allocation concealment (selection bias) Low risk Quote: “The studymedicationswere coded
with 6-number individual codes.”
Quote: “During the trial, the senior re-
searcher kept the code and was the primary
contact in the case of adverse effects or se-
vere complications. All study centres also
had the code in a closed envelope to be
opened only if the senior researcher could
not be reached.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: the medication bottles were
identically sealed.
Quote: “Physicians, participants, and the
main researcher remained blinded to
the treatments until the recruitment was
ended.”
Comment: the result of the ultrasound was
not disclosed to the participant
Comment: the main researcher did not
know the participant’s history, treatment,
or the result of the ultrasound examination
while interviewing the participant 14 to 16
days after inclusion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate: 8/150
(5,3%)
• no treatment data: 2
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• treatment group: 3 (side effects)
• control group: 3 (1 violation of the
study protocol (pregnancy), 1 not reached
by phone, 1 side effects)
Ratio of participants with missing data to
participants with events: 0.07
Comment:
• the authors analysed the data for the
main outcomes by intention-to-treat.
Withdrawals (trial medication or other
antibiotics) were analysed as treatment
failures.
• duration of sinusitis was analysed
only in participants who recovered fully
during the 2-week follow-up
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined
Other bias Low risk Number of participants per health centre:
15.8
Williamson 2007
Methods Study design: RCT (factorial design)
Study duration: from November 2001 to November 2005
Participants Setting: ambulatory care (58 family practices, 74 family physicians)
Country: UK
Health status: people presenting with uncomplicated acute illness (< 28 days) and at least
2 symptoms and 1 clinical sign of sinusitis (according to the Berg and Carenfelt criteria:
purulent nasal discharge predominating on 1 side, local facial pain predominating on 1
side, purulent nasal discharge on both sides, pus in the nasal cavity)
Numbers:
• total: treatment (113, including treatment group 1 and 2); control (127,
including treatment group 3 and control group)
• analysed: treatment (101, including treatment group 1 and 2); control (108,
including treatment group 3 and control group)
Age: mean 43 in amoxicillin group and 42 in placebo group
Sex: 72.5% women
Exclusion criteria: < 2 of the Berg and Carenfelt criteria (low probability of sinusitis),
history of recurrent sinusitis (≥ 2 attacks of acute sinusitis in the previous 12 months),
significant morbidities (poorly controlled diabetes or heart failure), pregnant or breast-
feeding, allergies, a history of adverse reactions to either medications, and receiving an-
tibiotics or steroids in the previous month
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Interventions Treatment group:
• Group 1
◦ intervention: amoxicillin
◦ dose, duration, frequency, administration: 750 mg, 7 days, twice daily, orally
◦ intervention: budesonide
◦ dose, duration, frequency, administration: 1 dosis, 10 days, once daily, nose
spray (in each nostril)
• Group 2
◦ intervention: amoxicillin
◦ dose, duration, frequency, administration: 750 mg, 7 days, twice daily, orally
◦ intervention: placebo
◦ dose, duration, frequency, administration: 10 days, once daily, nose spray (in
each nostril)
• Group 3
◦ intervention: placebo
◦ dose, duration, frequency, administration: 7 days, twice daily, orally
◦ intervention: budesonide
◦ dose, duration, frequency, administration: 1 dosis, 10 days, once daily, nose
spray (in each nostril)
Control group:
• intervention: placebo
• dose, duration, frequency, administration: 7 days, twice daily, orally
• intervention: placebo
• dose, duration, frequency, administration: 1 dosis, 10 days, once daily, nose spray
(in each nostril)
For this review, we reduced the 4 treatment arms to 2 (factorial design): treatment group
1 and 2 (treatment group) versus treatment group 3 and control group (control group)
Outcomes Primary outcome:
1. symptom resolution (all symptoms score 0 in the diary)
Secondary outcome:
1. symptom severity score
Notes Funding source: supported by the UK Department of Health. The UK Department of
Health did not participate in the design and conduct of the study, in the collection,
analysis, and interpretation of the data, or in the preparation, review, or approval of the
manuscript
Contact with study authors for additional information: none
Other notes:
• Registration at inclusion: baseline questionnaire including clinical signs and
confirmation of entry criteria completed by general practitioners, basic physical
examination of temperature recording, sinus tenderness, and anterior nasal cavity
inspection (anterior rhinoscopy), recording of symptom duration and pain severity,
collection of baseline demographic details.
• Follow-up:
◦ diary for 14 days (11 symptom variables, 7-point Likert scale)
◦ questionnaire on other variables (clinical features and satisfaction), and a
telephone call during the first week to encourage adherence and improve the quality of
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the diary returns
• Subgroup analysis of the pain and unwell group
• Results:
◦ Symptom resolution at day 10:
⋄ treatment group: 71/101
⋄ control group: 71/108
◦ Side effects: no information available
◦ Clinical failure (withdrawal because of ongoing symptoms)
⋄ treatment group: 1/101
⋄ control group: 1/108
⋄ no serious adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Recruitment plan was for 4 re-
cruited cases per family physician (1 block
randomised pack of 4 per physician and
2 physicians per practice).” Quote: “The
packs weremade up using random number
tables.”
Quote: “Randomisation was performed at
the level of the patient.”
Quote: “Each randomized pack therefore
consisted of an auditable sequence of the
4 possible combinations of the 2 interven-
tions and physicians were instructed to use
the packs in sequence.”
Allocation concealment (selection bias) Low risk Quote: “An independent person to the trial
team was employed for distribution using
the random sequence and trial code.”
Quote: “The code breakwas kept in a sealed
envelope in a locked filing cabinet at the
university throughout the study period.”
Quote: “All drug containers and all trial
materials were identifiable only by the ran-
domisation code number.”
Comment: blind-sequenced trial packs.
Quote: “The sealed, opaque, numbered
packages contained physician instructions
and either active or placebo drugs that were
distributed in batches in randomised blocks
of 4.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Neither the antibiotic nor the
nasal steroid spray was recognisable as ac-
tive or placebo medication, identical in
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taste and appearance.”
Comment: no significant difference in par-
ticipant’s belief in the effectiveness of the
treatment allocated (0-to-5 scales) for the
antibiotic tablet versus placebo tablet (P =
0.07), or for steroid spray versus placebo
spray (P = 0.25)
Comment: the single code break envelope
was not opened until all data collection
had been completed and all variables had
been entered into the database. All out-
come assessments were recorded on a cen-
tral database and checked and verifiedwhen
necessary by a research fellow blinded to
treatment grouping
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation dropout rate: 31/240
(12.9%) due to loss to follow-up
• treatment group: 12
• control group: 19
Reasons for missing data: loss to follow-up
2 additional participants withdrew (1 in
the amoxicillin group and 1 in the placebo
group) because of ongoing symptoms; we
considered these as failures in our review
Ratio of participants with missing data to
participants with events: 0.23
Comment:
1. the authors remarked that
participants who had pus on examination
and were male were more likely to be lost
to follow-up
2. the authors performed a sensitivity
analysis in 2 ways: with imputation of
data (assuming those lost to follow-up
were still symptomatic at day 14) and
with and without the additional telephone
information obtained. They found no
significant difference in results.
Selective reporting (reporting bias) Low risk Comment: the study protocol is described
in the methods section. The primary and
secondary endpoints were predefined
Other bias Low risk Comment:
1. there was no significant imbalance of
participant characteristics at baseline,
except for temperature (slightly higher
temperature in the placebo group, but the
76Antibiotics for acute rhinosinusitis in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Williamson 2007 (Continued)
difference was too small to have any
clinical importance).
2. with the available information, we
could not detect other reasons for bias (no
design-specific risks of bias, the study was
not stopped early, no imbalance of
participant characteristics at baseline,
blinding was not broken due to side
effects, no bias due to increased or
different diagnostic activity).
3. Dr Little reported receiving
consultancy fees for 2 half days from
Abbott Pharmaceuticals regarding
complications of respiratory tract
infections. No other authors reported
financial disclosures. Family physicians
received USD 50 per participant recruited
from government funding, but
participants received no reimbursement.
4. average number of participants per
practice: 3.6
CRP: C-reactive protein
CT: computed tomography
ENT: ear, nose, and throat
ITT: intention-to-treat
RCT: randomised controlled trial
SNOT: Sino-Nasal Outcome Test
VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gananca 1973 Randomised, double-blind, placebo-controlled trial. Acute sinusitis diagnostic criteria did not fulfil inclusion criteria
for this review (clinical symptoms and signs and bacteriologic criteria)
Gananca 1977 Randomised, double-blind, placebo-controlled trial. Acute sinusitis diagnostic criteria did not fulfil inclusion criteria
for this review (clinical symptoms and signs and bacteriologic criteria)
Hadley 2010 Prospective, multicentre, placebo-controlled, randomised, double-blind phase IIIb clinical trial. Acute sinusitis diag-
nostic criteria did not fulfil inclusion criteria for this review (clinical symptoms and signs, confirmed by radiography;
analysis only performed for participants with positive sinus culture)
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Hansen 2000a Randomised, double-blind, placebo-controlled trial. Acute sinusitis diagnostic criteria did not fulfil inclusion criteria
for this review (clinical symptoms (maxillary pain) and raised values of either C-reactive protein or erythrocyte
sedimentation rate
Haye 1998 Randomised, double-blind, placebo-controlled trial. Acute sinusitis diagnostic criteria did not fulfil inclusion criteria
for this review (exclusion of participants with empyema (defined as complete opacity or an air-fluid level, or a
mucosal thickness of 6 mm or more as measured at the upper lateral border of the maxillary sinus))
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics versus placebo for acute rhinosinusitis: cure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cure 11 2208 Odds Ratio (M-H, Fixed, 95% CI) 1.38 [1.15, 1.65]
1.1 Clinically diagnosed acute
rhinosinusitis
8 1687 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [1.02, 1.53]
1.2 Acute rhinosinusitis
confirmed by radiography
3 394 Odds Ratio (M-H, Fixed, 95% CI) 1.57 [1.03, 2.39]
1.3 Acute rhinosinusitis
confirmed by computed
tomography
1 127 Odds Ratio (M-H, Fixed, 95% CI) 4.89 [1.75, 13.72]
Comparison 2. Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severity or duration of different
clinical symptoms: resolution
of purulent secretion
3 660 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [1.13, 2.22]
2 Side effects: total 10 1816 Odds Ratio (M-H, Fixed, 95% CI) 2.21 [1.74, 2.82]
2.1 Clinically diagnosed
rhinosinusitis
7 1371 Odds Ratio (M-H, Fixed, 95% CI) 2.10 [1.60, 2.77]
2.2 Rhinosinusitis confirmed
by imaging
3 445 Odds Ratio (M-H, Fixed, 95% CI) 2.65 [1.58, 4.46]
3 Side effects: diarrhoea 7 1210 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.00 [1.41, 2.85]
4 Clinical failure 12 2603 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.48 [0.36, 0.63]
4.1 Clinically diagnosed
rhinosinusitis
8 2101 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.49 [0.36, 0.67]
4.2 Rhinosinusitis confirmed
by radiography
2 312 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.09 [0.52, 8.35]
4.3 Rhinosinusitis confirmed
by computed tomography
2 190 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.25 [0.11, 0.55]
79Antibiotics for acute rhinosinusitis in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 3. Sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinically diagnosed
rhinosinusitis
9 19409 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [1.14, 1.29]
1.1 Cure at 1 week 4 856 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.81, 1.41]
1.2 Cure at 10 days 4 1048 Odds Ratio (M-H, Fixed, 95% CI) 1.19 [0.92, 1.53]
1.3 Cure at 2 weeks 4 717 Odds Ratio (M-H, Fixed, 95% CI) 1.37 [0.98, 1.91]
1.4 Cure at 1 week, with
Garbutt data
5 1011 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [0.93, 1.54]
1.5 Cure at 10 days, with
Garbutt data
5 1203 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.91, 1.47]
1.6 Influence of missing
data: cure at any time point if
dropouts were successes
8 1785 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [1.02, 1.52]
1.7 Influence of missing
data: cure at any time point if
dropouts were failures
8 1785 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [1.02, 1.51]
1.8 Influence of missing
data: cure at any time point if
dropouts had the same cure
rate as control group
8 1785 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [1.02, 1.51]
1.9 Influence of missing data:
cure at 1 week if dropouts were
successes
4 901 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.79, 1.35]
1.10 Influence of missing
data: cure at 1 week if dropouts
were failures
4 901 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.84, 1.44]
1.11 Influence of missing
data: cure at 1 week if dropouts
had the same cure rate as
control group
3 632 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.79, 1.50]
1.12 Influence of missing
data: cure at 10 days if dropouts
were successes
3 840 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.94, 1.66]
1.13 Influence of missing
data: cure at 10 days if dropouts
were failures
3 840 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.94, 1.65]
1.14 Influence of missing
data: cure at 10 days if dropouts
had the same cure rate as
control group
3 840 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [0.93, 1.65]
1.15 Influence of missing data:
cure at 2 weeks if dropouts
were successes
4 1026 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [0.98, 1.73]
1.16 Influence of missing data:
cure at 2 weeks if dropouts
were failures
4 776 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [0.99, 1.84]
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1.17 Influence of missing data:
cure at 2 weeks if dropouts had
the same cure rate as control
group
4 776 Odds Ratio (M-H, Fixed, 95% CI) 1.35 [0.99, 1.86]
1.18 Overall treatment
effect (with Young 2008 data
concerning Stalman)
8 1687 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [1.04, 1.56]
2 Rhinosinusitis confirmed by
imaging
5 1086 Odds Ratio (M-H, Fixed, 95% CI) 1.85 [1.41, 2.44]
2.1 Cure at any time point 5 584 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [1.20, 2.45]
2.2 Cure or improvement at
any time point
4 502 Odds Ratio (M-H, Fixed, 95% CI) 2.08 [1.35, 3.21]
Analysis 1.1. Comparison 1 Antibiotics versus placebo for acute rhinosinusitis: cure, Outcome 1 Cure.
Review: Antibiotics for acute rhinosinusitis in adults
Comparison: 1 Antibiotics versus placebo for acute rhinosinusitis: cure
Outcome: 1 Cure
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Clinically diagnosed acute rhinosinusitis
Stalman 1997 56/94 55/92 11.0 % 0.99 [ 0.55, 1.78 ]
Williamson 2007 75/101 80/108 9.7 % 1.01 [ 0.54, 1.88 ]
Kaiser 2001 76/133 75/132 15.8 % 1.01 [ 0.62, 1.65 ]
Bucher 2003 95/124 93/126 10.6 % 1.16 [ 0.65, 2.07 ]
Norrelund 1978 40/71 33/64 7.4 % 1.21 [ 0.62, 2.39 ]
De Sutter 2002 73/189 59/195 17.4 % 1.45 [ 0.95, 2.21 ]
Merenstein 2005 32/56 25/60 5.1 % 1.87 [ 0.89, 3.90 ]
Varonen 2003 70/85 39/57 4.0 % 2.15 [ 0.98, 4.74 ]
Subtotal (95% CI) 853 834 81.0 % 1.25 [ 1.02, 1.53 ]
Total events: 517 (Antibiotics), 459 (Placebo)
Heterogeneity: Chi2 = 5.28, df = 7 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
2 Acute rhinosinusitis confirmed by radiography
Axelsson 1970 27/74 10/32 4.3 % 1.26 [ 0.52, 3.06 ]
Van Buchem 1997a 68/105 53/101 9.3 % 1.66 [ 0.95, 2.91 ]
Kaiser 2001 27/38 26/44 3.4 % 1.70 [ 0.67, 4.28 ]
0.002 0.1 1 10 500
Favours placebo Favours antibiotics
(Continued . . . )
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Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 217 177 17.1 % 1.57 [ 1.03, 2.39 ]
Total events: 122 (Antibiotics), 89 (Placebo)
Heterogeneity: Chi2 = 0.30, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
3 Acute rhinosinusitis confirmed by computed tomography
Lindbaek 1996 32/83 5/44 2.0 % 4.89 [ 1.75, 13.72 ]
Subtotal (95% CI) 83 44 2.0 % 4.89 [ 1.75, 13.72 ]
Total events: 32 (Antibiotics), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Total (95% CI) 1153 1055 100.0 % 1.38 [ 1.15, 1.65 ]
Total events: 671 (Antibiotics), 553 (Placebo)
Heterogeneity: Chi2 = 12.61, df = 11 (P = 0.32); I2 =13%
Test for overall effect: Z = 3.50 (P = 0.00046)
Test for subgroup differences: Chi2 = 7.01, df = 2 (P = 0.03), I2 =71%
0.002 0.1 1 10 500
Favours placebo Favours antibiotics
82Antibiotics for acute rhinosinusitis in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes,
Outcome 1 Severity or duration of different clinical symptoms: resolution of purulent secretion.
Review: Antibiotics for acute rhinosinusitis in adults
Comparison: 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes
Outcome: 1 Severity or duration of different clinical symptoms: resolution of purulent secretion
Study or subgroup Antibiotic Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Sutter 2002 140/187 116/179 55.8 % 1.62 [ 1.03, 2.54 ]
Norrelund 1978 30/71 18/64 20.5 % 1.87 [ 0.91, 3.84 ]
Stalman 1997 66/84 56/75 23.7 % 1.24 [ 0.60, 2.60 ]
Total (95% CI) 342 318 100.0 % 1.58 [ 1.13, 2.22 ]
Total events: 236 (Antibiotic), 190 (Placebo)
Heterogeneity: Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours placebo Favours antibiotics
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Analysis 2.2. Comparison 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes,
Outcome 2 Side effects: total.
Review: Antibiotics for acute rhinosinusitis in adults
Comparison: 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes
Outcome: 2 Side effects: total
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Clinically diagnosed rhinosinusitis
Garbutt 2012 13/81 10/74 9.7 % 1.22 [ 0.50, 2.99 ]
Varonen 2003 32/82 13/48 11.0 % 1.72 [ 0.79, 3.74 ]
De Sutter 2002 55/189 37/195 28.5 % 1.75 [ 1.09, 2.82 ]
Norrelund 1978 31/71 17/64 11.1 % 2.14 [ 1.04, 4.43 ]
Merenstein 2005 13/56 7/60 5.7 % 2.29 [ 0.84, 6.24 ]
Kaiser 2001 32/133 14/132 11.8 % 2.67 [ 1.35, 5.28 ]
Stalman 1997 17/94 2/92 1.8 % 9.94 [ 2.22, 44.37 ]
Subtotal (95% CI) 706 665 79.7 % 2.10 [ 1.60, 2.77 ]
Total events: 193 (Antibiotics), 100 (Placebo)
Heterogeneity: Chi2 = 6.86, df = 6 (P = 0.33); I2 =13%
Test for overall effect: Z = 5.29 (P < 0.00001)
2 Rhinosinusitis confirmed by imaging
Axelsson 1970 3/75 2/34 2.9 % 0.67 [ 0.11, 4.19 ]
Lindbaek 1996 49/86 16/44 10.1 % 2.32 [ 1.10, 4.90 ]
Van Buchem 1997a 29/105 9/101 7.3 % 3.90 [ 1.74, 8.74 ]
Subtotal (95% CI) 266 179 20.3 % 2.65 [ 1.58, 4.46 ]
Total events: 81 (Antibiotics), 27 (Placebo)
Heterogeneity: Chi2 = 3.17, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 3.68 (P = 0.00024)
Total (95% CI) 972 844 100.0 % 2.21 [ 1.74, 2.82 ]
Total events: 274 (Antibiotics), 127 (Placebo)
Heterogeneity: Chi2 = 10.73, df = 9 (P = 0.29); I2 =16%
Test for overall effect: Z = 6.41 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.60, df = 1 (P = 0.44), I2 =0.0%
0.002 0.1 1 10 500
Side effects placebo Side effects antibiotics
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Analysis 2.3. Comparison 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes,
Outcome 3 Side effects: diarrhoea.
Review: Antibiotics for acute rhinosinusitis in adults
Comparison: 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes
Outcome: 3 Side effects: diarrhoea
Study or subgroup Experimental Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Axelsson 1970 1/75 0/34 0.7 % 4.28 [ 0.06, 294.11 ]
De Sutter 2002 55/189 37/195 56.7 % 1.74 [ 1.09, 2.78 ]
Garbutt 2012 7/81 7/74 10.3 % 0.91 [ 0.30, 2.71 ]
Lindbaek 1996 36/86 5/44 20.5 % 4.06 [ 1.86, 8.85 ]
Merenstein 2005 4/56 1/60 3.9 % 3.73 [ 0.63, 22.24 ]
Stalman 1997 2/94 0/92 1.6 % 7.31 [ 0.45, 117.80 ]
Varonen 2003 6/82 3/48 6.4 % 1.18 [ 0.29, 4.77 ]
Total (95% CI) 663 547 100.0 % 2.00 [ 1.41, 2.85 ]
Total events: 111 (Experimental), 53 (Control)
Heterogeneity: Chi2 = 7.50, df = 6 (P = 0.28); I2 =20%
Test for overall effect: Z = 3.86 (P = 0.00011)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Side effects placebo Side effects antibiotics
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Analysis 2.4. Comparison 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes,
Outcome 4 Clinical failure.
Review: Antibiotics for acute rhinosinusitis in adults
Comparison: 2 Antibiotics versus placebo in acute rhinosinusitis: secondary outcomes
Outcome: 4 Clinical failure
Study or subgroup Antibiotics Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Clinically diagnosed rhinosinusitis
Kaiser 2001 1/133 14/132 7.4 % 0.16 [ 0.06, 0.45 ]
Varonen 2003 6/85 10/57 7.2 % 0.35 [ 0.12, 1.02 ]
Garbutt 2012 5/85 11/81 7.6 % 0.42 [ 0.15, 1.16 ]
Stalman 1997 3/94 7/92 5.0 % 0.42 [ 0.12, 1.50 ]
Bucher 2003 11/124 19/126 13.8 % 0.56 [ 0.26, 1.19 ]
De Sutter 2002 16/189 26/195 19.6 % 0.61 [ 0.32, 1.15 ]
Meltzer 2005 18/251 27/248 21.4 % 0.64 [ 0.35, 1.17 ]
Williamson 2007 1/101 1/108 1.0 % 1.07 [ 0.07, 17.24 ]
Subtotal (95% CI) 1062 1039 83.0 % 0.49 [ 0.36, 0.67 ]
Total events: 61 (Antibiotics), 115 (Placebo)
Heterogeneity: Chi2 = 6.56, df = 7 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.52 (P < 0.00001)
2 Rhinosinusitis confirmed by radiography
Axelsson 1970 4/74 1/32 2.1 % 1.65 [ 0.24, 11.58 ]
Van Buchem 1997a 3/105 1/101 2.1 % 2.65 [ 0.37, 19.12 ]
Subtotal (95% CI) 179 133 4.2 % 2.09 [ 0.52, 8.35 ]
Total events: 7 (Antibiotics), 2 (Placebo)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
3 Rhinosinusitis confirmed by computed tomography
Lindbaek 1996 14/83 20/44 11.9 % 0.24 [ 0.10, 0.54 ]
Lindbaek 1998 1/42 1/21 0.9 % 0.47 [ 0.02, 9.04 ]
Subtotal (95% CI) 125 65 12.8 % 0.25 [ 0.11, 0.55 ]
Total events: 15 (Antibiotics), 21 (Placebo)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 3.46 (P = 0.00054)
Total (95% CI) 1366 1237 100.0 % 0.48 [ 0.36, 0.63 ]
Total events: 83 (Antibiotics), 138 (Placebo)
Heterogeneity: Chi2 = 13.88, df = 11 (P = 0.24); I2 =21%
Test for overall effect: Z = 5.14 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.02, df = 2 (P = 0.03), I2 =72%
0.001 0.01 0.1 1 10 100 1000
Failure on placebo Failure on antibiotics
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Analysis 3.1. Comparison 3 Sensitivity analyses, Outcome 1 Clinically diagnosed rhinosinusitis.
Review: Antibiotics for acute rhinosinusitis in adults
Comparison: 3 Sensitivity analyses
Outcome: 1 Clinically diagnosed rhinosinusitis
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cure at 1 week
Bucher 2003 36/122 38/125 1.4 % 0.96 [ 0.56, 1.65 ]
Kaiser 2001 76/133 75/132 1.7 % 1.01 [ 0.62, 1.65 ]
Norrelund 1978 40/71 33/64 0.8 % 1.21 [ 0.62, 2.39 ]
Williamson 2007 53/101 52/108 1.2 % 1.19 [ 0.69, 2.05 ]
Subtotal (95% CI) 427 429 5.0 % 1.07 [ 0.81, 1.41 ]
Total events: 205 (Antibiotics), 198 (Placebo)
Heterogeneity: Chi2 = 0.48, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
2 Cure at 10 days
De Sutter 2002 73/189 59/195 1.8 % 1.45 [ 0.95, 2.21 ]
Kaiser 2001 77/135 76/134 1.7 % 1.01 [ 0.63, 1.64 ]
Stalman 1997 56/94 55/92 1.2 % 0.99 [ 0.55, 1.78 ]
Williamson 2007 71/101 71/108 1.0 % 1.23 [ 0.69, 2.21 ]
Subtotal (95% CI) 519 529 5.7 % 1.19 [ 0.92, 1.53 ]
Total events: 277 (Antibiotics), 261 (Placebo)
Heterogeneity: Chi2 = 1.66, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
3 Cure at 2 weeks
Bucher 2003 95/124 93/126 1.1 % 1.16 [ 0.65, 2.07 ]
Merenstein 2005 32/56 25/60 0.5 % 1.87 [ 0.89, 3.90 ]
Varonen 2003 70/85 39/57 0.4 % 2.15 [ 0.98, 4.74 ]
Williamson 2007 75/101 80/108 1.0 % 1.01 [ 0.54, 1.88 ]
Subtotal (95% CI) 366 351 3.1 % 1.37 [ 0.98, 1.91 ]
Total events: 272 (Antibiotics), 237 (Placebo)
Heterogeneity: Chi2 = 3.18, df = 3 (P = 0.36); I2 =6%
Test for overall effect: Z = 1.86 (P = 0.063)
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Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
4 Cure at 1 week, with Garbutt data
Bucher 2003 36/122 38/125 1.4 % 0.96 [ 0.56, 1.65 ]
Garbutt 2012 60/81 41/74 0.6 % 2.30 [ 1.17, 4.52 ]
Kaiser 2001 76/133 75/132 1.7 % 1.01 [ 0.62, 1.65 ]
Norrelund 1978 40/71 33/64 0.8 % 1.21 [ 0.62, 2.39 ]
Williamson 2007 53/101 52/108 1.2 % 1.19 [ 0.69, 2.05 ]
Subtotal (95% CI) 508 503 5.6 % 1.20 [ 0.93, 1.54 ]
Total events: 265 (Antibiotics), 239 (Placebo)
Heterogeneity: Chi2 = 4.68, df = 4 (P = 0.32); I2 =14%
Test for overall effect: Z = 1.39 (P = 0.16)
5 Cure at 10 days, with Garbutt data
De Sutter 2002 73/189 59/195 1.8 % 1.45 [ 0.95, 2.21 ]
Garbutt 2012 63/81 59/74 0.7 % 0.89 [ 0.41, 1.93 ]
Kaiser 2001 77/135 76/134 1.7 % 1.01 [ 0.63, 1.64 ]
Stalman 1997 56/94 55/92 1.2 % 0.99 [ 0.55, 1.78 ]
Williamson 2007 71/101 71/108 1.0 % 1.23 [ 0.69, 2.21 ]
Subtotal (95% CI) 600 603 6.4 % 1.16 [ 0.91, 1.47 ]
Total events: 340 (Antibiotics), 320 (Placebo)
Heterogeneity: Chi2 = 2.15, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
6 Influence of missing data: cure at any time point if dropouts were successes
Bucher 2003 96/125 94/127 1.1 % 1.16 [ 0.65, 2.06 ]
De Sutter 2002 86/202 70/206 2.0 % 1.44 [ 0.96, 2.15 ]
Kaiser 2001 78/135 77/134 1.7 % 1.01 [ 0.62, 1.64 ]
Merenstein 2005 43/67 33/68 0.6 % 1.90 [ 0.95, 3.79 ]
Norrelund 1978 42/73 37/67 0.8 % 1.10 [ 0.56, 2.14 ]
Stalman 1997 60/98 57/94 1.2 % 1.02 [ 0.57, 1.83 ]
Varonen 2003 74/89 42/60 0.4 % 2.11 [ 0.97, 4.63 ]
Williamson 2007 87/113 99/127 1.1 % 0.95 [ 0.52, 1.74 ]
Subtotal (95% CI) 902 883 9.0 % 1.24 [ 1.02, 1.52 ]
Total events: 566 (Antibiotics), 509 (Placebo)
Heterogeneity: Chi2 = 5.82, df = 7 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
7 Influence of missing data: cure at any time point if dropouts were failures
Bucher 2003 95/125 93/127 1.1 % 1.16 [ 0.66, 2.04 ]
De Sutter 2002 73/202 59/206 1.9 % 1.41 [ 0.93, 2.14 ]
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Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaiser 2001 76/135 75/134 1.7 % 1.01 [ 0.63, 1.64 ]
Merenstein 2005 32/67 25/68 0.7 % 1.57 [ 0.79, 3.13 ]
Norrelund 1978 40/73 33/67 0.8 % 1.25 [ 0.64, 2.43 ]
Stalman 1997 56/98 55/94 1.2 % 0.95 [ 0.53, 1.68 ]
Varonen 2003 70/89 39/60 0.5 % 1.98 [ 0.95, 4.13 ]
Williamson 2007 75/113 80/127 1.3 % 1.16 [ 0.68, 1.97 ]
Subtotal (95% CI) 902 883 9.2 % 1.24 [ 1.02, 1.51 ]
Total events: 517 (Antibiotics), 459 (Placebo)
Heterogeneity: Chi2 = 4.05, df = 7 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.032)
8 Influence of missing data: cure at any time point if dropouts had the same cure rate as control group
Bucher 2003 96/125 94/127 1.1 % 1.16 [ 0.65, 2.06 ]
De Sutter 2002 77/202 62/206 1.9 % 1.43 [ 0.95, 2.16 ]
Kaiser 2001 77/135 76/134 1.7 % 1.01 [ 0.63, 1.64 ]
Merenstein 2005 37/67 28/68 0.6 % 1.76 [ 0.89, 3.48 ]
Norrelund 1978 41/73 35/67 0.8 % 1.17 [ 0.60, 2.28 ]
Stalman 1997 58/98 56/94 1.2 % 0.98 [ 0.55, 1.75 ]
Varonen 2003 73/89 41/60 0.5 % 2.11 [ 0.98, 4.55 ]
Williamson 2007 84/113 94/127 1.2 % 1.02 [ 0.57, 1.81 ]
Subtotal (95% CI) 902 883 9.0 % 1.24 [ 1.02, 1.51 ]
Total events: 543 (Antibiotics), 486 (Placebo)
Heterogeneity: Chi2 = 5.16, df = 7 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.033)
9 Influence of missing data: cure at 1 week if dropouts were successes
Bucher 2003 39/125 40/127 1.4 % 0.99 [ 0.58, 1.68 ]
Kaiser 2001 78/135 77/134 1.7 % 1.01 [ 0.62, 1.64 ]
Norrelund 1978 42/73 37/67 0.8 % 1.10 [ 0.56, 2.14 ]
Williamson 2007 65/113 71/127 1.5 % 1.07 [ 0.64, 1.78 ]
Subtotal (95% CI) 446 455 5.4 % 1.03 [ 0.79, 1.35 ]
Total events: 224 (Antibiotics), 225 (Placebo)
Heterogeneity: Chi2 = 0.08, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
10 Influence of missing data: cure at 1 week if dropouts were failures
Bucher 2003 36/125 38/127 1.4 % 0.95 [ 0.55, 1.63 ]
Kaiser 2001 76/135 75/134 1.7 % 1.01 [ 0.63, 1.64 ]
Norrelund 1978 40/73 33/67 0.8 % 1.25 [ 0.64, 2.43 ]
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Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williamson 2007 53/113 52/127 1.3 % 1.27 [ 0.76, 2.12 ]
Subtotal (95% CI) 446 455 5.2 % 1.10 [ 0.84, 1.44 ]
Total events: 205 (Antibiotics), 198 (Placebo)
Heterogeneity: Chi2 = 0.86, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
11 Influence of missing data: cure at 1 week if dropouts had the same cure rate as control group
Bucher 2003 37/125 39/127 1.4 % 0.95 [ 0.55, 1.63 ]
Norrelund 1978 41/73 35/67 0.8 % 1.17 [ 0.60, 2.28 ]
Williamson 2007 59/113 61/127 1.4 % 1.18 [ 0.71, 1.96 ]
Subtotal (95% CI) 311 321 3.6 % 1.09 [ 0.79, 1.50 ]
Total events: 137 (Antibiotics), 135 (Placebo)
Heterogeneity: Chi2 = 0.40, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
12 Influence of missing data: cure at 10 days if dropouts were successes
De Sutter 2002 86/202 70/206 2.0 % 1.44 [ 0.96, 2.15 ]
Stalman 1997 60/98 57/94 1.2 % 1.02 [ 0.57, 1.83 ]
Williamson 2007 83/113 90/127 1.2 % 1.14 [ 0.65, 2.00 ]
Subtotal (95% CI) 413 427 4.4 % 1.25 [ 0.94, 1.66 ]
Total events: 229 (Antibiotics), 217 (Placebo)
Heterogeneity: Chi2 = 1.04, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
13 Influence of missing data: cure at 10 days if dropouts were failures
De Sutter 2002 73/202 59/206 1.9 % 1.41 [ 0.93, 2.14 ]
Stalman 1997 56/98 56/94 1.3 % 0.90 [ 0.51, 1.61 ]
Williamson 2007 71/113 71/127 1.3 % 1.33 [ 0.79, 2.24 ]
Subtotal (95% CI) 413 427 4.4 % 1.25 [ 0.94, 1.65 ]
Total events: 200 (Antibiotics), 186 (Placebo)
Heterogeneity: Chi2 = 1.60, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
14 Influence of missing data: cure at 10 days if dropouts had the same cure rate as control group
De Sutter 2002 77/202 62/206 1.9 % 1.43 [ 0.95, 2.16 ]
Stalman 1997 58/98 56/94 1.2 % 0.98 [ 0.55, 1.75 ]
Williamson 2007 79/113 84/127 1.2 % 1.19 [ 0.69, 2.05 ]
Subtotal (95% CI) 413 427 4.4 % 1.24 [ 0.93, 1.65 ]
Total events: 214 (Antibiotics), 202 (Placebo)
Heterogeneity: Chi2 = 1.11, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
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Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
15 Influence of missing data: cure at 2 weeks if dropouts were successes
Bucher 2003 95/124 93/126 1.1 % 1.16 [ 0.65, 2.07 ]
Bucher 2003 96/125 94/127 1.1 % 1.16 [ 0.65, 2.06 ]
Merenstein 2005 43/67 33/68 0.6 % 1.90 [ 0.95, 3.79 ]
Varonen 2003 74/89 42/60 0.4 % 2.11 [ 0.97, 4.63 ]
Williamson 2007 87/113 99/127 1.1 % 0.95 [ 0.52, 1.74 ]
Subtotal (95% CI) 518 508 4.3 % 1.30 [ 0.98, 1.73 ]
Total events: 395 (Antibiotics), 361 (Placebo)
Heterogeneity: Chi2 = 3.99, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.064)
16 Influence of missing data: cure at 2 weeks if dropouts were failures
Bucher 2003 95/125 93/127 1.1 % 1.16 [ 0.66, 2.04 ]
Merenstein 2005 32/67 25/68 0.7 % 1.57 [ 0.79, 3.13 ]
Varonen 2003 70/89 39/60 0.5 % 1.98 [ 0.95, 4.13 ]
Williamson 2007 75/113 80/127 1.3 % 1.16 [ 0.68, 1.97 ]
Subtotal (95% CI) 394 382 3.6 % 1.35 [ 0.99, 1.84 ]
Total events: 272 (Antibiotics), 237 (Placebo)
Heterogeneity: Chi2 = 1.84, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
17 Influence of missing data: cure at 2 weeks if dropouts had the same cure rate as control group
Bucher 2003 96/125 94/127 1.1 % 1.16 [ 0.65, 2.06 ]
Merenstein 2005 37/67 28/68 0.6 % 1.76 [ 0.89, 3.48 ]
Varonen 2003 73/89 41/60 0.5 % 2.11 [ 0.98, 4.55 ]
Williamson 2007 84/113 94/127 1.2 % 1.02 [ 0.57, 1.81 ]
Subtotal (95% CI) 394 382 3.4 % 1.35 [ 0.99, 1.86 ]
Total events: 290 (Antibiotics), 257 (Placebo)
Heterogeneity: Chi2 = 3.08, df = 3 (P = 0.38); I2 =3%
Test for overall effect: Z = 1.87 (P = 0.062)
18 Overall treatment effect (with Young 2008 data concerning Stalman)
Bucher 2003 95/124 93/126 1.1 % 1.16 [ 0.65, 2.07 ]
De Sutter 2002 73/189 59/195 1.8 % 1.45 [ 0.95, 2.21 ]
Kaiser 2001 76/133 75/132 1.7 % 1.01 [ 0.62, 1.65 ]
Merenstein 2005 32/56 25/60 0.5 % 1.87 [ 0.89, 3.90 ]
Norrelund 1978 40/71 33/64 0.8 % 1.21 [ 0.62, 2.39 ]
Stalman 1997 62/94 58/92 1.0 % 1.14 [ 0.62, 2.07 ]
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Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Varonen 2003 70/85 39/57 0.4 % 2.15 [ 0.98, 4.74 ]
Williamson 2007 75/101 80/108 1.0 % 1.01 [ 0.54, 1.88 ]
Subtotal (95% CI) 853 834 8.4 % 1.27 [ 1.04, 1.56 ]
Total events: 523 (Antibiotics), 462 (Placebo)
Heterogeneity: Chi2 = 4.74, df = 7 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.32 (P = 0.020)
Total (95% CI) 9727 9682 100.0 % 1.22 [ 1.14, 1.29 ]
Total events: 5674 (Antibiotics), 5189 (Placebo)
Heterogeneity: Chi2 = 51.35, df = 86 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 6.40 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.42, df = 17 (P = 1.00), I2 =0.0%
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Analysis 3.2. Comparison 3 Sensitivity analyses, Outcome 2 Rhinosinusitis confirmed by imaging.
Review: Antibiotics for acute rhinosinusitis in adults
Comparison: 3 Sensitivity analyses
Outcome: 2 Rhinosinusitis confirmed by imaging
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cure at any time point
Axelsson 1970 27/74 10/32 11.9 % 1.26 [ 0.52, 3.06 ]
Kaiser 2001 30/42 24/40 9.4 % 1.67 [ 0.66, 4.19 ]
Lindbaek 1996 32/83 5/44 5.4 % 4.89 [ 1.75, 13.72 ]
Lindbaek 1998 15/42 9/21 10.3 % 0.74 [ 0.25, 2.16 ]
Van Buchem 1997a 68/105 53/101 25.5 % 1.66 [ 0.95, 2.91 ]
Subtotal (95% CI) 346 238 62.5 % 1.71 [ 1.20, 2.45 ]
Total events: 172 (Antibiotics), 101 (Placebo)
Heterogeneity: Chi2 = 6.81, df = 4 (P = 0.15); I2 =41%
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Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 2.95 (P = 0.0032)
2 Cure or improvement at any time point
Axelsson 1970 62/74 23/32 7.0 % 2.02 [ 0.75, 5.43 ]
Lindbaek 1996 71/83 25/44 6.3 % 4.50 [ 1.91, 10.57 ]
Lindbaek 1998 32/42 14/21 6.0 % 1.60 [ 0.51, 5.06 ]
Van Buchem 1997a 87/105 78/101 18.3 % 1.43 [ 0.72, 2.84 ]
Subtotal (95% CI) 304 198 37.5 % 2.08 [ 1.35, 3.21 ]
Total events: 252 (Antibiotics), 140 (Placebo)
Heterogeneity: Chi2 = 4.49, df = 3 (P = 0.21); I2 =33%
Test for overall effect: Z = 3.33 (P = 0.00087)
Total (95% CI) 650 436 100.0 % 1.85 [ 1.41, 2.44 ]
Total events: 424 (Antibiotics), 241 (Placebo)
Heterogeneity: Chi2 = 11.93, df = 8 (P = 0.15); I2 =33%
Test for overall effect: Z = 4.38 (P = 0.000012)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
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A P P E N D I C E S
Appendix 1. MEDLINE and CENTRAL search strategy
MEDLINE (Ovid)
1 exp Sinusitis/
2 sinusit*.tw.
3 Rhinitis/
4 rhinit*.tw.
5 rhinosinusit*.tw.
6 nasosinusit*.tw.
7 ((suppurative or purulent) adj2 (nasal discharge or rhinitis or rhinorrhoea or rhinorrhoea)).tw.
8 or/1-7
9 exp Anti-Bacterial Agents/
10 antibacterial*.tw.
11 antibiotic*.tw.
12 exp Amoxicillin/
13 amoxicillin*.tw,nm.
14 Ampicillin/
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15 ampicillin*.tw,nm.
16 Azithromycin/
17 azithromycin.tw,nm.
18 Cefaclor/
19 cefaclor.tw,nm.
20 exp Cefadroxil/
21 cefadroxil.tw,nm.
22 cefatrizine.tw,nm.
23 Cefuroxime/
24 cefuroxim*.tw,nm.
25 Cephalexin/
26 cephalexin*.tw,nm.
27 Cephalosporins/
28 cephalosporin*.tw,nm.
29 Ciprofloxacin/
30 ciprofloxacin*.tw,nm.
31 Clarithromycin/
32 clarithromycin*.tw,nm.
33 Clindamycin/
34 clindamycin*.tw,nm.
35 Doxycycline/
36 doxycyclin*.tw,nm.
37 Erythromycin/
38 erythromycin*.tw,nm.
39 Fluoroquinolones/
40 fluoroquinolone*.tw,nm.
41 levofloxacin.tw,nm.
42 Lincomycin/
43 lincomycin*.tw,nm.
44 Macrolides/
45 macrolide*.tw,nm.
46 Minocycline/
47 minocyclin*.tw,nm.
48 Miocamycin/
49 (miocamycin* or miokamycin*).tw,nm.
50 moxifloxacin*.tw,nm.
51 norfloxacin.tw,nm.
52 Norfloxacin/
53 Ofloxacin/
54 ofloxacin.tw,nm.
55 Penicillins/
56 penicillin*.tw,nm.
57 Quinolones/
58 quinolone*.tw,nm.
59 Spiramycin/
60 spiramycin.tw,nm.
61 telithromycin.tw,nm.
62 tetracyclines/ or tetracycline/
63 tetracycline*.tw,nm.
64 Trimethoprim-Sulfamethoxazole Combination/
65 trimethoprim-sulfamethoxazole combination.tw,nm.
66 cotrimoxazole*.tw,nm.
67 or/9-66
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Appendix 2. Embase (Elsevier) search strategy
#21 #12 AND #20
#20 #15 NOT #19
#19 #16 NOT #18
#18 #16 AND #17
#17 ’human’/de
#16 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#15 #13 OR #14
#14 crossover*:ab,ti OR ’cross-over’:ab,ti OR ’cross over’:ab,ti OR placebo*:ab,ti OR (doubl* NEXT/1 blind*):ab,ti OR allocat*:ab,ti
OR random*:ab,ti OR trial:ti
#13 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#12 #6 AND #11
#11 #7 OR #8 OR #9 OR #10
#10 amoxicillin:ab,ti OR ampicillin*:ab,ti OR azithromycin:ab,ti OR cefaclor:ab,ti OR cefadroxil:ab,ti OR cefatrizine:ab,ti OR ce-
furoxim*:ab,ti OR cephalexin*:ab,ti OR cephalosporin*:ab,ti OR ciprofloxacin*:ab,ti OR clarithromycin*:ab,ti OR clindamycin:ab,ti
OR doxycyclin*:ab,ti OR erythromycin*:ab,ti OR fluoroquinolone*:ab,ti OR levofloxacin*:ab,ti OR lincomycin*:ab,ti ORmacrolide*:
ab,tiORminocyclin*:ab,tiORmiocamycin*:ab,tiORmiokamycin*:ab,tiORmoxifloxacin*:ab,tiORnorfloxacin*:ab,tiORofloxacin*:
ab,ti OR penicillin*:ab,ti OR quinolone*:ab,ti OR spiramycin*:ab,ti OR telithromycin*:ab,ti OR tetracyclin*:ab,ti OR trimethoprim*:
ab,ti OR cotrimoxazol*:ab,ti
#9 ’amoxicillin’/de OR ’ampicillin’/de OR ’azithromycin’/de OR ’cefaclor’/de OR ’cefadroxil’/de OR ’cefuroxime’/de OR ’cefalexin’/
de OR ’cephalosporin’/de OR ’ciprofloxacin’/de OR ’clarithromycin’/de OR ’clindamycin’/de OR ’doxycycline’/de OR ’erythromycin’/
de OR ’lincomycin’/de OR ’macrolide’/de OR ’quinolone derivative’/de OR ’minocycline’/de OR ’miokamycin’/exp OR ’norfloxacin’/
de OR ’ofloxacin’/de OR ’penicillin derivative’/de OR ’spiramycin’/de OR ’tetracycline derivative’/de OR ’cotrimoxazole’/de
#8 antibiotic*:ab,ti
#7 ’antibiotic agent’/exp
#6 #1 OR #2 OR #3 OR #4 OR #5
#5 ((suppurative OR purulent) NEAR/2 (’nasal discharge’ OR rhinitis OR rhinorrhea OR rhinorrhoea)):ab,ti
#4 rhinit*:ab,ti OR rhinosinusit*:ab,ti OR nasosinusit*:ab,ti
#3 ’rhinitis’/de OR ’rhinosinusitis’/de
#2 sinusit*:ab,ti
#1 ’sinusitis’/exp
Appendix 3. WHO International Clinical Trials Registry Platform (ICTRP) search strategy
sinusit* AND antibacterial*
OR rhinit* AND antibacterial*
OR rhinosinusit* AND antibacterial*
OR nasosinusit* AND antibacterial*
OR suppurative nasal discharge AND antibacterial*
OR purulent nasal discharge AND antibacterial*
OR suppurative rhinorrhoea AND antibacterial*
OR purulent rhinorrhoea AND antibacterial*
OR suppurative rhinorrhea AND antibacterial*
OR purulent rhinorrhea AND antibacterial*
OR sinusit* AND antibiotic*
OR rhinit* AND antibiotic*
OR rhinosinusit* AND antibiotic*
OR nasosinusit* AND antibiotic*
OR suppurative nasal discharge AND antibiotic*
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OR purulent nasal discharge AND antibiotic*
OR suppurative rhinorrhoea AND antibiotic*
OR purulent rhinorrhoea AND antibiotic*
OR suppurative rhinorrhea AND antibiotic*
OR purulent rhinorrhea AND antibiotic*
Appendix 4. ClinicalTrials.gov search strategy
(sinusitis OR rhinitis OR rhinosinusitis OR nasosinusitis OR ((suppurative OR purulent) AND nasal discharge OR rhinorrhoea OR
rhinorrhea)) AND (antibacterial OR anti-bacterial OR antibiotic OR antibiotics)
WH A T ’ S N E W
Last assessed as up-to-date: 18 January 2018.
Date Event Description
18 January 2018 New citation required but conclusions have not changed Two Cochrane Reviews, ’Antibiotics for acute maxil-
lary sinusitis in adults’ (Ahovuo-Saloranta 2014) and
’Antibiotics for clinically diagnosed acute rhinosinusi-
tis in adults’ (De Sutter 2012), described the effect of
antibiotics for acute rhinosinusitis. Although both re-
views studied the same condition, they studied differ-
ent populations: people diagnosed according to clini-
cal signs, confirmed or not by imaging or bacterial cul-
ture (Ahovuo-Saloranta 2014), and people diagnosed
according to clinical signs and symptoms (De Sutter
2012). Different approaches resulted in different con-
clusions, which was confusing for clinicians. We there-
foremerged these Cochrane Reviewswhilstmaintaining
the relevant distinction between populations diagnosed
by clinical signs and symptoms, or imaging
18 January 2018 New search has been performed Searches updated. As a consequence of merging two
Cochrane Reviews, we incorporated five trials from
Ahovuo-Saloranta 2014 in the analyses (Axelsson 1970;
Lindbaek 1996; Lindbaek 1998; Rantanen 1973; Van
Buchem 1997a). The comparison between antibiotics,
as published by Ahovuo-Saloranta 2014, was omitted.
Instead of clinical trials, local up-to-date antibiotic re-
sistance patterns should guide clinicians in making the
best choice for the appropriate antibiotic and dose in
the subgroup of people with suspected bacterial rhinos-
inusitis. No new studies were added as a result of the
update
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H I S T O R Y
Protocol first published: Issue 3, 2006
Review first published: Issue 10, 2012
Date Event Description
2 April 2014 New search has been performed Searches updated.
7 April 2008 Amended Converted to new review format
C O N T R I B U T I O N S O F A U T H O R S
An De Sutter (ADS) wrote the first draft of the protocol.
Marieke Lemiengre (ML) wrote the first draft of the amalgamation of the separate reviews Ahovuo-Saloranta 2014 and De Sutter 2012.
ADS, Mieke van Driel (MVD), Dan Merenstein (DM), Helena Liira (HL), and Marjukka Mäkelä (MM) commented on the draft and
suggested changes that consequently led to a new version.
D E C L A R A T I O N S O F I N T E R E S T
Marieke B Lemiengre: none known.
Mieke L van Driel: Co-author of De Sutter 2002. No other conflicts of interest known.
Dan Merenstein: Main investigator of Merenstein 2005. No other conflicts of interest known.
Helena Liira: Main investigator of Varonen 2003. No other conflicts of interest known.
Marjukka Mäkelä: Co-author of Varonen 2003. No other conflicts of interest known.
An IM De Sutter: Main investigator of De Sutter 2002. No other conflicts of interest known.
S O U R C E S O F S U P P O R T
Internal sources
• Ghent University, Belgium.
Salary
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Two Cochrane Reviews, ’Antibiotics for acute maxillary sinusitis in adults’ and ’Antibiotics for clinically diagnosed acute rhinosinusitis
in adults’ (Ahovuo-Saloranta 2014; De Sutter 2012), described the effects of antibiotics for acute rhinosinusitis. Although both reviews
studied the same condition, they evaluated different populations, namely participants who were diagnosed by imaging (Ahovuo-
Saloranta 2014), versus participants who were diagnosed by clinical signs and symptoms (De Sutter 2012). Different approaches
resulted in different conclusions, which was confusing for clinicians. We therefore merged these Cochrane Reviews while maintaining
the relevant distinction between both populations. The comparison between antibiotics, as published by Ahovuo-Saloranta 2014,
was omitted. Instead of clinical trials, local up-to-date antibiotic resistance patterns should guide clinicians in making the best choice
regarding which antibiotic and dose in the subgroup of people with suspected bacterial rhinosinusitis should be prescribed.
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